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Summary
Silica nanoparticles are increasingly used as drug delivery systems and for biomedical imaging.
Therapeutic and diagnostic agents can be incorporated into the silica matrix to improve the sta-
bility and solubility of hydrophobic drugs in biological systems. However, the safety of silica
nanoparticles as drug carriers remains controversial. To date, no validated and accepted nano-
specific tests exist to predict the potentially harmful impact of these materials on the human body.
The mechanism proposed for hemolysis of unmodified silica nanoparticles is based on the electro-
static interaction between the silanol surface groups and the quaternary ammonium in the choline
head group of the phospholipids. However, a detailed understanding of this process is missing.
In this thesis, different silica nanoparticles where synthesized, characterized, and tested in two cell
lines regarding viability and oxidative stress. Hemolysis was assessed using red blood cells. Fur-
thermore, the hemolytic mechanism of a chosen silica nanoparticle type was investigated in depth
using a biophysical chemistry approach. We used the dye-leakage assay, isothermal titration
calorimetry, solid state nuclear magnetic resonance, and flow cytometry to elucidate this mech-
anism.
Our results revealed that silica nanoparticles with a porous surface and negative surface charge
had the strongest impact on viability in a concentration dependent manner. This is in contrast to
non-porous silica nanoparticles. None of the studied particles caused oxidative stress in either cell
lines. Particles with a negative surface charge induced hemolysis. The mechanism responsible for
the hemolysis for silica nanoparticles had no electrostatic component. The nuclear magnetic reso-
nance data revealed no interaction with the choline group. However, nuclear magnetic resonance
data suggested the presence of faster tumbling species.
Our toxicological and mechanistic studies showed potential hazards of spherical amorphous sil-
ica nanoparticles. Physico-chemical properties mediating toxicity in living cells were identified.
We propose that our standardized silica nanoparticles may serve as a readily available reference
material for nanotoxicological investigations. Mechanistic data did not support an electrostatic
interaction as postulated in the literature, but rather a strong adsorption process that may lead
to hemolysis. Furthermore, the presence of faster tumbling species suggested the formation of
smaller lipid bilayer structures upon silica nanoparticles exposure. Flow cytometry data revealed
that their size is about 100 nm. It remains to be proven if the bilayer wraps around the hemolytic
silica nanoparticles, if an exclusive formation of smaller species without wrapping is present, or
both of the aforementioned.
1

Chapter 1
Introduction
1.1 Definition and application
"Nano" stems from the greek word nannos and means "dwarf". One nanometer is defined as 10-9 m.
Hence, nanotechnology is interested in very small objects and has been widely known and used
throughout history. For example, in ancient Egypt and China colloidal gold had already been in-
troduced to medicine. Later on, nano-sized gold and silver were used to embellish glass. In the
Middle Ages, church windows were colored with nanomaterials. But it was not until 1875, that
M. Faraday was able to synthesize gold nanoparticles intentionally by the reduction of gold chlo-
ride [1]. Colloidal sciences were born at that time. Later, nanotechnology had emerged from the
colloidal sciences by the famous lecture of Richard Feynman in 1959 ("There is plenty of room at
the bottom") [2]. With the invention of various microscopic techniques such as the scanning tun-
nel microscope or the atomic force microscopy (AFM), objects at the nanoscale could be observed
in real time [1].
Amongst others, terms like nanomaterials, nanorods, and nanoparticles are frequently used as
synonyms. However, it is important to discriminate between several terms that contain the prefix
"nano". Each of these terms is defined by its dimensions, as depicted in Figure 1.1. Common to
all nano-related terms is the size-dependent definition that spans from 1 nm to 100 nm, as defined
by the OECD, ISO, and DIN [3]. A nanomaterial is defined by its inner or outer dimensions, with
either of them in the range of 1-100 nm. This definition also includes microscaled particles with
pores in the nanorange. A nano-object is confined by its outer dimensions only. Nano-objects
can furthermore be divided into three sub-classes, starting with one dimension (nanoplates), two
dimensions (nanofibers) and three dimensions in the nanoscale (nanoparticles).
This cut-off of the upper size limit (100 nm) is not scientifically justified. It is assumed, that so
called quantum effects start at this size for some materials [4]. For example gold nanoparticles
change their excitation and emission spectra due to their size [5]. This feature is not present in
gold particles that exceed a critical size above 100nm. Another example is that inert material such
as titanium becomes explosive at the nano-size range [6]. However, some scientists postulated
that these special nano-effect occurs below 30 nm [7]. Otherwise, nanoparticles up to 300 nm or
even 500 nm are interacting with biological systems and can be endocytosed by cells. This is a fea-
ture that microparticles hardly possess. Among toxicologists and pharmacologists it is commonly
3
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Figure 1.1: Definition of nanomaterials. "D" stands for dimension; 1D is nanoscaled in the x-
dimension; 2D in x and y dimensions and 3D in x, y, and z-dimension.
known that particles below 250 nm can distribute throughout the human body and are therefore
referred as nanoparticles. In this size range we also find most of the drug delivery systemsdrug
delivery system (DDS). Therefore, federal institutions like the Food and Drug Administration
further extended the upper boundary of nanoparticles up to 1000 nm, if the particle exhibits dis-
tinct properties from the bulk (physical, chemical, biological). Throughout this thesis, the term
nanoparticles will be used up to 500 nm.
Today, nanoparticles are used in our daily life. Amongst various applications, they are used in
consumer products, nanomedicine, and in the environment [1]. In consumer products they func-
tion as food additives to aid flowing (Aerosil R©), or they can be found in the cosmetic sector as
antioxidants or blockers of ultra violet light. For example, titanium dioxide is used in sunscreen
and is proposed as an alternative to chemical sunscreen. Apart from this, they are found in so-
lar cells, where the use of quantum dots enhances the efficiency compared to conventional solar
cells [8].
1.2 Nanoparticles as drug delivery systems- history and application
In the 1970s, nanoparticles were first proposed to be used as DDS. Research started with lipid
bilayer particles (liposomes) as organic carriers and to date, nanoformulated drugs such as lipo-
somal encapsulated doxorubicin (Doxil R©) have been marketed successfully. After Doxil R© was
launched to the market, various lipid formulations followed and were mainly used for treating
4
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cancer [9]. One of the non-liposomal nanodrug on the market is Abraxane R©, where the hydropho-
bic drug paclitaxel is coupled to albumin. Only recently, inorganic nanoparticles like porous silica
were proposed as DDS [10]. Silica nanoparticles consist of silicium dioxide and is the same mate-
rial used to make glass. Compared to liposomes, porous silica has the advantage of a high specific
surface area and can therefore guest a considerable amount of drug. Additionally, core-shell silica
nanoparticles (SNPs) are emerging: in 2005 they were proposed to use as imaging agents [11]. The
excellent photostability of encapsulated dyes into the silica matrix and their subsequent accumu-
lation in a tumor makes them an attractive alternative for imaging. These so-called CU (Cornell
University) Dots are currently tested in clinical trials [12].
Most of the marketed drugs are small molecules (molecular weight up to 500 Da). Depending on
their route of entry to the human body, they are distributed according to their chemical properties
i.e. molecular weight, electron donors, electron acceptors, and logP (water-octanol partition coef-
ficient). [13]. Small molecules can also bind throughout the body to non-specific targets and hence
cause adverse drug reactions, or are even cytotoxic for healthy cells [14]. In contrary to free drugs,
drugs encapsulated into nanoparticulate delivery systems can minimize this effect.
Kettiger at al. discuss obstacles which DDS must overcome in order to exert a pharmacological
effect [15]. The size of a nanocarrier is crucial to ensure successful pharmacological efficacy. The
carrier should be large enough (around 100-200 nm) to ensure sufficient drug loading. However,
it should not exceed a certain size, because otherwise it will be recognized by macrophages [15].
Once injected into the blood stream, the DDS comes into contact with cells and proteins. These
proteins will start to adsorb immediately to the nanoparticle. If so-called opsonins (proteins that
render foreign material "visible" to macrophages) bind to the DDS, premature clearing from the
circulation due to macrophage uptake reduces drug efficacy. Hence, stealth properties need to be
introduced to a carrier to render them invisible for opsonins.
When a DDS is distributed via blood stream, accumulation on the target side (mostly tumors)
is crucial. This is mainly achieved by passive diffusion out of a leaky vasculature in the tumor
region. Accumulation in diseased cells is enhanced by decorating the carrier system with a target-
ing moiety to specifically get incorporated by diseased cells. Ideally, healthy cells do not recognize
the targeting moiety. Furthermore, targeted drug delivery reduces multiple drug resistance [16].
Unfortunately, only some fractions of the injected dose are reaching the tumor, so off-target effects
are mainly expected in the clearing organs as liver and spleen. Hence, the carrier itself should be
essentially non-toxic and be degraded safely.
5
CHAPTER 1. INTRODUCTION
1.3 Safety of nanoparticles: the need of a new toxicological science?
Toxicology is the science of measuring adverse effects of chemicals to living organisms including
human, animals, and the environment [17]. Paracelsus’ famous sentence "Alle Dinge sind Gift, und
nichts ist ohne Gift; allein die Dosis machts, dass ein Ding kein Gift sei" is often mentioned to illustrate
a well-known dose-response curve for small molecules. Nanotoxicology however is, compared
to small molecules toxicology, a relatively new domain in toxicology and has emerged years after
the boom of nanotechnology. At this time point, numerous new and unregulated nanoparticles
have already been introduced to the market. Nanoparticles have properties which are helpful for
consumers and industrial applications. However, the same properties that render them unique
compared to the bulk material give rise to a certain biological reactivity. Until now, many tests
have been proposed to determine the safety of nanoparticles. However, no clear statement is pos-
sible. Moreover, standard methods for testing the safety of nanoparticles are missing [18]
While a lot is known about bulk and small molecule safety, only little is known about safety in
the transitional range. In the 1970s a lot of effort was put in understanding the health impact of
so-called ultra fine particles, i.e. particles below 100 nm in size. The focus was put on the health
impact of airborne particles. One of the most prominent findings of this research was the relation
between inhaled asbestos and chronic lung inflammation with subsequent tumors in the lung [19].
The ability of nanoparticles to interact with biological systems in an adverse way was recognized
in the 1990s [1].
Since then, a lot of effort has been put in establishing safety margins, always with the asbestos sam-
ple in mind. Human epidemiological data are available on airborne ultra fine particles. However,
there is still a knowledge gap regarding the interaction between living organisms and nanopar-
ticles. With the ability to be taken up by living cells and crossing barriers, such particles are
rendered as bioactive. Their appearance may change dramatically with their changing environ-
ment (i.e. a native nanoparticles compared to a protein-coated particle may already exert different
toxicological profiles in vitro.).
Table 1.1 shows the difference between three groups, namely small molecules, nanoparticles,
and microparticles. Compared to small molecule toxicity, where relatively well characterized
structure-activity-relationship exists, it is still difficult to determine, what renders nanoparticles
cytotoxic. As listed in table 1.1, various physico-chemical properties could mediate cytotxicity.
However, it is difficult to conclude from bulk material toxicity to nanotoxicity, although a recent
review questions nanotoxicity [20]. Nevertheless, several in vivo studies are suggesting to pay
special attention, not only to inhaled nanoparticles, but also to DDS or particles used for imaging.
Additionally, the research was mainly focused on airborne particles in the last years. In contrary
to airborne particles, DDS and particles for imaging are directly injected into the blood stream.
6
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< 1nm 100nm > 1000nm
Diffusion, Brownian motion Sedimentation and diffusion Sedimentation
Log P, molecular weight, hy-
drophilicity
size, shape, surface modi-
fication, surface area, crys-
tallinity
size, shape, surface modi-
fication, surface area, crys-
tallinity
Passive (membrane) or active
(transporters)
active (phago-endocytotic
processes)
negligible
Table 1.1: Main differences between small molecules, nanoparticles, and microparticles. The dif-
ference between the three species lies in size, force of movement, chemical or physico-chemical
properties, and uptake into cells.
Hence, safety assessment is faced with different questions and needs other approaches.
1.4 Mode of nanotoxicity
1.4.1 General mode of nanotoxicity
Nanoparticles have various physico-chemical properties and may hence exert different toxicolog-
ical profiles related to these properties (depicted in Figure 1.2). One of the most studied impacts
on nanotoxicity is its size. A smaller nanoparticle is generally considered more cytotoxic com-
pared to their larger counterpart. This has been shown for a variety of materials including gold
nanoparticles [21], silver nanoparticles [22], and quantum dots [23], just to mention a few. The
enhanced toxicity by smaller nanoparticles can be explained as follows. With a decrease in size
an exponential increase in surface area is the consequence. This leads to a higher curvature and
therefore an increased reactivity of the atoms on the particle surface. These high-energy surfaces
can initiate or catalyze reactions, such as unfolding of proteins or generation of reactive oxidative
stress (ROS) (Figure 1.2). The second feature is the solubility enhancement of a nanosized mate-
rial. For particles with a toxic core material like quantum dots (some of them consist of cadmium)
the release of toxic ions from the particle mediates a viability decrease. This mechanism is also
responsible for copper nano particles toxicity [24]. For silver nanoparticles, which also release
ions and cause cytotoxitity, it is still under debate, if the toxicity is mediated by the size, the ionic
7
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Figure 1.2: Interactions of nanoparticles with their environment. Catalyzing reactions, redox-
cycling, particle dissolution, and generation of reactive oxidative species can result in cytotoxicity.
Figure reproduced from [4].
constitution or both [25].
The surface groups influence the hydrophilicity or hydrophobicity, where hydrophobic surfaces
tend to agglomerate and interact strongly with the cellular membrane. This can lead to membrane
distortion or passive uptake [26]. If the surface is modified with functional groups, it changes
the appearance of the particle. The charge density on the surface of a nanoparticle can also im-
pact the toxicity. If the charge density on the surface is too high, this leads to cytotoxicity. This
phenomenon of high charge density is well known from transfection reagents like poly-ethylene
imine, which carry a large amount of positive charges [27]. To render a surface non-toxic, the sur-
face can be modified by a non-toxic polymer like poly-ethylene glycol [15].
Beside these factors, shape and crystallinity play an important role in nanoparticle-mediated tox-
icity. Well-known examples for shape-mediated cytotoxicity are mainly high aspect ratio particles
like asbestos or carbon nanotubes [28]. The tubes are causing oxidative stress, which is mediated
by the tubes themselves or by impurities from the synthesis. This leads to ultimate cell death.
Crystallinity is a key factor for the toxicity of quartz (crystalline silica), which causes silicosis.
Here, a chronic inflammation is provoked by the crystals [29]. Titanium nanoparticles may present
8
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two different crystalline forms, anatase and rutile, where anatase generates ROS and rutile does
not [30].
1.4.2 Mode of toxicity for silica nanoparticles
The first studies on toxic effects of silica based material focused on crystalline silica in occupational
inhalation exposure [29]. The particles were in the size range of 500 nm up to 10 µm. The conse-
quences of inhaled crystalline silica is silicosis, a progressive fibrotic lung disease [29]. However,
the mechanism is not well understood at a cellular level. It was described, that an inflammation
process is initiated, when organisms are exposed to crystalline silica [31]. The generation of ROS is
also well documented [32]. ROS can lead to DNA damage or oxidative membrane damage. It was
shown that particle surface reactivity and the particle for (shape, size) are potentially hazardous
factors to induce crystalline silica toxicity.
Due to the high abundance of amorphous nanosilica in consumer products, toxicological research
shifted towards smaller non-crystalline SNPs. Although many factors are known to mediate cy-
totoxicity like size or different shapes, it is not yet clear, which parameter is predominantly re-
sponsible for a viability decrease SNPs [18]. Different studies have shown that a viability decrease
could be observed in a concentration dependent manner [33–35]. Smaller sizes have a stronger
influence on the viability decrease, as described earlier. A plethora of studies is available, which
mainly show that amorphous silica at smaller sizes is able to induce oxidative stress, where in turn
oxidative DNA damage is observed. However, the vast amount of studies is difficult to compare,
since particle syntheses differ (or particles were provided by an external supplier) and only one
cell line was used [18]. Mesoporous SNPs (i.e. SNPs with pores in their matrix) were mainly tested
with regard to their hemolytic properties. They showed mainly to be non-hemolytic, regardless of
their size, surface groups, and dosage [33, 36]. Furthermore, certain cell lines are less susceptible
of getting damaged in the presence of SNPs than others [18]. Zhang et al. have shown in a study
how the synthesis influences the cytotoxicity of different amorphous SNPs [37].
1.5 Choice of material
In pharmaceutical technology, silica has gained a lot of interest in solid dosage form processing,
since it is used as a flowing agent (Aerosil R©). SNPs were proposed as imaging tools, when la-
beled with a fluorophore [38]. Recently, also mesoporous SNPs have been proposed to use as i.v.
DDS [10]. Since one of the nano-mediated toxic mechanisms is the dissolution of the core material
and a subsequently high concentration of metal ions (like cadmium or silver), a core material was
chosen of which the degradation products were inherently non-toxic. In contrast to other oxide
nanoparticles, SNPs do not release toxic ions which in turn lead to locally high concentration and
therefore kill the cells. The degradation products of silica have been described to be essentially
9
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non-toxic [39]. Additionally, the synthesis is well studied and allows changing one specific pa-
rameter at the time by only slightly changing the synthesis protocol. Furthermore, the desired
material should have already application and the potential to serve as a future DDS.
Silica exhibits all these features and was hence chosen as a reference material for further nanotox-
icological experiments.
1.6 Synthesis methods for silica nanoparticles- the sol-gel route
1.6.1 Non-porous silica nanoparticles
The process of forming SNPs with the sol-gel route involves three steps. The reaction is displayed
below. In a first instance, a metal alkoxide such as tetraethylorthosciliate (TEOS) is hydrolyzed to
silanol monomers (SiOH4), as shown in step 1a. This process is catalyzed by the presence of either
an acid like HCl or a base like NH3. The next step in the reaction is the water condensation of the
silanol monomers. .
(1) Si(OC2H5)4 + H2O —> Si(OC2H5)3OH + C2H5OH Hydrolysis
(2a) Si-O-H + H-O-Si —> Si-O-Si +H2O Water condensation
(2b) Si-OC2H5 + H-O-Si —> Si-O-Si + C2H5OH Alcohol condensation
Step 2a represents the condensation between silanol groups. This condensation results in siloxane
bridges. Step 2b shows the formation of siloxane bonds from ethoxy groups and silanols. The
resultant siloxanes are the same, except the byproduct is either water (2a) or ethanol (2b). These
siloxane bridges are forming cyclic structures and then primary particles, as depicted in Figure 1.3.
Depending on the chosen catalyst, different gels are formed. Under acidic conditions, the hydrol-
ysis is faster than the condensation step (1a»2a), and a lot of smaller particles are formed which
then agglomerate into a 3D gel-network, as depicted in Figure 1.3. If a base is used as catalyst, the
hydrolysis is much slower than the condensation step (1a«2a). In contrast to the acid-catalyzed
reaction, the particles grow in size and decrease in number, since small (soluble) particles dissolve
and precipitate on larger, less soluble particles. The particle growth is called Ostwald ripening.
The first systematic study, where the influence of all reactants and the temperature was investi-
gated was published in 1968 by Stöber et al. [41]. With the now termed "Stöber" synthesis, it was
possible to obtain spherical SNPs with size ranges from 50 nm to 2 µm.
1.6.2 Mesoporous silica nanoparticles
It was in 1991, when scientists from the Mobil Oil Research first synthesized mesoporous material
with the aid of supramolecular surfactant aggregates as templates for mesopores (pore size 2-50
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Figure 1.3: Silica nanoparticles can be grown by the sol-gel process. Depending on the reaction
conditions, they grow to aggregated gels (acid-catalysis) or to monodisperse silica nanoparticles
(base-catalysis). Figure reproduced from [40].
nm [42]). When mesopores are introduced to the silica nanoparticles (SNPs), the specific surface
area dramatically increases up to 1000 m2/g (Comparison to non-porous particles: 30-200 m2/g).
Mesoporous SNPs synthesis need mainly four components: Like for the synthesis of non-porous
SNPs, a silica precursor is needed, a catalyst, solvents, and surfactant to form the pores. Surfac-
tants self-assemble into a wide range of three dimensional ordered structures and act as templates
for the mesopores. Depending on the ratio of water, organic phase and surfactant, the surfactant
forms different supramolecular structures as micelles, linear tubes, hexagonal tubes, or others.
For mesoporous SNPs, cylindrical micelles or hexagonal tubes are the most studied ones. Around
these surfactant templates, the silica matrix is grown as described in chapter 1.6.1. The surfactant
template needs to be removed carefully [43]. This is important, since most of these surfactants are
highly cytotoxic [44].
1.6.3 Removal of the template
There are two common processes for template removal [45]. The first one is calcination, where the
synthesized particles are heated up to 800 ◦C in order to burn the surfactant. However, with this
treatment the particle surface is altered, as the surface silanols are contracted and form siloxane
bonds [37]. Furthermore, the contraction of the silica network may lead to a decrease in pore size.
With heat treatment, the SNPs additionally become more hydrophobic [29].
Another possibility to remove the surfactant from the pores is solvent extraction. The extraction
procedure is strongly depending on the chosen synthesis route: where for acidic synthesis routes,
11
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water at a certain temperature (70 ◦C) is already sufficient in template removal, the basic synthe-
sis route needs ion exchange to remove the template completely [46]. Normally, this is done by
refluxing the particles in acidic ethanol solution. Another method like extraction with ammonium
nitrate during multiple washing steps can remove the template successfully as well [47]. What-
ever method is used for surfactant removal, it is crucial to check for traces in the particles. Even
small amounts can influence the toxicological profile of the mesoporous SNPs. Normally, this is
checked by infrared spectroscopy or thermogravimetric analysis.
1.6.4 Alteration of the surface
When SNPs are synthesized as described above, they exhibit several different surface groups,
mostly silanols (Si-OH) or siloxanes (Si-O-Si). The amount of silanols and siloxanes is related to
the thermal history of the particle [48]. The native silica surface can be modified with different sil-
ica precursors either by co-condensation or post-grafting. Co-condensation is a one pot approach,
where the functional group as a silane precursor is added during the particle growth. The precur-
sor is equally incorporated into the silica matrix. Opposite to this, the post-grafting approach uses
plain SNPs which were previously synthesized. Then, the desired surface group is grafted onto
the bare silica surface as a additional layer. Hence, this is a two-step synthesis.
1.7 Physico-chemical characterization
Characterization of nanoparticles prior to cytotoxicity testing is crucial [3]. Unlike small molecules,
where characterization is normally confined to chemical composition and purity, nanoparticles
require more extensive identification [49]. Several reviews published within the last years sug-
gest to characterize size and size distribution in biological relevant medium, specific surface area,
morphology, solubility, and surface charge [3, 50, 51]. This characterization ensures a better com-
parability amongst results. Even if particles were obtained from a supplier, the specifications
should be double checked. Data given by manufacturers may differ from what researchers have
measured [52].
1.7.1 Size and morphology- dry state
Size and size distribution are the utmost important parameters to be characterized, since the quan-
tum effects of nanoparticles sets in at different sizes, as described earlier. A plethora of methods
are available for size determination, however, each of the methods is limited by its principles.
The most common techniques for size determination in dry state include microscopy like trans-
mission electron microscopy (TEM), scanning electron microscopy (SEM), and AFM [1]. The ad-
vantage of microscopic approaches is that more than one parameter can be measured at the same
time: Besides size and size distribution, shape can also be directly determined. More sophisticated
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microscopes are equipped with energy-dispersive X-ray spectroscopy and can inform about the
elemental composition. Some researchers also use microscopy to get information about the state
of agglomeration; however, due to the drying process, the particles may contract, which results
in an artifact [53]. Sound results for size measurements are time-consuming, because a sufficient
number of particles per frame are required for statistical analysis. Furthermore, attention needs
to be paid to the true identity of nanoparticles in a TEM sample. This is especially demanding, if
nanoparticles are observed inside cells using TEM [54].
1.7.2 Size- dispersive state
To measure the hydrodynamic size, light scattering methods are used, where the most common
is dynamic light scattering (DLS) or in more diluted form static light scattering. DLS measures
the fluctuations of the scattering intensity in a time dependent manner. These scattering patterns
is obtained by the Brownian motion. Usually, the diameter given by DLS is bigger than the one
measured with for example TEM. DLS also measures agglomeration in different solvents, or at
various salt concentrations, and biological fluids [55]. The main drawback of DLS is that the data
is normally intensity-weighted. This means, that bigger particles scatter more light which results
in a stronger signal (106), so that few bigger particles in the suspension skew the results towards
bigger diameters. In this case, the volume distribution could be used, which does still overesti-
mate the bigger particles, but only by 103. It should always be noted if the size is measured by
intensity distribution or by volume distribution. The size distribution is given by the polydisper-
sity index (PDI) in DLS. The higher this number, the more polydisperse is a suspension. Newer
techniques include nanoparticle tracking and analysis, and field flow fractionation with induced
couple plasma mass spectrometry (ICP-MS).
1.7.3 Surface measurements
It is important to know the surface area of a nanoparticle because it represents the area that comes
in contact either with proteins in the cell culture medium or the cell membrane. Also the inner,
i.e. accessible pores may play a role in cytotoxicity, because they can guest solutes and nutrients
from the cell culture medium [56]. The method of choice to measure the specific surface area is
the nitrogen gas adsorption, since it measures simultaneously the specific surface area, the pore
volume, and the pore size distribution. The adsorption and desorption of nitrogen molecules on
the surface of particles is measured. When the layer of gas is formed, the desorption starts and the
amount of desorbed nitrogen is measured upon vaporization. This method allows also to measure
mesopores.
The forms of these mesopores can also differ, i.e. cylindrical tubes or hexagonal tubes. The method
of choice to determine the pore ordering is X-ray diffraction (XRD). XRD is used to measure the
13
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structure of a material with repeating structure elements at the angstrom level. Mesoporous ma-
terial diffract in the low angle range and their arranging can be measured with small angle X-ray
scattering.
The zeta potential gives information about the surface charge, although it is not directly the sur-
face charge that is measured. When a particle is dispersed, ions in the dispersant will immediately
adsorb firmly to the particle surface by electrostatic interaction or Van-der-Waals interactions. The
type of interaction depends on both, the particle’s surface and the solutes in the dispersant. This
firm layer is the so-called Stern layer. The next layer consists of less strongly adsorbed ions. To-
gether, these layers are termed electric double layer. When the particle is now moving, according
to an applied electric field, this double layer is moving along with it. The border between this
layer and the surrounding dispersant is called shear plane. The potential at the surface of the
shear plane is the zeta potential.
The main application of the zeta potential is an indication for colloidal stability via electrostatic
repulsion. The larger the value is, the more stable is the suspension. A value of ± 30 mV is gen-
erally considered as stable. The zeta potential is strongly depending on the surrounding medium.
Higher salt concentrations are "neutralizing" the surface charges and may lower colloidal stability
based on electrostatic repulsion. Furthermore, pH plays an important role. Hence, a zeta potential
without its quoted pH and electrolyte concentration is meaningless.
1.7.4 Other parameters
The most common physico-chemical properties can be characterized by the methods described
above. However, other characteristics like the elemental composition of a nanoparticle can be mea-
sured by different techniques with mass spectrometry (MS). In combination with TEM, energy-
dispersive X-ray spectroscopy can measure the composition of the same probe as used for dry
state size measurements.
For soluble nanoparticles, the rate of dissolution can be measured in either in vitro or in a model
fluid, like the simulated body fluid [57]. Solubility can be determined by measuring the solubi-
lized species in the supernatant of the particles, which is normally done by ICP-MS. Additionally,
colorimetric products that complex the dissolved species can also give insight into the dissolution
kinetics [58]. X-ray scattering and small angle x-ray scattering are used to determine the crystalline
or amorphous structure of nanoparticles [1, 43].
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1.8 In vitro systems and cell-based assays
1.8.1 Cell type
The underlying mechanism of cellular uptake is a key factor in understanding the biological fate
of nanoparticles. The uptake route can impact the intracellular fate of a particle. Mostly, nanopar-
ticles are endocytosed via the clathrin dependent uptake (for details see chapter 3.1). However, it
is difficult to categorize uptake and intracellular fate according to the physico-chemical properties
of a nanoparticle. Results in the literature are disparate, and the great variety of materials studied,
the different cell lines used, and other factors hamper to draw an straight forward conclusion [18].
Since the uptake and subsequent adverse effects of nanoparticles can vary from cell line to cell
line, one should consider including more than one cell line for nanotoxicological studies. Hence,
it is suggested to use one phagocytic and one non-phagocytic cell line.
1.8.2 Dosimetry
The dose in nanotoxicological studies is most often expressed by mass per volume, i.e. µg/ml.
Other metrics include mass per unit surface area of the culture dish (µg/cm2), since it is more
comparable. However, the dose administered is not necessarily the dose that reaches the cells.
The particles that have reached the cells are not necessarily taken up by the cells, as depicted
in Figure 1.4. This figure explains, that only fractions of the administered dose may reach the
Figure 1.4: Dosimetry in in vitro systems. The mass administered may differ from the mass that is
endocytosed by cells. From exposure to delivered dose to cellular dose, the mass administered is
affected by medium volume, medium and particle density, and time. Figure reproduced from [59].
cells. Depending on the mass, the density of the medium, and the density of the nanoparticles,
the number of particles reaching the cell surface may vary dramatically. Once in contact with
15
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the cellular membrane, the surface groups determine the rate of uptake into the cell (with surface
groups, hydrophilicity/hydrophobicity is included). Particles can agglomerate due to plasma
proteins and are thus no longer available for uptake (for uptake into the cells, see review in section
3.1). Nevertheless, agglomerates can still interact with the cell surface and disturb the lipid bilayer.
Teeguarden et al. thus suggested to first measure the portion of nanoparticles taken up by the
cell, and, if not applicable, use their model to estimate how many of the administered particles
will adsorb to the plasma membrane and be then internalized [59, 60]. However, the majority of
nanotoxicological studies are administering a dose as mass/volume. This dose can also easily
be converted into other doses as particles exposed per cell surface, particles surface exposed per
number of cells and others.
1.8.3 Viability
When cytotoxicity is measured, the most frequently investigated element is the viability [61]. The
viability of cell is defined by its ability to live and to develop. There are several in vitro assays mea-
suring cell viability, the most common ones use tetrazolium salts. These compounds are metaboli-
cally reduced to formazans, followed by a change in color. The product can be detected by UV/Vis
spectroscopy.
A frequently used viability assay is the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) [62]. This assay bases on the principle that a yellowish substrate is transformed by
viable cells into water insoluble violet formazan crystals. This intracellular reaction is achieved by
enzymes of the endoplasmatic reticulum. It uses reduced pyridine nucleotides like nicotinamide
adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide 2’-phosphate (NADPH),
the latter to a smaller extent. Since the violet formazan crystals are water insoluble, an additional
solution step is required prior to absorption measurement. Recently, newer variants of the MTT
reagent have come to the market, where this dissolving step is not necessary anymore. How-
ever, they are reacting in the extracellular space and involve other mechanisms compared to the
MTT [63].
Other viability assays include lactate dehydrogenase (LDH), an enzyme that is released into the
cell culture medium upon membrane leakiness [64]. This assay measures necrosis. A possibility to
distinguish the mechanism of cell death (apoptosis versus necrosis) is the annexin V/propidium
iodide (PI) assay [65]. Annexin V is a protein that detects phosphatidyl serine (PS) on the mem-
brane. PS in healthy cells is only present on the inner leaflet of the plamsa membrane and therefore
not accessible to annexin V [66]. In the presence of calcium, fluorescently labeled annexin V binds
to PS and can be detected. The annexin a5 protein binds to apoptotic cells in a calcium-dependent
manner using PS-containing membrane surfaces that are usually present only on the inner leaflet
of the membrane. PI, a dye which intercalates with the DNA needs to be used in parallel. Due to
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the necrotic process, the plamsa membrane leaks and annexin V can bind to the PS in the inner
leaflet, resulting in apoptosis. Hence, PI needs to be used in parallel, because it exclusively stains
necrotic cells.
1.8.4 Oxidative stress
ROS include oxygen ions, superoxide anion, hydroxyl radicals, and peroxygens. They are present
in the cell as side products of the aerobic metabolism [67]. However, the overproduction of ROS
is directly linked with oxidative stress inside the cell. Above a certain threshold, the antioxidant
defense of the cell cannot compete any longer, and the resulting imbalance induces oxidative dam-
age in the cells [68].
Oxidative species are highly reactive due to the presence of an unpaired electron. A variety
of oxidative species have different reactivity with the hydroxyl radical being the most reactive
one, followed by the superoxide anion radical and hydrogen peroxide. These intermediates ex-
ist for different times, with hydrogen peroxide as a rather stable molecule compared to the other
ones [69]. Among the most common oxidative stress assay is the dichloro-dihydro-fluorescein
diacetate (DCFH-DA) assay. The non-polar DCFH-DA passively enters the cell where it first gets
deacetylated by intracellular esterases to 2’,7’-dichlorofluorescin (DCFH) and later on oxidized by
reactive species to the fluorescent 2’,7’-dichlorofluorescein (DCF). DCF can be measured spectro-
scopically [68]. However, the terms oxidative stress, ROS and reactive nitrogen species (RNS) are
often not specified. Moreover, assays may claim to measure "total" ROS, but a majority of them
is in fact not measuring the superoxide anion [68]. The proposed mechanism to cause adverse
effects in presence of nanoparticles is oxidative stress [70–72].
1.8.5 Genotoxicity and inflammation
Inflammatory processes can be detected via enzyme-linked immunosorbent assays (ELISA). These
markers are specifically detected in the supernatant of the cells by antibodies [73]. Among the
most common markers tested with nanoparticles are the chemokine interleukin-8 (IL-8) followed
by TNF-α, and IL-6 [74]. When testing nanoparticles with regard to their inflammatory potential,
it is crucial to test, if the nanoparticles are endotoxin-free. Here, the Limulus amebocyte lysate
(LAL) test is frequently used to detect endotoxins [75]. An alternative for the LAL assay is the
macrophage activation test [76].
Nanoparticles can enter the nucleus of a cell via pores or by penetrating the nucleus membrane.
Hence, they can interact with the DNA and may exert adverse effects there. Genotoxicity of
nanoparticles is frequently tested by the following assays: comet assay [77], the micronucleus as-
say, the chromosome aberrations test [78], and the bacterial reverse mutation assay (AMES) [74].
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In the comet assay cells are embedded in agarose on a microscope slide. Then, they are treated
with detergent and high salt to "isolate" the DNA. If DNA breaks are present, relaxed loops of the
DNA are extending during electrophoresis. The resulting comet-tail can be visualized by fluores-
cence microscopy. The intensity of the tail is indicative for breaks in the DNA [74].
1.8.6 Hemolysis
Red blood cells (RBC) are important cells in our body since they deliver oxygen to organs and
cells. RBC do not possess a nucleus when mature and also lack organelles resulting in more
space to increase the capacity of oxygen transportation [79]. Hence, they also do not possess an
endocytotic uptake machinery, which renders them attractive to study unspecific (i.e. non-energy
dependent) uptake or membrane interaction. The majority of the plasma membrane (outer leaflet)
of RBC consists of phosphatidylcholine, sphingomyelin, and cholesterol. Hemolysis is character-
ized as the rupture of RBC. Thereby, the erythrocytes release their contents to the surrounding
fluid. The resulting loss of erythrocytes leads to anemia, which is associated with more serious
blood conditions [80]. In vitro hemolysis is assessed by exposing erythrocytes to the nanoparticles.
After an incubation time, undamaged cells are separated by centrifugation from the supernatant.
Oxyhemoglobin present in the supernatant can be detected spectroscopically.
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Chapter 2
Aim of the thesis
As described in the introduction, three main factors are important in nanotoxicology, as depicted
in Figure 2.1. Chemistry, physico-chemical properties and biological systems are in constant in-
terplay with each other in nanotoxicology. The titles in the dotted boxes below the three key
points represent the publications in the corresponding section written during this thesis. Chem-
Figure 2.1: Pillars of nanotoxicology. Three main components were studied during this thesis,
namely chemicals that mitigate acute toxicity and can be transformed into nanoparticles, which
lead to a delayed and cumulative toxicity. Here, the physico-chemical properties were studied and
connected to the interaction with biological systems. The dashed boxes name the publications in
the respective fields.
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ical properties are important if the particle solubility is high. As described earlier, released ions
from nanoparticles can mitigate toxicity. In this thesis, the knowledge from nanotoxicology was
transferred in joint-projects with small-molecules toxicologists. Physico-chemical properties of
particles play the key role when studying the interaction of nanoparticles with the environment.
In one publication, the physico-chemical properties were connected with the outcome of three
cytotoxicity assays. The hemolytic potential of some SNPs were investigated in more depth and
drafted as a manuscript. In a third publication, a new DDS was tested with respect to its cyototxi-
city.
The chosen biological system plays a key role in nanotoxicology. Different cell lines are capable
of taking up nanoparticles via various uptake mechanisms. Depending on the cell line, the extent
of uptake is also connected to size and surface charge. A review was written and addressed the
questions of nanoparticulate uptake into the cell and in vivo biodistribution. The arrows in Figure
2.1 show the connection between the three pillars.
Up to date, nanotoxicological studies suffer from proper material characterization, essential inter-
ference controls for common cytotoxicity assays, and mechanistic approaches to explain the mode
of toxicity. This thesis hence addresses the following points:
• Synthesis of silica nanoparticles. The in-house synthesis has the main advantage that all chem-
icals used during the synthesis are known and their removal can be monitored. The surfac-
tant was removed by extraction in order to maintain the silanols on the surface. The SNPs
were further modified to create different sizes (80 nm and 250 nm), specific surface areas
(<100 m2/g and >1000 m2/g), and different surface charges (negatively charged, neutrally
charged, and positively charged). Throughout this thesis, co-condensation was employed to
alter the surface of the SNPs.
• Physico-chemical characterization. The synthesized SNPs were characterized regarding their
size, specific surface area, porosity, surface charge, and residues from the synthesis. The
colloidal stability and redispersibility were studied in different biological relevant media.
• Cell-based assays. The SNPs were tested regarding their viability and oxidative stress. Nanopar-
ticles can interfere with cytotoxicity assays in three different ways. For each assay, these in-
terferences were tested carefully to avoid over- or underestimation of the results. Both tests
were performed in a phagocytic cell line and a non-phagocytic cell line to reflect cell-specific
differences. Furthermore, the hemolytic potential of the SNPs was assessed.
• Mechanistic approach. With different biophysical methods such as isothermal titration calorime-
try (ITC) or solid state nuclear magnetic resonance, the underlying mechanism of hemolytic
20
SNPs was investigated in depth.
• Transferring knowledge. Knowledge gained from cell-based assays with nanoparticles was
used to further test safety of small molecules in different projects.
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Abstract: Improved understanding of interactions between nanoparticles and biological 
systems is needed to develop safety standards and to design new generations of nanomaterials. 
This article reviews the molecular mechanisms of cellular uptake of engineered nanoparticles, 
their intracellular fate, and their distribution within an organism. We have reviewed the avail-
able literature on the uptake and disposition of engineered nanoparticles. Special emphasis 
was placed on the analysis of experimental systems and their limitations with respect to their 
usefulness to predict the in vivo situation. The available literature confirms the need to study 
particle characteristics in an environment that simulates the situation encountered in biological 
systems. Phenomena such as protein binding and opsonization are of prime importance since 
they may have a strong impact on cellular internalization, biodistribution, and immunogenicity 
of nanoparticles in vitro and in vivo. Extrapolation from in vitro results to the in vivo situation in 
the whole organism remains a challenge. However, improved understanding of physicochemical 
properties of engineered nanoparticles and their influence on biological systems facilitates the 
design of nanomaterials that are safe, well tolerated, and suitable for diagnostic or therapeutic 
use in humans.
Keywords: biodistribution, cellular transport, cellular uptake, endocytosis, engineered nano-
materials, nanosafety
Introduction
Engineered nanomaterials (ENMs) are defined as materials composed of particles 
in an unbound state, or as an aggregate or agglomerate with one or more external 
dimensions in the size range from 1 nm to 100 nm.1 Since active cellular uptake and 
tissue translocation of ENMs have been described for particles larger than 100 nm,2,3 
we included literature reports on ENMs up to a size of 300 nm. There are many 
examples of clinical uses of ENMs. The majority of ENMs used as therapeutics on 
the market and in late clinical studies have diameters above 100 nm.4 Small particles 
with a size of less than 2 nm show passive uptake into erythrocytes.27 However, uptake 
mechanisms of such very small particles will not be discussed in this review. Due to 
their small size, ENMs have unique properties (ie, optical, thermal, catalytic, and 
biological) compared to larger particles.5,6 During the last two decades, ENMs with 
tailored physicochemical properties have emerged in different fields of our daily life. 
They are used for a variety of applications, such as color pigments, solar cells, and 
waste water treatment. Furthermore, ENMs are found in consumer products that may 
be in contact with the human organism, eg, food packaging, shampoos, sunscreens, 
and toothpastes. Thus, regulatory agencies are faced with new materials for which no 
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nano-specific safety standards have been established. More-
over, products containing ENMs are often not declared since 
formal requirements are lacking.5 The ingredients of ENMs 
tend to be listed as chemicals or micronized substances, and 
information about the ENMs’ content in the product may 
be missing. Little is known on how ENMs interact with the 
environment, including animals and human beings.7 When 
used in a physiological environment, ENMs are faced with 
biological fluids, phospholipid membranes, clearing mecha-
nisms, and harsh intracellular conditions. Due to their distinct 
physicochemical properties, ENMs interact in a different way 
with living cells as compared to dissolved molecules. It is a 
challenge to predict the mechanism of uptake in relation to 
one specific physicochemical property. Figure 1 highlights 
the differences between ENMs and small molecules with 
regard to their physical and chemical properties, cellular 
uptake mechanisms, intracellular fate, and toxic effects.
Small molecules are defined as compounds with a 
molecular weight of less than 1,000 Da. It is generally 
believed that lipophilic molecules below this threshold are 
able to penetrate cell membranes by passive diffusion. They 
have the potential to be taken up actively as well as passively 
by cells and to overcome cellular barriers within the body 
including the blood–brain barrier.8,9 In contrast, ENMs and 
macromolecules are mostly unable to diffuse passively into 
a living cell. They are colloidally dispersed and therefore 
require an active transport process for their uptake by target 
cells.10,11 Furthermore, ENMs are characterized by a high 
surface area to volume ratio as well as different geometries 
and surface characteristics. Particles of the same material 
can differ in shape, size, and porosity; whereas a molecule 
is a well-defined system.12 The state of dispersion and the 
variable size and shape of ENMs induces different uptake 
mechanisms for the same material.
The present review focuses on interactions of ENMs 
with biological systems on a cellular level (ie, mechanisms 
of cellular uptake and intracellular accumulation) and on the 
level of the whole organism (ie, circulation, distribution, and 
elimination). These interactions are a function of the intrinsic 
physicochemical properties of ENMs. An additional factor 
is protein binding. Protein adsorption onto the surface of an 
ENM leads to the formation of a protein corona and changes 
properties such as size or surface charge dramatically.13–15 
We reviewed published experimental procedures since the 
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Figure 1 Interactions of cells with small molecules and nanoparticles.
Notes: Schematic representation of a eukaryotic cell and its interaction with nanoparticles (left part of picture) and small molecules (right part of picture). Interactions with 
nanoparticles are preceded by active cellular uptake leading to intracellular accumulation. Acute effects induced by small molecules are a consequence of both active and 
passive cell membrane permeation. endocytosis leads to uptake of particles into endosomes (eN) and lysosomes (LY), followed by lysosomal degradation. endosomal escape 
may lead to accumulation of particles in the cytoplasm or within mitochondria (Mito).
Abbreviations: eN, endosomes; LY, lysosomes; Mito, mitochondria; P-gp, P-glycoprotein.
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handling of ENMs is often a challenge, leading to statistical 
variability and artifacts.
General considerations
The state of dispersion of ENMs depends on their surface 
properties and the medium composition. Uptake stud-
ies should be performed with nonagglomerated ENMs. 
Agglomeration occurs by material interaction (ie, associa-
tion of ENMs into clusters) or material-protein interaction. 
The resulting agglomerates sediment according to Stoke’s 
law. The rate of agglomeration should be studied prior to 
in vitro uptake studies in the correspondent medium, for 
example, with dynamic light scattering (DLS). However, 
when complex biological media are involved (as in vivo), 
DLS is unsuited for studying agglomeration kinetics since 
blood components may interfere, fluorescence single particle-
tracking (fSPT) may be an alternative method to be used 
under these conditions.16
Since the majority of ENM uptake studies use fluo-
rescence as a tracking signal, it is crucial to minimize dye 
leakage from the ENM.10 Approaches to test dye leakage 
are centrifugation, sodiumdodecyl sulfate polyacrylamide 
gel electrophoresis (PAGE), or fluorescence correlation 
spectroscopy (FCS).17–19 Special care should be taken when 
choosing an appropriate dye since lipophilic dyes may parti-
tion from the particulate structure into the lipid membranes 
of the cell. To circumvent dye leakage, intrinsic fluorescence 
of nanoparticles is an attractive alternative, as has been 
described for gold.20,21
To study the entry route of a specific ENM, physical 
and pharmacological blockers may be used. All methods 
used to induce a physical or pharmacological block of 
uptake pathways have certain limitations. Most pharmaco-
logical inhibitors are not specific and may influence alter-
native internalization routes and the actin cytoskeleton.22 
 Pharmacological inhibitors interfere with vital cell functions 
and are therefore intrinsically toxic. Experiments have to be 
designed to prevent toxic effects, such as the complete dis-
ruption of all actin-dependent processes by actin-interfering 
agents. Moreover, compensatory routes of uptake may be 
activated in target cells upon inhibition of specific trans-
port pathways. Finally, it should be taken into account that 
different cell lines have different uptake strategies. This 
impedes extrapolation of experimental results from one cell 
line to another. A recent review by Iversen et al summarizes 
the pharmacological blocking strategies and highlights the 
pitfalls of these reagents.23 It should be mentioned that 
genetically modified cells offer an interesting alternative to 
pharmacological intervention.24
The influence of plasma protein 
binding on opsonization
The properties of ENMs have the potential to modulate bio-
logical interactions between particles and target cells by dif-
ferent molecular mechanisms.6,25 Adsorption of biomolecules 
to surfaces influences the interactions at the nano-bio inter-
face.26–28 In this way, bound proteins and biomolecules form a 
dynamic protein corona shaping the biological identity of the 
ENM. The composition of the protein corona varies over time 
due to continuous protein association and dissociation.29,30 
Surface properties of ENMs will influence the composition 
of the protein corona. Hydrophobic ENMs easily adsorb 
proteins whereas hydrophilic ones are less prone to protein 
binding.31 Therefore, hydrophobic ENMs agglomerate readily 
and interact with other hydrophobic residues of proteins or 
peptides (eg, blood or membrane proteins), thus promoting 
internalization.30 Equally, positively charged ENMs adsorb 
different sets of proteins on their surface than negatively 
charged ones, elucidating distinct cellular interactions.32 
This influences the mode of cell entry, biodistribution, and 
biocompatibility of ENMs. Interestingly, ENMs with iden-
tical chemical composition but different size may attract 
different proteins, thereby giving rise to different biological 
identities.33 An ENM in blood will have a different biological 
identity than the same ENM in body fluid and is therefore 
processed differently. The protein corona, in turn, modifies 
certain properties of the original ENM, such as surface charge 
and size. For example, highly positively charged nanopar-
ticles with a positive zeta-potential may change their apparent 
charge to negative in cell-culture medium.34 These factors 
should be carefully considered when using ENMs as drug 
delivery devices, as the targeting ability of functionalized 
ENMs may be shielded by adsorbed proteins.35
Cellular uptake of nanoparticles
The phospholipid membrane of cells regulates the transport 
of molecules into the cells, thereby representing a univer-
sal barrier protecting fragile intracellular structures from 
extracellular materials (Figure 2). To enter the cell, polar or 
charged biomolecules, such as amino acids, nucleosides, or 
glucose, require active transport systems involving proteins 
or ion channels. Many macromolecules are actively taken 
up by cells via endocytosis, which is a vesicular transport 
mechanism.36,37 Because ENMs may exist in the size range 
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of proteins, eg, the hydrodynamic radius of an IgG antibody 
is close to 5 nm,38 they are able to interact with the cel-
lular machinery in a similar way to macromolecules.10,25,26 
Experimental studies revealed that most ENMs are actively 
incorporated into the cell via different endocytic pathways 
(Figure 2) comprising phagocytosis (“cell-eating”) and 
pinocytosis (“cell-drinking”). The latter pathway can be 
divided into clathrin-mediated endocytosis (CME), caveolae-
mediated endocytosis (CvME), and alternative routes.39,40 
The resulting transport vesicles differ with respect to the 
composition of the protein coat of the engulfed vesicle, 
size of the detached vesicle, and fate of the ingested cargo. 
ENMs have the potential to access cells by all entry portals 
depending on their size, shape, chemical composition, and 
surface modification. As stated above, it remains a challenge 
to correlate a given ENM property with an uptake route. In 
the following, we discuss the main cellular entry routes (ie, 
phagocytosis and pinocytosis) to establish a tentative link 
between nanoscale characteristics of ENMs and specific 
mechanisms of cellular uptake.
Phagocytosis
Phagocytosis is performed predominantly by specialized 
cells of the immune system (ie, macrophages, monocytes, 
neutrophils, and dendritic cells), to remove particles larger 
than 500 nm from the organism, mainly through the mode 
of a receptor-mediated process (Figure 2).41,42 Particles are 
recognized by small proteins (opsonins) including immu-
noglobulins type G or M, complement fragments (C3, C5), 
or blood serum proteins such as fibronectin and laminin.43 
This process promotes the specific binding of protein-
coated particles to internalizing receptors on the cell plasma 
membrane, ie, Fc receptors of the immunoglobulin superfam-
ily or complement receptors.41 Other receptors involved in 
the uptake of ENMs are the mannose/fucose receptor44,45 as 
well as the scavenger receptor,46 where the involvement of 
the latter one may depend on the cell line used. The receptor-
ligand interaction triggers a signal cascade in the target cell 
resulting in actin assembly and formation of a cell surface 
extension that zippers around the particle, engulfing it in an 
intracellular vesicle with a diameter of approximately 0.5 to 
1 µm.42 These vesicles, or phagosomes, mature by several 
fission and fusion events with late endosomes and lysosomes, 
resulting in the formation of phagolysosomes. Internalized 
particles are subsequently degraded, and the receptors are 
cycled back to the cell surface. The rate of these successive 
events depends greatly on the ingested particle and typically 
lasts from 30 minutes to several hours.47 Although phago-
cytosis is generally thought to be involved in the uptake of 
larger particles, ie, particles sized .500 nm, recent reports 
document the phagocytic uptake of considerably smaller 
particles.48–50 The phagocytic uptake route seems to be rather 
unspecific since it depends on opsonization. ENMs taken up 
as agglomerate tend to be less easily degraded by the host 
as they can be detected in macrophages for several months, 
thus bearing a risk of long-term toxicity.51,52
Pinocytosis
Small particles ranging from a few nanometers to several 
hundred nanometers are generally taken up by pinocytosis 
(ie, fluid-phase uptake) occurring in almost all cell types 
(Figure 2). There are four modes of pinocytosis, ie, macropi-
nocytosis, adsorptive and receptor-mediated endocytosis, and 
alternative routes of uptake.36 With macropinocytosis, large 
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Figure 2 Known pathways of cellular uptake of nanoparticles.
Notes: Uptake of nanoparticles by eukaryotic cells is an active process. endocytotic pathways include phagocytosis, and pinocytosis.
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amounts of external fluid are taken up nonspecifically. ENMs 
located near the plasma membrane are thereby coincidentally 
internalized. During adsorptive pinocytosis, ENMs interact 
in a nonspecific manner with generic complementary bind-
ing sites on the cell surface. In contrast to macropinocytosis 
and adsorptive pinocytosis, RME is highly specific since it 
depends on the interaction between a ligand (eg, insulin or 
transferrin) and its complementary receptor on the surface 
of a target cell. RME is mediated predominantly either via 
the clathrin pathway or the caveolin pathway, depending 
on the specific nanoparticle-receptor interaction.23,53 Thus, 
several distinct pinocytic entry portals exist, depending on 
the type of interaction with the plasma membrane, size of 
incorporated vesicles, and type of proteins involved, eg, 
clathrin, caveolin, or receptors.36 Thereby, the size of endo-
cytic vesicles of approximately 60 nm (caveolae) and 120 nm 
(clathrin-coated vesicles) imposes limitations with respect to 
the maximum size of ENMs entering these pathways. Differ-
ent mechanisms of pinocytic uptake into cells are discussed 
in more detail below.
Macropinocytosis
During macropinocytosis, ENMs with a size of .1 µm are 
taken up nonspecifically. This process is stimulated, for 
example, by growth factors interacting with receptor tyrosine 
kinases.54 Activation of the signaling cascade results in the 
formation of actin-driven circular membrane protrusions that 
collapse onto the membrane and fuse with it. This gener-
ates uncoated endocytic vesicles with a size of 1 µm. These 
macropinosomes are of irregular shape and are handled by 
the endosomal/lysosomal route.36 Macropinocytosis contrib-
utes to the internalization of larger ENMs, albeit in a rather 
unspecific manner and often in conjunction with other entry 
mechanism.11,55 The capacity of this uptake pathway for 
ENMs is very high, suggesting a possibility for pharmaceu-
tical delivery.56
Clathrin-mediated endocytosis
CME is considered to be the “classical” and best charac-
terized route of cellular entry.37 In polarized cells such 
as endothelial or epithelial cells, transport is initialized 
at the apical membrane domain.36,57 ENMs with a size of 
120–150 nm are internalized within clathrin-coated vesicles 
entering the endosomal/lysosomal trafficking route.58,59 
The upper size limit reported for particles entering the cell 
via this pathway is 200 nm.55 CME is either adsorptive14 
or receptor-mediated.60 Cationic particles or proteins bind 
nonspecifically to the negatively charged cell surface.61–63 
This triggers adsorptive CME. In contrast, the receptor-
mediated process is highly selective and specific. Receptor 
ligands being internalized by this pathway include low-
density lipoprotein (LDL), transferrin, growth factors, and 
insulin.14
Caveolin-mediated endocytosis
CvME is the most prominent clathrin-independent uptake 
mechanism. This pathway is most pronounced in endothe-
lial cells on the basolateral side, where it is an important 
uptake route for ENMs.36,64 The caveola is a small, flask-like 
structure, with a diameter of about 50–80 nm that is coated 
with caveolin-1.65 These vesicles invaginate with the help 
of dynamin from hydrophobic membrane domains, which 
are rich in cholesterol and glycosphingolipids.66 Caveolae 
are stable plasma membrane-associated structures.67,68 
However, they can be induced to bud off by interaction with 
pathogens such as SV40 virus,69 cholera toxin subunit B, or 
Shiga toxin.70 With respect to ENMs, small particles seem 
to be transported more efficiently. For example, uptake of 
nanoparticles of 20 and 40 nm in size was demonstrated 
to be 5–10 times faster than that of nanoparticles sized 
100 nm.64,71 Larger particles (.500 nm) appear to be taken 
up only in exceptional cases.55 However, it is possible that 
ENM associating with the membrane may cover enough 
surface and colocalize by chance with certain markers like 
the caveolar marker. This does not mean that the uptake is 
actively dependent on caveolae.
The intracellular trafficking routes of caveolae are dis-
cussed controversially. While nonacidic, nondigestive path-
ways are favored, an additional link between caveolae and 
lysosomal routes for degradation cannot be excluded.65,70,72 In 
addition, the so-called caveosomes (previously supposed to 
represent a special type of caveolar endosome) were shown 
to be an artifact created by overexpression of caveolin or 
caveolin mutants.73 Pathogens escape from normal degrada-
tion in lysosomes and are directly transported to the Golgi 
and/or endoplasmic reticulum.74 Thus, pathogens and ENMs 
can bypass lysosomal degradation.75
Alternative routes of uptake
More recently, several endocytic routes that do not fit into 
the categories described above have emerged. Many of them 
are clathrin- and caveolin-independent. These routes depend 
on specific regulation by proteins such as Ras homolog 
family member A, ADP-ribosylation factor 6, or the cell 
division control protein 42 homolog, Cdc42.37,68 Although 
these mechanisms are still poorly understood, available data 
CHAPTER 3. PUBLISHED AND SUBMITTED RESULTS
28
International Journal of Nanomedicine 2013:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3260
Kettiger et al
suggest that particles larger than 100 nm are internalized 
via these routes.66
Characteristics of ENMs  
influencing cellular uptake
The size of ENMs is not the only criterion that predicts 
the mechanism of ENM uptake. Nonetheless, trends based 
on particle size exist and are summarized in Figure 2. 
Nanoparticles with a diameter of 50 nm are more efficiently 
internalized by cells than smaller (about 15–30 nm) or 
larger (about 70–240 nm) particles.58,76 Nanoparticles with 
a diameter of 30–50 nm efficiently recruit and interact with 
membrane receptors and are subsequently taken up by 
receptor-mediated endocytosis.77
Besides size, ENM shape is an important factor.  Spherical 
ENMs are taken up much faster and more efficiently than 
rod-shaped ENMs, presumably due to the longer mem-
brane wrapping time required for the longer rod-shaped 
particles.78,79 This notion is supported by in vivo experi-
ments in rodents, where intravenous (IV)-injected elongated 
polymer micelles (filomicelles) remained in the circulation 
10 times longer than spherical ENMs.80 However, contro-
versial findings were obtained using different materials. For 
example, Gratton et al71 investigated hydrogel particle uptake 
into HeLa cells. The highest internalization rate was found 
for particles with an aspect ratio of three. ENMs seemed to 
use all internalization routes simultaneously.72 Recent find-
ings suggest that silica rods with an aspect ratio of 2.1 to 
2.5 are taken up to a higher extent into HeLa cells than their 
spherical counterparts. In addition, uptake of rods with higher 
aspect ratios was marginal.81 Tissue macrophages struggle to 
incorporate long and rigid fibers into phagosomes, thereby 
releasing harmful oxygen radicals and hydrolytic enzymes, 
causing chronic inflammation.82 Similarly, the needle-like 
structure of carbon nanotubes may penetrate biological mem-
branes, inflicting mechanical damage. These controversial 
results suggest that additional factors promote cellular uptake 
besides ENM size and shape.
Surface functionalities (eg, surface charge and functional 
groups) mediate interactions between ENMs and the cell 
surface. Positively charged particles interact strongly with 
the slightly anionic plasma membrane. They are taken up 
more readily83 or may disrupt plasma membrane integrity.84 
Positively charged ENMs are taken up via adsorptive medi-
ated pinocytosis, whereas negatively charged ENMs use 
alternative uptake routes.85 Nonionic particles tend not to 
interact with the cell membrane, as demonstrated for the 
polymer polyethylene glycol (PEG).86 Nanoparticles can be 
functionalized with a plethora of ligands such as antibodies, 
peptides, or sugars. Their density, spatial distribution, and 
molecular weight plays an important role in determining 
the fate of ENMs in biological systems.87 In addition, the 
chain length of chemical linkers like PEG, which are used 
to attach ligands to the surface of nanoparticles, may affect 
delivery to target cells.88
Finally, specific cell types may interact with identical 
ENMs differently.23,89 It has been shown, for example, that 
macropinocytosis or phagocytosis is absent in brain capillary 
endothelial cells.8 Red blood cells are known to be incapable 
of endocytosis. Furthermore, recent studies revealed an 
influence of the cell cycle phase on the cell’s capacity to 
take up ENMs.90
Intracellular fate  
and endosomal escape
Once ENMs have been taken up by target cells, they are 
directed to the endosomal/lysosomal pathway in most 
instances. The intracellular vesicles either gradually mature 
(acidify) to late endosomes through multiple fission and 
fusion events, or they are recycled back to the cellular surface 
as trafficking endosomes (Figure 1).91 ENMs entrapped in 
late endosomes are likely to proceed to lysosomes where 
they are degraded. These compartments harbor proteases, 
hydrolases, and other enzymes promoting ENM degrada-
tion.92 However, some ENMs (in particular positively charged, 
basic nanoparticles) are capable of escaping the endosome. 
This phenomenon has previously been described as the 
“proton sponge effect”.25,93 Osmotic swelling of the organelles 
leads to their rupture, as shown in the case of polyethylene 
imine.93,94 To implement drug delivery strategies, endosomal/
lysosomal escape can be induced actively. pH-sensitive 
fusiogenic liposomes, for example, contain synthetic sterols 
and phospholipids, which undergo phase transition upon 
protonation at low pH. This results in the conversion of the 
hexagonal to lamellar structure of the liposomal membrane, 
thus disrupting the endosomal/lysosomal membrane.95–97 
Similar effects can be induced using pH-sensitive fusiogenic 
peptides (eg, amphiphilic peptides with repetitive GALA 
sequences) in combination with cationic liposomes.98 Other 
ENMs (eg, certain types of carbon nanotubes) penetrate the 
vesicle (or cell) membrane directly and enter the cytosol.99 
Once in the cytosol, ENMs may induce the production of 
reactive oxygen species and inflict oxidative stress.100 In 
addition, potentially toxic interactions with other cellular 
organelles, such as mitochondria and the cell nucleus, may 
occur.2 Effects that may be harmful for a healthy cell are 
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desired in tumor cells, where an endosomal escape is needed 
to deliver a specific nanoparticulate drug to its intracellular 
compartment of action.
Methods to determine  
nanoparticle uptake
Widely used methods to study cellular uptake of ENMs 
are flow cytometry and microscopy. While flow cytometry 
allows for an efficient, fast, and quantitative assessment of 
particle uptake, microscopy provides qualitative insight into 
the subcellular localization of particles by analyzing small 
sample volumes. Flow cytometry as a quantitative approach 
to measure uptake cannot distinguish between externally 
attached and fully internalized ENM. Interaction with the cell 
surface can be studied experimentally if cellular uptake is 
inhibited. For example, endocytotic pathways can be blocked 
using pharmacological inhibitors.22,101 Alternatively, cells can 
be incubated at lowered temperatures to interrupt endocytic 
processing of particles. Temperatures around 20°C prevent 
progression of particles from early to late endosomes.102 
Further temperature lowering to 4°C, for example, blocks all 
energy-dependent processes.103 Consequently, signals from 
fluorescent ENMs located at the surface of cells or within 
specific intracellular vesicles or organelles can, for example, 
be detected quantitatively by flow cytometry or qualitatively 
by confocal scanning laser microscopy.104,105 Intracellular 
localization of particles can be further confirmed using the 
quenching agent, trypan blue. This dye quenches signals 
from fluorescent dyes such as fluorescein isothiocyanate. 
Since trypan blue does not penetrate the membrane, only 
extracellular signals of free or surface-bound dye molecules 
are quenched.106
Another quantitative approach is induced coupled plasma 
mass spectroscopy (ICP-MS). ICP-MS is a powerful tool for 
intracellular quantification of electron-dense materials and 
is a sensitive (ie, nanogram range) method for detecting ele-
ments with the exception of H, C, O, N, F, S, and inert gases. 
Due to this limitation, “soft” nanoparticles, such as liposomes, 
polymers, or dendrimers, are not detected. Additionally, 
ICP-MS is not able to distinguish between dissolved ions and 
nanoparticles. However, loading nanoparticles with a heavy 
metal may make the use of ICP-MS possible in such cases, 
as long as the physicochemical properties of the particles are 
not changed by the loading procedure.107
Alternatively, confocal microscopy provides information 
on the three-dimensional structure of objects. Fluorescence 
colocalization studies give insight into intracellular traffick-
ing after fixation of cells or by live-cell imaging. The latter 
technique relies on highly photostable fluorophores but 
avoids artifacts introduced by fixation reagents such as 
paraformaldehyde.108 Subcellular fractionation can give 
additional insight into partitioning of ENMs inside the 
cell. Transmission electron microscopy is used to confirm 
subcellular particle localization with high resolution. This 
method allows quantitative assessments, but the procedure 
is time-consuming.109,110
It is advisable to use transmission electron microscopy 
in combination with energy-dispersive X-ray spectroscopy 
(EDX) to conf irm the presence of nanoparticles.111 
 Brandenberger et al studied intracellular particle distribution 
using quantum dots as reference material.112 In this study, 
EDX was used to confirm the identity of quantum dots based 
on X-ray emission spectra of the elements Cd and S. This 
method seems to be particularly useful for identifying very 
small (5–10 nm) particles.113
The biological fate of ENMs
In previous sections, we discussed interactions of ENMs 
with biological systems on a cellular level. This section 
focuses on in vivo kinetic properties of ENMs, addressing 
processes related to circulation, distribution, degradation, 
and excretion. There are different routes of administra-
tion including pulmonal,114 dermal,115,116 oral,117,118 and IV 
routes.119 However, this review will focus only on the IV route 
in healthy subjects. Figure 3 illustrates technical hurdles, 
challenges, and the different steps taken by ENMs before 
and during interaction with the living organism.
Circulation of eNMs
The state of dispersion in both the injected solution and 
the blood stream has to be defined, since agglomerates or 
precipitated material in the syringe may lead to dose vari-
ability (Figure 3A). Advanced pharmaceutical technologies 
are needed to stabilize nanosuspensions during storage and 
administration.120 Size is an important parameter regard-
ing circulation and distribution within the organism. In the 
blood stream, agglomerates may cause embolism with a 
potentially fatal outcome. Agglomerated particles have a 
tendency to accumulate after IV administration within the 
lung since venous blood is directed from the right heart 
ventricle to this organ. In vivo studies in the rat using 
polystyrene particles demonstrated passive accumulation in 
the lung for particles with a size exceeding a threshold of 
10 µm.121 Thus, findings of lung targeting of ENMs may be 
indicative of “accidental” trapping of agglomerates.122 As 
mentioned above, phagocytosis of ENMs is an additional 
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factor  limiting prolonged circulation of particles bigger than 
0.5 µm ( Figure 2). On the other hand, small ENMs (,5 nm 
to 10 nm) are cleared by kidney glomerular filtration.123,124
Opsonization and immunologic responses
When injected into the blood stream, foreign materials 
encounter different blood constituents such as red blood 
cells, white blood cells, platelets, and a variety of proteins. 
ENMs are known to interact with both proteins26 and cells.125 
Protein binding and opsonization are processes that change 
the surface properties of ENMs (Figure 3B). ENMs used for 
imaging or as a drug delivery system should be assessed with 
regard to their potential to cause hemolysis, thrombocyte 
aggregation, and complement activation.47,126 Hemolysis has 
been described for rigid materials such as silica nanopar-
ticles127 or for soft nanoparticles such as liposomes.128 Due 
to protein binding, these measurements should be done in 
presence of plasma proteins.129
Protein coating of an ENM is a highly dynamic process, 
starting immediately upon IV injection.130 The resulting pro-
tein corona is complex and varies depending on the size,13 
hydrophobicity/surface charge,30 and shape131 of the particles. 
In the first instance, readily available proteins such as albumin 
are adsorbed onto the ENM surface, but may be replaced 
by other proteins (eg, lipoproteins or opsonins) over time, 
depending on the surface structure of the ENMs. Prediction 
of the extent of protein binding to ENM remains a challenge. 
Recent findings indicate that uncharged ENMs are opsonized 
more slowly than charged ENMs. The size of ENMs influ-
ences the binding of opsonins to spherical particles. Due to 
the higher curvature, smaller ENMs (,20 nm) will attract 
fewer opsonins than bigger ENMs (.200 nm). This explains 
why agglomerates are cleared by the mononuclear phagocytic 
system (MPS) more easily. The same is true for hydrophobic 
ENMs.132 Recent studies revealed a strong shape dependency 
in relation with MPS recognition. Duan and Li133 stated that 
an ellipsoidal ENM can be attacked by a macrophage in 
two different ways: when the macrophage attaches to the 
pointed end, the ENM will be internalized; however, when it 
attaches on the flat surface of the ellipsoid, it just spreads on 
the ENM and prolongs its circulation. This observation is in 
agreement with the findings of Arnida et al who found that 
gold nanorods were less recognized by the MPS compared 
to their spherical counterparts.134
The question arises as to how ENMs can be designed to 
specifically adsorb certain proteins or avoid their adsorption. 
The best known strategy to diminish protein adsorption is 
by masking the particle surface with PEG. This hydrophilic, 
biocompatible, and nontoxic polymer is used to minimize 
interactions of macromolecules, eg, cytokines135 and nano-
particles, ie, liposomal carriers101 with phagocytic cells of 
the immune system. The protective properties of PEG as 
a function of PEG chain length and PEG surface density 
were reviewed by Li and Huang.136 Nevertheless, PEG is not 
able to fully prevent protein adsorption or opsonization. For 
example, for 5 nm gold nanoparticles, the protective effect 
of PEG diminishes within hours.137 In addition, PEG may 
elicit an immunological response resulting in an accelerated 
blood clearance of ENMs. It has been observed that repeat-
edly injected PEGylated liposomal formulations are mark-
edly less efficacious, probably because of anti-PEG antibody 
formation.138 As an alternative to PEGylation, ENMs can be 
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Figure 3 experimental challenges and hurdles.
Notes: Specific physicochemical properties of eNMs may lead to technical challenges and artifacts in experimental systems. Particle agglomeration (A) reduces dosing 
accuracy or may lead to embolism after Iv injection. Plasma-protein binding and opsonization of nanoparticles (B) may trigger a humoral immune response. Interaction of 
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coated with amino acids such as lysine or cysteine. Such a 
mixed-charge monolayer-coating prevented protein adsorp-
tion in fetal bovine serum to 5 nm gold nanoparticles.139 In 
summary, a hydrophilic coating (eg, PEG) and a neutral 
charge (expressed as the zeta potential in the correspondent 
medium) can minimize particle recognition by the immune 
system. Targeting strategies are often implemented using 
PEG-coated ENMs with surface ligands (such as folic acid, 
cell adhesion molecules, or transferrin42) in order to enhance 
cellular uptake into target tissues and to avoid exposure of 
healthy cells. By this approach, it is crucial to maintain the 
stealth properties of the PEG, despite the bound ligands, to 
avoid interactions with cells of the immune system.101
Distribution
ENMs are distributed throughout the body via the blood 
stream and extravasate this transport system according to 
their size. Extravasation of ENMs is restricted to specific 
tissues since the presence of tight junctions prevents ENMs 
larger than 2 nm to leave the circulation.140 The fenestrations 
of blood vessels vary from organ to organ and can have dif-
ferent ranges in different species.140 Moreover, the state of 
disease is changing the fenestration size,141 with typical size 
for tumors ranging from 200–780 nm in mice.142 ENMs with 
sizes ranging from 150–300 nm are mainly found in the liver 
and spleen, whereas smaller counterparts extravasate into 
the bone marrow. ENMs are cleared from the circulation in 
different organs. As depicted in Figure 3C, they are often 
trapped in the liver and spleen as these organs host the larg-
est concentration of tissue resident macrophages (ie, MPS 
cells such as hepatic Kupffer cells). Glomerular filtration 
eliminates ENMs with a hydrodynamic diameter of ,5 nm 
to 10 nm. Nonetheless, the relationship between the physico-
chemical properties and pharmacokinetic behavior of ENMs 
is poorly understood. Interpretation of experimental data is 
difficult since a plethora of different materials, excipients, 
and animal species are used. However, trends were identified 
for selected materials such as gold nanoparticles of differ-
ent sizes and surface characteristics.143,144 Increased liver 
accumulation was found for particles with a size of $5 nm 
as compared to particles with a size of 1.4 nm. Particle size-
dependent accumulation was found in no other organ than 
the liver. However, elevated levels of charged (positive and 
negative) gold nanoparticles were found in the spleen. In 
another study, PEG-coated gold nanoparticles with a size 
of 20–80 nm were investigated.145 The length of the PEG 
chains was 2,000–5,000 Da. PEGylated gold nanoparticles 
were not recognized by macrophages. The PEG-5,000 coated 
gold particles with a size of 20 nm accumulated in solid 
tumors of experimental animals to an extent of 6.5% of the 
injected dose. Most of the remaining particles accumulated 
in other organs, mainly liver and spleen. Xie et al investi-
gated the influence of the size of silica nanoparticles on their 
biodistribution.146 After 30 days, they found silica particles 
trapped in the lungs, liver, and spleen and observed signs of 
liver injury. Compared to small silica particles (20 nm), larger 
particles (80 nm) were cleared faster from the body. A recent 
study investigated the difference in biodistribution of solid 
silica nanoparticles, mesoporous silica nanoparticles, and 
rod-shaped silica nanoparticles.147 All particle types had a 
positively charged surface and showed extensive distribution 
to liver and spleen. Thus, most particles were recognized and 
eliminated by phagocytic macrophages. Porous particles with 
an aspect ratio of eight preferentially accumulated in the lung, 
whereas the nonporous particles were less prevalent in the 
lung. Amine modified silica nanoparticles reduced the affin-
ity to lungs and kidneys. Silica nanoparticles were degraded 
and excreted via the hepatobiliary and renal routes. It has 
been reported that elongated fibers such as filomicelles80 
or gold nanorods134 display a longer circulation time since 
they are able to align with the blood flow. Compared to their 
spherical counterparts, rods are less preferentially taken up 
by macrophages, which reduce accumulation in MPS organs 
like the liver and spleen. Furthermore, gold nanorods had a 
higher accumulation in tumor tissue compared to spherical 
gold nanoparticles.134
ENMs can be designed in a way to promote or avoid 
interactions with specific tissues or organs. The topic of active 
drug targeting was recently reviewed by Moghimi et al.148 
With such targeting strategies, ENMs can be designed and 
used for diagnostic imaging purposes or to deliver drugs to 
diseased tissues such as solid tumors (Figure 3D). The passive 
accumulation in the tumor is due to the enhanced perme-
ability and retention effect, which is present in some tumors 
and dictates the maximum size for ENMs to extravasate into 
tumor tissue. This phenomenon is discussed in more detail 
by Jain.149
Degradation and excretion
The term “metabolism” as defined in classical pharmacoki-
netics is not suitable for ENMs. In this section, the term 
“degradation” will be used instead to collectively cover 
multiple processes such as erosion, deagglomeration, disin-
tegration, dissolution, or chemical degradation of particles. 
Available excretion and degradation studies solely included 
single administration of ENMs at a certain concentration. 
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Accumulation effects after multiple dosing and bioaccu-
mulation have only been studied in zebra fish.150 Chemical 
reactivity and composition of the shell and core materials 
play an important role in degradation. ENMs known to 
“safely” degrade are porous silica nanoparticles20 and iron 
oxide particles.151 Degradation of silica nanoparticles leads 
to the formation of silicic acid, which is excreted via feces 
and urine.152 Due to the high specific surface area of the 
mesoporous material, hydrolysis of the silica network is a 
fast process.153 Metal oxides including iron oxides are trans-
formed by metallothionein that is abundantly expressed in 
liver and kidney.154 Levy et al used two different methods 
to trace biodegradation of super paramagnetic iron oxide 
nanoparticles (SPIONs).155 Upon degradation, these iron 
species lose their paramagnetic behavior and are trans-
formed to ferritin. Thus, intact particles can be identified 
and traced due to their magnetic properties. However, deg-
radation is a slow process. After two months, paramagnetic 
iron was still present in macrophages. Over prolonged 
time, the storage form of iron (ie, nonparamagnetic spe-
cies) was more prevalent. The authors hypothesized that 
degradation of SPIONs took place in the acidic lysosomal 
 compartment. It remains to be elucidated if these mecha-
nisms of degradation might apply to other nanomaterials 
including other metal oxide materials with poor solubil-
ity. ENMs, like polymeric particles, have been shown to 
degrade by hydrolysis or enzymatic digestion in vitro.156 
Similar effects were observed in vivo.157
Materials with poor solubility may remain in the organism 
over several weeks to months. When considering the use of a 
specific ENM as a drug delivery tool, its biodegradation and 
excretion pathways have to be known. Upon multiple dos-
ing, ENMs may accumulate in MPS organs and cause severe 
damage. For example, Ye et al have studied long-term effects 
of quantum dots containing Cd-Se in rhesus monkeys.158 In 
vivo, acute toxicity of theses nanoparticles was very low. 
However, chemical analysis after 90 days revealed that more 
than 90% of the injected Cd dose remained in the animals’ 
organs. In view of the limited availability of data, much more 
work needs to be done in the field of nanosafety.
Conclusion
ENMs have emerged in different fields of our daily life. 
However, their interaction with biological systems and their 
biological fate remain incompletely understood. It is there-
fore important to elucidate molecular mechanisms involved 
in cellular binding, uptake, and processing of ENMs. This 
knowledge is needed to design novel pharmaceutical appli-
cations for ENMs such as, for example, drug delivery and 
drug targeting strategies. By the same token, optimized ENM 
design may help to avoid unwanted interactions and toxicity, 
thereby making human use of novel materials possible.
Molecule
Particle
Cell
Organ/organism
Particle size
Agglomeration
Active transport
Physico-chemical properties
Protein binding
Absorption
Immune response
Tissue distribution
Metabolism
Excretion
Particle shape
Particle surface
In vivo
In vitro
< complex biological system
< cellular biology
< physical chemistry
<  chemistry
Figure 4 extrapolation from in vitro data to the in vivo situation.
Notes: In vitro experimental systems can be used to characterize nanoparticles with respect to their chemical composition and physicochemical properties. Cell-culture-
based experimental systems can be used to study molecular mechanisms of cellular uptake and intracellular processing of particles. However, additional information is needed 
to address questions related to the in vivo behavior of nanomaterials and their interaction with complex biological systems. In particular, the prediction of pharmacokinetic 
parameters remains a challenge.
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The interaction of ENMs with complex biological sys-
tems, such as the human body, is still poorly understood. In 
vitro characterization of ENMs may help to obtain a mecha-
nistic insight into their behavior in a biological environment 
(Figure 4). This includes information on chemical proper-
ties and reactivity as well as particle dynamics in biological 
fluids. Studies have shown that protein binding may alter the 
properties of ENM surfaces influencing cellular binding and 
uptake. Interactions with the immune system depend on ENM 
size, geometry, and surface charge. However, this information 
cannot be easily extrapolated to any given cell line or even 
to another ENM with the same surface properties but differ-
ent core materials. We propose to combine in vitro systems 
with ex vivo models such as lung models,159 cell coculture 
systems, chicken egg models harboring xenografted tumors,50 
and placenta models.3 These tools will be instrumental when 
designing nanomaterials with favorable pharmacokinetic 
properties and low intrinsic toxicity.160 In any case, ENMs 
should be designed to be biocompatible and biodegradable to 
prevent their accumulation in the human body and limit their 
long-term toxic effects upon chronic exposure. Combining 
this knowledge about ENMs with smart drug delivery and 
drug targeting strategies will lead to innovative diagnostic 
and therapeutic applications.
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 Abstract 
Purpose: Silica nanoparticles (SNPs) are increasingly used as drug delivery systems (DDS) and for 
biomedical imaging. Therapeutic and diagnostic agents can be incorporated into the silica matrix to improve 
the stability and dissolution of drug substances in biological systems. However, the safety of SNPs as drug 
carriers remains controversial. To date, no validated and accepted nano-specific tests exist to predict the 
potentially harmful impact of these materials on the human body. 
Methods: We systematically synthesized 12 different types of SNPs with varying size, surface topology 
(porous vs non-porous), and surface modifications. We characterized these particles in terms of dry state 
and hydrodynamic diameter, specific surface area, and net surface charge (zeta potential). For cellular 
studies, we exposed non-phagocytic (HepG2) cells, phagocytic (THP-1) cells, and erythrocytes to SNPs. 
Cellular uptake and stability of fluorescently labeled SNPs were analyzed by confocal microscopy and flow 
cytometry. 
Results: SNPs with a porous surface and negative net surface charge had the strongest impact on cell 
viability. This is in contrast to non-porous SNPs. None of the studied particles induced oxidative stress in 
either cell lines. Particles with a negative surface charge induced hemolysis in a concentration-dependent 
manner. 
Conclusions: Our study revealed potential hazards of spherical amorphous SNPs. Physico-chemical 
properties mediating toxicity in living cells were identified. We propose that our standardized SNPs may 
serve as a readily available reference material for nanotoxicological investigations. 
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 Introduction 
During the past years, interest in the use of silica nanoparticles (SNPs) has increased. Such nanoparticles 
have been traditionally used as filler, desiccant, thickener for liquid dosage forms, or anticaking agent in 
powders. An example of such materials is fumed or pyrogenic silica which was introduced in 1942 under the 
brand name of Aerosil®. Recently, amorphous SNPs were proposed to be used as drug delivery systems 
(DDS) (Rosenholm et al., 2009; Wu et al., 2011) or imaging probes (Ow et al., 2004). Hence, humans are 
increasingly exposed to SNPs.  
For DDS, different routes of administration have been proposed, namely oral intake as a suspension or 
tablet (Ensign et al., 2012), transdermal delivery (Escobar-Chavez et al., 2012), or inhalation (Bailey and 
Berkland, 2009). In all cases, the DDS has to cross cellular barriers, such as the inner surface of the 
gastrointestinal tract, before reaching its target. When administered intravenously, the nanoscaled DDS is 
distributed throughout the body, thus raising the question whether these materials are safe and well tolerated 
in humans (Kettiger et al., 2013; Wu et al., 2011). Nanoparticles can enter the cell via various energy-
dependent routes and are able to penetrate the nucleus (dos Santos et al., 2011; Tao et al., 2009). Tight cell 
layers, such as the blood-brain barrier, can be crossed by small-sized SNPs in vivo (Barandeh et al., 2012).  
Several in vitro toxicity studies have been carried out to assess the toxicity of different nanoparticles. 
Frequently used endpoints include cell viability, membrane leakage, generation of reactive oxygen species 
(ROS), and genotoxicity (Kroll et al., 2011). It is generally assumed that smaller nanoparticles are more toxic 
than bigger particles (Sohaebuddin et al., 2010). Shape and crystalline state additionally affect the toxicity 
profile. Frequently cited examples are “the fiber paradigm” for carbon nanotubes (Donaldson et al., 2010) or 
silicosis for crystalline silica (Byrne and Baugh, 2008). The large specific surface area may enhance solubility 
and release of metal ions, as was described for copper oxide or silver nanoparticles (Nel et al., 2006). 
Additionally, plasma proteins, nutrients, or growth factors can adsorb to this surface and lead to an indirect 
loss of cell viability (Casey et al., 2008). 
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 For SNPs, there are different synthetic routes available. Sol-gel synthesis results in exposed silanol groups 
on the particle surface, whereas fumed silica is characterized by the presence of siloxane groups on the 
surface (Figure 1). It is commonly believed that silanols remain intact when the SNPs are dried under 
vacuum at ambient temperature. Siloxane formation on the particle’s surface is observed under vacuum at 
temperatures above 100 °C (Zhuravlev, 2000). The synthesis route influences biological outcomes like 
oxidative stress generation and hemolysis. This may partially explain the heterogeneous data available on 
SNPs toxicity (Zhang et al., 2012). Furthermore, results may vary among different cell lines and experimental 
conditions depending on the presence or absence of serum. Serum addition resulted in lower toxic potential 
of nanoparticles (Ge et al., 2011).  
 
Figure 1: Schematic representation of an amorphous silica surface. 
Suppliers of commercially available SNPs do not necessarily disclose their protocols for the synthesis of 
nanoparticles. Consequently, information on surface properties of commercial nanoparticles is hardly 
available. This is a major concern since the strategy used for the synthesis and preparation of nanoparticles 
can also influence their surface properties and hence their interaction with cells. Additionally, it has been 
reported that particle information provided by a commercial supplier should always be double-checked 
(Sayes et al., 2007). 
The aim of this study was to avoid this uncertainty by using in house synthesized SNPs. Hence, we have 
synthesized 12 types of SNPs and altered their physico-chemical properties step by step. The SNPs vary in 
their size, surface charge, and porosity. We related the physico-chemical properties of different SNPs with 
the outcome of cytotoxicity, generation of oxidative stress, and hemolysis. In contrast to commercial SNPs, 
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 our particles have a known thermal history and were characterized carefully. Furthermore, special controls 
for each assay were added to avoid over- or underestimation of the results.  
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 Materials and methods 
Materials 
Absolute ethanol (EtOH), tetraethylorthosilicate (TEOS, 98%), (3-aminopropyl)triethoxysilane (APTES), 
thiazolyl blue tetrazolium bromide (MTT), fluorescein isothiocyanate isomer 1, 2’,7’-dichlorofluorescin 
diacetate (FITC), hexadecyltrimethylammonium bromide (CTAB), ethylene glycol (EG), dichloro-dihydro-
fluorescein diacetate (DCFH-DA), and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma-
Aldrich (Buchs, Switzerland). Ammonium hydroxide solution (30 wt. %) was obtained from Roth (Arlesheim, 
Switzerland).  
Synthesis of non-porous silica nanoparticles 
In accordance with Stöber et al., we prepared non-porous SNPs of two different sizes (non-porous small 
SNPs (SS) and non-porous big SNPs (SB)) (Stoeber et al., 1968). In brief, reaction solution for the small 
SNPs had a molar composition of 1 TEOS: 0.087 NH3: 64.3 EtOH: 27.8 H2O and for the big ones 1 TEOS: 
0.35 NH3: 64.3 EtOH: 27.8 H2O. Alteration of net surface charge was carried out by direct incorporation of 
amine groups by co-condensation of an aminosilane ((3-aminopropyl)triethoxysilane, APTES) by altering the 
amount of APTES relative to TEOS (2.5 mol %, 5 mol %,10 mol %). This resulted in SNPs with a negative  
(-), a neutral (0), and a positive (+) surface charge. The mixture was stirred under ambient conditions for 3 h 
(SS) and 4 h (SB). The SNPs were collected by centrifugation, washed three times with EtOH, and dried 
overnight in a vacuum oven at ambient temperature.  
Fluorescent particles (SB(-)) were needed for cellular uptake studies. Fluorescent dye was introduced into 
the synthesis as described elsewhere (Karaman et al., 2012). Briefly, an excess of FITC was added to pre-
conjugate with APTES in ethanol solution and was stirred for 2 h under argon. This mixture was then 
introduced into the synthesis of the SB(-) as described above. 
Synthesis of mesoporous silica nanoparticles 
Mesoporous SNPs were synthesized as described above, albeit with certain modifications (Karaman et al., 
2012). In brief, an ethanol basic aqueous reaction solution was prepared and structure directing agent CTAB 
was added. Subsequently, TEOS was added as silica source. Briefly, the prepared reaction solution 
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 contained the reagents with the molar composition 1 TEOS: 0.12 CTAB: 946 H2O:73 EtOH: 0.32 NaOH. 
After mixing the reagents, the reaction mixture was stirred overnight at room temperature. In order to modify 
particle surfaces to obtain different net surface charges, APTES was introduced as above. For these 
synthesis solutions, molar composition was 1 TEOS: 0.04 APTES: 0.12 CTAB: 946 H2O:73 EtOH: 0.32 
NaOH and 1 TEOS: 0.1 APTES: 0.12 CTAB: 946 H2O:73 EtOH: 0.32 NaOH. For mesoporous small SNPs 
(MS), a modified synthesis protocol was used (Gu et al., 2007). The synthesis solution for MS consisted of a 
molar ratio of 1 TEOS: 0.45 CTAB: 12.9 NH3:1392 H2O:74.7 EG. The synthesis solution was subjected to 
vigorous stirring for 2 h at 50 °C, and then kept under static conditions at 50 °C overnight. In the same 
manner as for MB, APTES was added to the reaction mixture to obtain different net surface charges of 
SNPs. The resulting particles were collected by centrifugation and washed at least three times with 50 mL 
extraction solution (ethanol ammonium nitrate solution) to completely remove the CTAB template (Han et al., 
2011). FITC was introduced into the synthesis of MB(-) as described above. 
Suspension stability of silica nanoparticles 
For size determination of the SNPs, we used two approaches. Dynamic light scattering (DLS) was used to 
measure the hydrodynamic diameter of SNPs in suspensions in two solutions, namely 10 mM HEPES (pH 
7.2) and cell medium. The polydispersity index (PDI) indicated the size distribution. Secondly, we measured 
the dry diameter of all SNPs by transmission electron microscopy (TEM). With TEM, we were additionally 
able to assess the porosity of the SNPs. The TEM samples were previously negative-stained and then 
observed under a Philips CM100, operating in the bright field mode at 80 kV. In order to confirm the success 
of surface charge altering by incorporating APTES, ζ- potential measurements were performed in ethanol. 
Additionally, ζ- potential measurements were carried out in 10 mM HEPES buffer and cell medium to mimic 
the SNPs behavior as suspension in cell experiments. The amount of APTES incorporated was determined 
by thermo-gravimetric analysis (TGA), as seen in supplementary information (Figure S1). The structural 
parameters related to the surface of SNPs (i.e. specific surface area) were determined by nitrogen sorption 
measurements (ASAP 2020; Micromeritics Instrument Corp., Norcross, GA, USA) using the Brunauer-
Emmet-Teller (BET) method.  
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 Cell culture 
Dulbecco’s modified Eagle medium (DMEM) was supplemented with 1x HEPES buffer, 10% FCS, 1% 
penicillin-streptomycin (P/S), and 1% non-essential amino acids (denoted as cell medium). All products used 
for medium preparation were purchased from Sigma-Aldrich, except FCS that was obtained from Amimed 
(Bioconcept, Switzerland). HepG2 cells were kindly provided by Prof. Dr. Dietrich von Schweinitz (University 
Hospital Basel, Switzerland) and were maintained in DMEM comp. THP-1 cells (ATCC, TIB-202) were 
maintained in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% FCS, 1% P/S, 10 
mM HEPES, 1% sodium pyruvate, and 0.05 mM mercaptoethanol. Freshly drawn sheep blood from the 
slaughterhouse Basel was collected in Vacutainer® tubes coated with potassium ethylenediaminetetraacetic 
acid (K2EDTA) and was used within 4 h after collection. 
Viability 
HepG2 cells were seeded at a density of 1.5 x 104 cells per well in a 96-well plate and allowed to attach for 
24 h at 37 °C. THP-1 cells were seeded at a density of 4 x 104 cells and were differentiated by 100 nM PMA 
over 72 h. The SNPs suspensions were prepared by ultrasonication for 30 min in 10 mM HEPES at 2.5 
mg/mL. Then, the stocks were diluted with cell medium at different concentrations (10, 50, 100, and 
250 μg/mL) and added to the cells. After exposure of cells for 24 h, 48 h, and 72 h, the medium was 
removed, 100 μL of MTT solution (0.5 mg/mL) was added to each well, and the cells were incubated for 
another 2 h at 37° C. The resulting formazan crystals were solubilized with 100 μL of acidified isopropyl 
alcohol and 20 µL of 3% SDS (Seeland et al., 2013). The absorption was read at a wavelength of 560 nm, 
and unspecific signals at 670 nm were subtracted (Spectramax M2 plate reader, Molecular Devices, 
Sunnyvale, CA). Cytotoxicity was expressed as the percentage of cell viability, where untreated cells were 
set to be 100% viable. A commercially available kit with a water-soluble formazan salt (CellTiter 96® 
AQueous One Solution Cell Proliferation Assay, MTS) was obtained from Promega (Dübendorf, Switzerland) 
and used according to the manufacturer’s instructions.  
Oxidative stress 
Induction of oxidative stress was determined using DCFH-DA. HepG2 cells were seeded at a density of 
5 x 104 cells per well in a black 96-well plate with a clear bottom and were allowed to attach for 24 h. THP-1 
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 cells were seeded and differentiated as described above, using black plates with clear bottom. Phenol red 
free cell culture medium was used. Prior to exposing SNPs, cell medium was removed and 50 μM of DCFH-
DA in protein-free medium was added to each well for 1 h. After washing the cells twice with phosphate-
buffered saline (PBS), the particle suspensions in cell medium (10, 50, 100, and 250 μg/mL) were added to 
the cells. Fluorescence signals were measured through the bottom of the cell culture plates at an excitation 
wavelength of 485 nm and an emission wavelength of 528 nm (Spectramax M2 plate reader) after 1 h, 4 h, 
and 24 h of exposure. A commercially available total ROS detection kit (Enzo, Lausen, Switzerland) was 
used according to the manufacturer’s instructions.  
Hemolysis 
Hemolysis was tested as previously described (Yu et al., 2011). Briefly, a 4 mL sample of blood was mixed 
with 8 mL PBS. The red blood cells (RBCs) were collected by centrifugation at 4500 rpm for 5 min and 
washed five times with sterile PBS. Purified RBCs were diluted in 40 mL PBS. Then, 0.2 mL of RBCs was 
mixed with 0.8 mL of SNP suspensions. Two concentrations (25 μg/mL and 250 μg/mL) were tested for each 
particle type. The RBC-SNP suspensions were left at room temperature for 4 h. After centrifugation, 
absorbance of the supernatant was measured at 577 nm (oxyhemoglobin). Unspecific signals at 655 nm 
were subtracted. The results are given as the percentage of hemolysis compared to a positive control (MilliQ 
water). 
Interference of nanoparticles with test systems 
For each assay, optical, catalytic, and adsorptive interference was tested. Optical and catalytic interference 
were tested as described elsewhere (Kroll et al., 2012). Catalytic interference of the DCFH-DA assay was 
assessed by prior de-acetylation of the reporter as described in the literature (Kroll et al., 2012; Napierska et 
al., 2012). Adsorptive interference was tested by incubating the SNPs with the reporter and subsequent 
centrifugation. Then, optical density or fluorescence of the supernatant was measured to determine the 
fraction of bound reporter to the particles.  
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 Uptake and degradation of silica nanoparticles 
Representative uptake into HepG2 and THP-1 cells was determined for two fluorescently labeled SNP types, 
namely the non-porous SB(-) and the mesoporous MB(-). We chose MB(-) due to the results in the MTT, and 
the SB(-) as a “non-toxic” control with the same physico-chemical characteristics except the porosity. Cells 
were cultured at 50% confluence on poly-d-lysine-coated glass slides and left for attachment for 24 h. Then, 
SNPs were incubated at 50 µg/mL, and uptake was determined after 1 h, 8 h, and 24 h. The nuclei were 
stained with Hoechst 33342 for 5 min at the end of the uptake experiment. Actin staining was performed 
after cell fixation with rhodamine phalloidin. The samples were embedded in Prolong Gold antifade agent 
(Gibco) and sealed with nail polisher. After 24 h, uptake was qualitatively visualized with confocal 
microscopy (Olympus FV-1000, Tokyo, Japan) using a 60x PlanApo N oil immersion objective. The images 
were further processed by GIMP 2.8 software (GNU image manipulation program). For live-cell imaging, we 
proceeded in the same way; the cells were maintained in the chamber with 5% CO2 and at 37° C for 2 h to 
monitor the disintegration of the SNPs. Additionally, we determined the amount of free silicon with the blue 
silicomolybdic acid assay as reported earlier (Coradin et al., 2004). For quantitative uptake, we measured 
the green fluorescence shift relative to the control (non-treated cells) in a time-dependent manner (FACS 
Canto II). For each experiment, 10,000 viable cells were counted. To quench extracellular fluorescence, cell 
suspensions were diluted with one volume of 0.4% trypan blue in buffer (Vranic et al., 2013).  
Statistical analysis 
Each experiment was performed in triplicate and repeated three times (MTT, DCFH-DA, and hemolysis). 
Statistical significance was determined by using one-way analysis of variance (ANOVA), followed by Tukey’s 
post-hoc test. Differences were considered significant at p < 0.05. 
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 Results 
Characterization of silica nanoparticles 
Systematic material characterization of SNPs is crucial (Krug and Wick, 2011). We therefore decided to 
synthesize and characterize silica particles used in the present study in our laboratory and not to rely on 
commercially available nanomaterials. In this study, the sol-gel method was used to prepare SNPs with 
different characteristics.  
Table 1: Physico-chemical properties of SNPs. Particle size was determined by transmission electron 
microscopy (TEM) and dynamic light scattering (DLS) in HEPES buffer in presence or absence of 10% 
serum. The different types of SNPs used in the present study are named as follows: First prefix “S” = non-
porous, “M” = mesoporous. Second prefix “S” = small particle size and “B” = big particle size. “–“ = negative 
ζ-potential in 10 mM HEPES buffer. “0” = net neutral ζ-potential in 10 mM HEPES. “+” = positive ζ-potential. 
PDI: polydispersity index determined by DLS. BET: Brunauer Emmett Teller (as determined by nitrogen 
sorption). nd: not determined. 
 
Size (nm) 
______________________________________ 
Surface 
_______________________ 
Name TEM HEPES (PDI) 10% serum (PDI) ζ-potential (mV) BET (m2/g) 
SS(-) 105 135.6 (0.12) 160.9 (0.017) -18 35 
SS(0) 110 506.8 (0.25) 164.5 (0.19) -7 nd 
SS(+) 100 166.5 (0.14) 194.6 (0.20) 21 nd 
SB(-) 250 369 (0.08) 327.6 (0.30) -23 18 
SB(0) 230 399 (0.06) 411.1 (0.25) 8 nd 
SB(+) 235 359.7 (0.13) 226.2 (0.16) 23 nd 
MS(-) 80 196.6 (0.16) 243.2 (0.21) -24 1380 
MS(0) 85 agglomerate agglomerate -3 nd 
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 MS(+) 80 1400 (0.41) 270.9 (0.19) 22 nd 
MB(-) 200 287.1 (0.1) 301.4 (0.28) -29 1223 
MB(0) 220 1780.6 (0.22) 337.6 (0.28) -11 nd 
MB(+) 250 433 (0.09) 484.4 (0.38) 32 nd 
 
Table 1 provides an overview of the physico-chemical characteristics and indicates the abbreviations for 
each SNP type. There, the first letter represents solid (S) or mesoporous (M) SNP, the second one denoted 
the size (S for small and B for big), while the value in brackets represented the zeta potential in 10 mM 
HEPES. For example, MB(-) stands for mesoporous, big, negatively charged SNPs. We have chosen a size 
of 100 nm for the small SNPs and about 250 nm for the big SNPs, since these sizes are common for drug 
delivery systems. Particle size distribution of the SNP suspensions was evaluated by hydrodynamic size 
measurements in cell medium. According to the results obtained, colloidal particle suspensions with low 
poly-dispersity index values were obtained for all non-porous SNPs (SS and SB series) and the mesoporous 
large SNPs (MB) series, whereas no measurable hydrodynamic diameter results were obtained for the MS 
suspensions. For instance, the MS(0) sample with net neutral surface charge value both in HEPES buffer 
and cell medium resulted in agglomeration and subsequent sedimentation of the particles, which prevented 
DLS measurements. Figure 2 shows the dry-state diameter of representative SNPs and gives insight into the 
porous structure by TEM. The specific surface area measurements additionally revealed the porous 
structure of the mesoporous series, with a pore size of about 3 nm. These results were confirmed by small 
angle X-ray scattering (data not shown). Furthermore, BET measurements revealed specific surface areas 
below 35 m2/g for non-porous SNPs, while for mesoporous SNPs, the value was above 1200 m2/g. The 
ζ-potential of the SNPs varied between negative (approx. -25 mV) and positive (approx. +30 mV) values (10 
mM HEPES buffer), which confirmed the success of the surface modification. For particles with sufficiently 
high absolute ζ-potential values, suspension stability is maintained chiefly by electrostatic repulsion. 
However, particles with a ζ-potential close to zero millivolts (neutral net surface charge) tend to agglomerate 
in buffer due to the absence of strong repulsive forces between the particles. However, even if the 
3.2. SAFETY OF SILICA NANOPARTICLES
51
 electrostatic repulsion is low, particles can be suspended and stabilized with the aid of supplemented serum 
proteins, which are present in the cell medium to maintain cell viability. These proteins adsorb rapidly onto 
the nanoparticle’s surface and create a so-called protein corona (Meißner et al., 2009). In our case, this 
corona prevented the agglomeration of SNPs with a net neutral charge. In addition, the successful APTES 
incorporation into the silica network was confirmed by TGA (Figure S1). As residual surfactant may cause 
cytotoxicity, we confirmed the removal of the template by FTIR (Figure S2).  
 
Figure 2: Representative TEM (A-D) and SEM (E, F) images of SNP: A: SS(-); B: MS(-); C: SB(-); D: MB(-); 
E: SEM of SS(-); F: SEM of SB(-). Scale bar: always 200 nm. 
Cell viability 
We evaluated the loss of cell viability upon exposure of HepG2 cells and THP-1 cells to SNPs for 24 h, 48 h, 
and 72 h. SNP concentrations ranged from 10 µg/mL to 250 µg/mL. Figure 3 shows the viability of HepG2 
cells and THP-1 cells after 24 h. The left diagram (HepG2) shows that most SNPs did not induce a severe 
viability decrease at any concentrations tested. The strongest effect was occurring for the big mesoporous 
series, regardless of their surface charge. A slight time-dependent effect was observed in both cell lines 
(data not shown). In addition, the higher SNP concentrations had a more pronounced impact, especially for 
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 bigger SNPs. Smaller SNPs also led to a cell viability decrease that was more marked after 72 h (data not 
shown).  
 
Figure 3: Cell viability. Viability percentages are ranked and indicated by a corresponding color. The rank 
sum summarizes the level of cytotoxicity for each particle type. Bottom: Exemplary results from MTT assay 
over 24 h. Left side: HepG2 cells; right side: THP-1 cells. Data are means of three independent experiments 
with triplicate for each sample. Significance (*) was tested with one-way ANOVA and Tukey’s post-hoc test 
(p<0.05). 
THP-1 cells seemed to be more sensitive towards SNPs, especially at higher concentrations. In both cell 
lines, MB(-) caused the highest viability decrease at 250 µg/mL. In THP-1 cells, this could be prevented 
when functionalizing the surface with primary amines. In contrary, HepG2 cells showed no change in the 
viability pattern when the surface charge was altered. In turn, a positive ζ-potential of solid big SNPs led to a 
more pronounced decrease of HepG2 cell viability. No viability decrease was shown for any MS samples. 
This may be attributed to the smaller size and prior dissolution of these SNPs (see below).  
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 Oxidative stress and Hemolysis 
We used the well-established DCFH-DA assay to determine oxidative stress induced by SNPs. After 1 h, 
4 h, and 24 h, no elevated fluorescence signal was detected for any of the SNPs compared to the control 
(data not shown), indicating that there was no oxidative stress under the test conditions. However, the 
DCFH-DA assay only detects certain oxidative species and does not capture superoxide anion or hydrogen 
(Halliwell and Whiteman, 2004). We therefore aimed to confirm our results with a commercially available 
total ROS detection kit, with special emphasis placed on the superoxide anion. No oxidative stress was 
found (data not shown). 
 
Figure 4: Concentration-dependent hemolysis of sheep erythrocytes in the presence of (-) SNPs. Data are 
mean ±SD of three individual experiments with triplicates for each sample. Positively and neutrally charged 
SNPs did not cause any significant hemolysis (< 5%). 
To further test if membrane interaction could lead to cytotoxicity, we performed the hemolysis assay. Indeed, 
all negatively charged SNPs showed hemolytic behavior in a concentration-dependent manner, except  
MS(-). The SS(-) showed hemolysis to a higher degree than their bigger counterparts (Figure 4). 
Interference 
For all assays, negligible adsorptive, catalytic, or optical interference was found. Previously, exocytosis of 
the water insoluble formazan crystals in the MTT assay lead to an overestimation of viability loss (Fisichella 
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 et al., 2009). To confirm our MTT results, we also measured cellular viability with the MTS assay which uses 
a water-soluble indicator as opposed to the poorly water-soluble formazan. Our results showed no difference 
in cellular viability in the MTT and MTS assays. 
Uptake into HepG2 and THP-1 cells 
Both cell lines showed a time-dependent uptake of SNPs, whereas THP-1 cells internalized SNPs to a larger 
extent (Figure 5). These results were consistent with the confocal microscopy images. In Figure 5 C-F, the 
confocal images show a time-dependent uptake of SB(-) and MB(-) into THP-1 cells.  
 
Figure 5: Quantitative and qualitative uptake of MB(-) and SB(-) into THP-1 cells. A, B: Flow cytometry 
results from time-dependent uptake in THP-1 cells. A: Uptake of MB(-) after 2 h (dashed) and 24 h (heavy 
line). Normal line = negative control. B: Uptake of SB- after 2 h (dashed) and 24 h (heavy line). Normal line = 
negative control. C-F: Representative confocal images of time-dependent uptake. Blue: nuclei, red: 
cytoskeleton, green: MB-. C: 0 h; D: 2 h; E: 7 h, F: 24 h. Scale bar: 40 µm. 
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 The uptake shift of the fluorescently labelled non-porous particles was stronger than the one of the 
mesoporous particles due to more rapid dissolution of porous silica particles, in this case MB(-). This 
dissolution was confirmed with live-cell imaging and the blue silicomolybdic assay (Figure 6A).  
 
Figure 6: Degradation of mesoporous SNPs. A: Degradation data from blue silicomolybdic assay. Non-filled 
squares: MB(+); filled squares: MB(-). B-D: Representative qualitative live-cell experiments in HepG2. A: 
SB(-) in HepG2 after 15 min; B: SB(-) in HepG2 after 3 h; C: MB(-) in HepG2 after 15 min; D: MB(-) in 
HepG2 after 3 h. Scale bar is 40 µm (applies to all). Nuclei are shown in blue, cytoskeleton in red and SNPs 
in green.  
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 Discussion 
We assessed the physico-chemical properties of 12 SNPs with varying size, surface charge, and porosity 
and tested their cytotoxicity and oxidative stress in two cell lines. A phagocytic (THP-1) and non-phagocytic 
(HepG2) cell line allowed us to distinguish between different routes of cellular uptake of SNPs. Red blood 
cells, which are not capable of active uptake, were used to study SNP-membrane interaction. Nanoparticles 
are known to interfere with many test system and causing optical interference, catalytic interference, and 
adsorptive interference (Kroll et al., 2012). This can cause over- or underestimation of the readout of 
commonly applied toxicological assays. In the present study, appropriate measures were taken to avoid 
such artefacts.  
Viability 
Loss of cell viability occurred in a concentration-dependent manner and was dependent on the cell type and 
specific surface area of the SNPs. Almost all SNPs displayed a more marked loss of cell viability in THP-1 
cells. Moreover, this effect was dependent on the incubation time, with longer incubation times showing a 
more marked loss of cell viability.  The most extensive loss of cell viability occurred with MB(-) at 250 µg/mL.  
Data in the literature show a tendency that smaller SNPs are more cytotoxic. However, this has been 
described for very small SNPs, e.g. those with a diameter of 16 nm (Napierska et al., 2012). This effect 
eventually plateaus for SNPs bigger than 100 nm (Lin and Haynes, 2010). However, it is difficult to compare 
results, since the route of synthesis of SNPs was not always specified. We found no viability decrease for 
the small mesoporous series due to prior dissolution. The dissolved species have shown to be essentially 
non-toxic (He et al., 2009).  
The positive SNPs did not substantially affect cell viability, in line with reports on other nanoparticles with 
high positive charge (Zhang et al., 2011). Probably, the net surface charge density of the SNPs plays a 
crucial role in charge-mediated cytotoxicity as described above. There seems to be a ζ-potential threshold 
which was not reached with the highest amount of APTES used here, which might be due to the even 
distribution of APTES in the silica network as a result of the chosen co-condensation approach.  
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 The non-porous nanoparticles induced little decrease in viability, and there appeared to be no influence of 
different surface groups. The viability decrease caused by MB(0) and MB(+) was not as marked, suggesting 
that the primary amines in this concentration prevented the loss of cell viability seen with the non-modified 
MB(-) in THP-1 cells.  
Fisichella et al. reported that there is an overestimation of viability decrease when using mesoporous SNPs 
in the MTT assay (Fisichella et al., 2009). This is attributed to the exocytosed blue-violet formazan crystals. 
We therefore tested MB(-) with the MTS assay, which does not form crystals. For MB(-), we observed the 
same viability decrease in both assays. Moreover, we observed a strong morphological change in the cells 
exposed to MB(-). The observed difference to the literature may be due to another method to remove the 
template or in the cell lines used herein.  
Oxidative stress 
Since we used a sol-gel synthesis for all SNPs, oxidative stress induction was not expected because very 
few siloxanes are present on the surface of SNPs prepared with this method (Zhuravlev, 2000). This was 
confirmed by using two different assays, i.e. the commonly used DCFH-DA assay and a commercially 
available kit. None of our SNPs induced any oxidative stress in cell-free and cell-containing environments in 
either the DCFH-DA assay or the kit, which also captured superoxide anion. A recent study reported that 
annealing of the SNPs is predominantly responsible for oxidative stress in cells (Zhang et al., 2012). Our 
results are in agreement with those reported by Zhang et al. since our SNPs were synthesized by the sol-gel 
method. Oxidative stress associated with SNPs has mostly been described for very small particles (e.g. 
sized 16 nm), where the high surface curvature enhances the surface reactivity (Ahmad et al., 2012). 
Furthermore, Kim et al. showed that oxidative stress in macrophages was caused by small silica particles 
(15 nm) but not by solid SNPs of larger size (50 nm and 100 nm) (Kim et al., 2012). They concluded that the 
toxic mechanism shifts with particle size, with small-sized SNPs mediating ROS-induced toxicity.  
Hemolysis 
To study direct interaction of SNPs with a plasma membrane, we measured the hemolytic potential of the 12 
SNPs. A clear dose-dependent relationship was observed for SS(-), SB(-), and MB(-). Non-porous SNPs 
with a “bare” silica surface are known to cause hemolysis (Slowing et al., 2009). This effect is abrogated 
CHAPTER 3. PUBLISHED AND SUBMITTED RESULTS
58
 when covering the surface with a polymer, i.e. poly ethylene glycol. In our case, we found no hemolysis 
when altering the surface with primary amines. In contrast, Yu et al. found enhanced RBC lysis for amine-
modified SNPs (Yu et al., 2011). A reason for this discrepancy could be a certain threshold of positive 
charge/area unit. Since we synthesized our modified SNPs with the co-condensation method, we assume 
that the charge density on the surface was not sufficient to induce hemolysis, which is in line with published 
data (Yu et al., 2011; Yildirim et al., 2013).  
The hypothesized hemolytic mechanism for solid SNPs is an electrostatic interaction between the silanol 
groups on the surface of the SNP and the choline headgroup in the phospholipids (Slowing et al., 2009). 
In our study, MB(-) caused severe hemolysis in a dose-dependent manner, whereas MS(-) did not affect the 
RBC membrane. Assuming that smaller particles are more likely to cause hemolysis, it is puzzling that MS(-) 
did not induce RBC lysis. We attributed this to the prior dissolution of the SNPs. Dissolution experiments in 
live-cell incubations showed severe degradation after 3 h only, as shown in Figure 6 (B-D). In addition, the 
blue silicomolybdic assay showed dissolution of both MB(-) and MB(+). Since the SNPs of the MS series had 
a higher specific surface area, we assumed that dissolution was even faster than dissolution of SNPs of the 
MB series. Regarding hemolysis caused by mesoporous SNPs, there are contradictory results found in the 
literature. Slowing et al. found no hemolysis for mesoporous SNPs with a size and zeta potential comparable 
to the ones we synthesized (Slowing et al., 2009). However, Lin et al. described concentration- and size-
dependent hemolytic properties of mesoporous SNPs, with a weaker hemolytic potential seen with larger 
SNPs (Lin and Haynes, 2010). Their results are in agreement with our finding that mesoporous silica 
particles can induce hemolysis, although we observed a much stronger hemolytic effect for particles of 
similar size and zeta potential. 
Finally, residual surfactant (CTAB) may cause hemolysis, but TGA and FTIR confirmed the complete 
removal of the surfactant template in our study. Lin et al. investigated the effects of residual CTAB on 
hemolysis and found no correlation (Lin and Haynes, 2010). Thus, the mechanism of the effect of SNPs on 
RBCs remains insufficiently well understood and warrants further research. 
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 Conclusions 
We synthesized and analyzed 12 different SNPs systematically. Due to a step-by-step change of the 
physico-chemical parameters (size, surface charge and surface area) it was possible to investigate the 
influence of each parameter separately. However, cytotoxicity and also hemolysis do not seem to be 
restricted to only one specific physico-chemical parameter. Cell viability decrease was dependent on the 
concentration, surface charge, time, and cell line used. Cytotoxicity of SNPs was more pronounced at higher 
concentrations. We found no oxidative stress induction for any of the tested SNPs. Here, only negatively 
charged SNPs could induce hemolysis, whereas the introduction of primary amines into the SNPs reduced 
the hemolytic effect, irrespective of their size or specific surface area. SNPs which showed no effect were 
shown to degrade fast. We found no to negligible interference potential of all tested SNPs. Since all SNP 
types were synthesized and characterized in house, this study provides a comparable overview of one 
nanomaterial with different physico-chemical parameters and its biological interaction. The study can be a 
guideline for designing of safe drug delivery systems. Ongoing research is dedicated to elucidating the 
biophysical interaction with lipid membranes.  
We propose that our standardized SNPs serve as a readily available reference material for nanotoxicological 
investigations. 
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Supplementary information 
Thermogravimetric analysis (TGA) was carried out to define the amount of APTES incorporated 
into the SNPs. Measurements (TGA-Netzsch STA 449F1 Jupiter) were carried with the resolution 
of is 0.025 µg under air atmosphere and in alumina crucibles, at the scanning rate of 10K/min. 
During the measurements, thermograms were recorded within the range of 30–900° C, and the 
results were analyzed with the software Proteus 5.1. Successful removal of CTAB template was 
confirmed with TGA (Figure S1) and FTIR measurements (Figure S2). 
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Figure S1: TGA results for all SNPs 
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Figure S2: Template removal from MB(-) with FTIR. Black spectra: extracted MB(-). Grey: 
surfactant free control MB(-). No surfactant was left in the MB(-). 
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3.3 Hemolysis of silica nanoparticles: a mechanistic approach
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ABSTRACT
Silica nanoparticles are proposed as drug delivery systems or imaging agents. However, bare
silica nanoparticles are known to induce hemolysis. To date, two mechanisms are hypothesized
in the literature, namely the electrostatic interaction between surface silanols and quaternary
ammonia of the choline head groups in the plasma membrane. The other mechanism describes
that hemolysis of silica nanoparticles is a consequence of reactive oxygen generation.
Here, we focused on the first approach and used biophysical techniques to investigate the
interaction of hemolytic and non-hemolytic silica nanoparticles with a model membrane. We
have studied this interaction with dye-leakage assay, dynamic light scattering, isothermal
titration calorimetry, solid state nuclear magnetic resonance, and flow cytometry.
Our results showed that the electrostatic interaction between hemolytic silica nanoparticles
and model membranes is negligible. We observed a rather strong adsorptive process and
agglomeration upon mixing silica nanoparticles with model membrane vesicles. Furthermore,
data from solid state nuclear magnetic resonance suggest that smaller lipid species were
formed in presence of hemolytic silica nanoparticles. The presence of these species was
assessed with flow cytometry.
The overall hemolytic effect mediated by a membrane interaction in the given set up is relatively
low (10-20%). Other mechanisms such as osmotic pressure difference or interaction with
membrane proteins may play a more important role in the hemolytic process.
Keywords: Hemolysis, silica nanoparticles, isothermal titration calorimetry, solid state
nuclear magnetic resonance
INTRODUCTION
Silica nanoparticles (SNPs) have been long known in pharmaceutical technology. There,
Aerosil R©is used as flowing agent in solid dosage forms since almost 100 years. But only
recently, SNPs were also proposed to use as drug delivery systems (DDS) or imaging agents
(Rosenholm et al., 2009; Ow et al., 2005). As DDS, different routes of uptake are possible
including skin penetration, oral absorption, upon inhalation or via intravenous (i.v.) injection.
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The i.v. administration is the preferred route for nanoparticulate DDS since there is no need
to cross an additional barrier like the gut wall or the blood-air interface (Bertrand and Leroux,
2012).
Upon i.v. injection, the nanoparticles come in direct contact with blood constituents as red
blood cells (RBC) and plasma proteins. Depending on their physico-chemical properties, the
nanoparticles interact after few seconds with these constituents (Kettiger et al., 2013). One of
these interactions is the RBC-nanoparticles interaction. This interaction can cause hemolysis,
i.e. severe damage to RBC. Abundant hemolysis in vivo causes different inherent diseases
(Misztal and Tomasiak, 2011). This poses the question of the SNPs safety and their future use as
DDS. Small nanoparticles have shown to passively diffuse through the lipid bilayer (Wang et al.,
2012), while others undergo active uptake (Kettiger et al., 2013). In the case of RBC, no active
uptake is involved and hence, the hemolytic effect is probably caused by an interaction with the
lipid bilayer (Rothen-Rutishauser et al., 2006). Various studies showed the hemolytic effect of
SNPs (Lin and Haynes, 2010; Zhao et al., 2011; Slowing et al., 2009). However, the underlying
hemolytic mechanism of SNPs remains unknown.
So far, two different mechanisms of hemolysis are predominant in the literature. The first one
is an electrostatic interaction with the silanol groups (Si-OH) of the silica surface with the
quaternary ammonium on the lipid bilayer. (Slowing et al., 2009; Depasse and Warlus, 1976).
The second one relies on the capacity to cause oxidative stress from siloxane bond distortion,
where the reactive oxygen species (ROS) are responsible for the hemolysis via oxidation of the
phospholipids in the cellular membrane (Zhang et al., 2012a).
Isothermal titration calorimetry can be used to study interactions of various kinds. These
include protein-protein interactions, peptide-membrane interactions, and recently also protein-
nanoparticles interactions (Cedervall et al., 2007). It is possible to determine the enthalpy of
the interactions. When modifying the experimental setup, it is possible to determine the type of
binding.
Solid state 31P NMR spectroscopy is a technique which allows studying the structure and dy-
namics of both model and biological lipid membranes. Phospholipids are the major components
of cell membranes and the natural abundance of the 31P nucleus is 100%, therefore 31P NMR
allows studying phospholipid membranes and to distinguish between bilayer, hexagonal structure
or micelles as each of the lipid phase is characterized by its typical 31P NMR spectrum with
defined the chemical shift anisotropy (Seelig, 1978; Sauder et al., 2011).
Solid state 2H NMR reveals lipid order and packing of deuterium labeled phospholipids. The
phospholipid molecule can be specifically labeled at the headgroup, the glycerol backbone or
the fatty acyl chains. The natural abundance of deuterium is very low and deuterium magnetic
resonance in the 2H NMR signal can be easily assigned to the deuterium labeled site. In an
unorientated sample the deuterium quadrupole interactions give characteristic powder-pattern
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spectra with two distinct peaks separated by the deuterium quadrupole splitting and provide
structural information about the lipid system.
We have shown previously, that amorphous SNPs with a primary size of 85 nm cause hemolysis.
The same particles did not show any oxidative stress in cellular and in non-cellular environment.
We were therefore exclusively interested in the electrostatic mechanism. To investigate this, we
have used different approaches, namely the dye leakage assay, dynamic light scattering (DLS),
isothermal titration calorimetry (ITC), solid state nuclear magnetic resonance (ssNMR), and
flow cytometry. With these methods, we studied the interaction between SNP surface groups
(silanols) with a choline-rich model membrane. As a non-hemolytic SNP control, we used
surface modified SNPs, which have previously shown to be non-hemolytic. All experiments
were conducted under physiological conditions.
MATERIALS AND METHODS
Materials
All chemicals for the nanoparticle synthesis were obtained from Sigma-Aldrich (Buchs, Switzer-
land). All lipids, including the fluorescent tail-labeled lipid (1-oleoyl-2-{6-(7-nitro-2-1,3-
benzoxadiazol-4-yl)amino)hexanoyl}-sn-glycero-3-phosphocholine) and lipids for ssNMR (1-
Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine-1,1,2,2-d4 (d4- POPC) and 1-Palmitoyl-
d31-2-oleoyl-sn-glycero-3-phosphatidylcholine (d31-POPC)) were obtained from Avanti Polar
Lipids (Alabaster, USA). 8-Aminonaphthalene-1,3,6-Trisulfonic Acid, Disodium Salt (ANTS)
and p-Xylene-Bis-Pyridinium Bromide (DPX) were obtained from Life Technologies, Switzer-
land.
Synthesis and characterization of silica nanoparticles
The SNPs were synthesized and characterized as follows. Briefly, the reaction solutions had the
molar composition of 1 TEOS: 0.087 NH3: 64.3 EtOH: 27.8 H2O. Alteration of SNPs net surface
charge was carried out by direct incorporation of amine groups through the co-condensation
of aminosilanes (3-Aminopropyl)triethoxysilane during the synthesis (10 mol% of existing
TEOS). The mixture was stirred under ambient conditions for 3h. The SNPs were collected by
centrifugation and washed 3 times thoroughly with EtOH and dried overnight in a vacuum oven
at ambient temperature. The resultant particles were analyzed with dynamic light scattering
(DLS) to obtain their hydrodynamic diameters in DPBS and HEPES, their dry state diameter
was measured by transmission electron microscopy (TEM). We also measured the specific
surface area by the Brunnauer-Emmet-Teller (BET) method. The zeta potential was measured by
electrophoretic light scattering from the Doppler shift of scattered light (Delsa Nano C, Beckman,
Nyon, Switzerland).
Preparation of lipid vesicles
For our studies we used small unilamellar vesicles (SUVs, mean diameter 20 nm), large unilamel-
lar vesicles (LUVs, mean diameter 100 nm), and multi lamellar vesicles (LMVs, mean diameter
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1000 nm). For SUVs, LUVs, and non-labeled MLVs, a defined amount of 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC) was dried from a stock solution in chloroform with a
gentle stream of nitrogen followed by vacuum overnight. For the preparation of the SUVs, we
rehydrated the film with DPBS containing 150 mM NaCl. Then, the suspension was sonicated
using a titanium tip ultrasonicator (Branson Sonifier, Danbury, CT) until an almost clear solution
was obtained (45 min). Metal debris from the sonicator tip was removed by centrifugation for
4 min in an Eppendorf 5415 C benchtop centrifuge (Vaudaux-Eppendorf AG, Schonenbuch,
Switzerland).
LUVs for the dye leakage assay were prepared as follows. The desired lipid films (POPC;
POPC-sphingomyelin; POPC-cholesterol; POPC-sphingomyelin-cholesterol) were prepared as
described for the SUVs. The lipid films were then rehydrated with a mixture of a fluorophore
(ANTS, 12.5 mM) and a quencher (DPX, 45 mM) in DPBS with 150 mM NaCl. They were sub-
jected to 5 freeze-thaw cycles and extruded through a 200 nm pore size filter. Non-incorporated
dye was removed from the LUVs with size-exclusion chromatography on a Superose 6 prep
column (GE Healthcare) eluting with 10 mM DPBS, pH 7.4.
MLVs were prepared as follows for flow cytometry experiments. Lipids (POPC and fluorescent
tail lipid, 0.5%) were dried as above and MLVs were obtained by 5 freeze-thaw cycles and
vortex in between. The film was rehydrated with the SNPs already in buffer. For ssNMR, MLVs
were prepared as follows. Twenty to 25 mg of d4-POPC or d31-POPC were dried from a stock
solution in chloroform with a gentle stream of nitrogen followed by a high vacuum for several
hours. The lipid films were dispersed in 400 µL of buffer (10 mM Hepes, 150 mM NaCl in
deuterium depleted water, pH 7.4) containing different amount of SNPs. The samples were
vortexed, freeze-thawed (5 times) and vortexed again.
Dye leakage assay and dynamic light scattering
The dye leakage assay has been performed as described earlier (Sauder et al., 2011). We mixed
the LUVs with hemolytic and non-hemolytic SNPs in a weight ratio of 1:1 and 1:0.15. The
fluorescent dye released from the LUVs was monitored over time at excitation wavelength of
360nm and emission of 518nm. The maximum release was obtained by adding 25 µ L of a
5% Triton X-100 solution and was set 100% leakage. The relative leakage was calculated as
RFUsample-RFU0/RFUmax-RFU0, where RFU is the relative fluorescence unit.
We have measured the degree of agglomeration of POPC-SUVs with DLS to obtain insight into
the SNPs:SUVs ratios, where agglomeration starts. We used the Beckman-Coulter Delsa Nano
C (Beckman Coulter, Nyon, Switzerland). The data was plotted volume-weighted.
Isothermal titration calorimetry
A MicroCal VP-ITC (MicroCal, Northampton, MA) was used. Lipid-into-SNPs titrations were
performed by injection of 4 – 10 µL aliquots of lipid suspension at a concentration of 3.8 mg/mL
– 7.6 mg/mL into the calorimeter cell (VCell = 1.4105 mL) containing SNPs at a concentration of
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CSNPs 0.5 – 1.0 mg/mL. The heats of dilution were determined in control titrations by injecting
the lipid suspension into buffer. The heats of dilution were small and were included in the final
analysis. Raw data were processed using the Origin software provided with the instrument.
Solid state NMR
Solid-state NMR experiments were performed on a Bruker Advance III 500 MHz spectrometer
(Bruker BioSpin AG, Fa¨llanden, Switzerland). Solid-state 31P NMR spectra were recorded at 202
MHz using a Hahn-echo sequence with broadband proton decoupling (SPINAL64) and a recycle
delay of 5 s. The excitation and refocusing pulse lengths were 4.25 µs and 8.50 µs respectively.
2048 free induction decays (FID) were accumulated and prior to Fourier transformation the FIDs
were multiplied with an exponential window corresponding to a 100 Hz line broadening. Solid-
state 2H NMR experiments were recorded at 76.8 MHz using the quadrupole echo technique.
The excitation pulse had a length of 3.5 µs. Four thousands (4096) FIDs were accumulated with
a recycle delay of 1 s.
Flow cytometry
MLVs and SNPs (1:1 weight ratio) mixtures were prepared as described for ssNMR experiments.
Then, the SNPs were subsequently removed by centrifugation (15’000g, 10min, 4◦ C). The
supernatant was analyzed by flow cytometry (FACS Canto II). We first lowered the threshold and
added previously prepared LUVs (100 nm by DLS, PDI about 0.1) to set an appropriate gate for
our target vesicles. Between the samples, the flow chamber was cleaned with filtered DPBS to
exclude sample-to-sample spill-over. Then, we set a gate where no particles were detected and
counted the events in the 100 nm-frame for 120 s by forward scatter area and sideward scatter
area.
RESULTS
Dye leakage assay
We have tested POPC alone, POPC with cholesterol, POPC with sphingomyelin, and POPC
with sphingomyelin and cholesterol. Upon pore formation, distortion, the close proximity of
quencher and fluorophore inside the vesicles is canceled resulting in a fluorescent signal in the
probe. For hemolytic SNPs, we observed a total dye release up to 10% (data not shown) with
POPC LUVs. For non-hemolytic SNPs we did not observe any dye-leakage from the LUVs.
Moreover, the lipid composition of the LUVs did not alter the % leakage for hemolytic and
non-hemolytic SNPs. It has been earlier reported that nanoparticles can interfere with dyes by
non-specific adsorption (Kroll et al., 2009). We checked for adsorptive interference, i.e. if the
free dye could bind to the nanoparticles and hence produce false negative data. This was not the
case for hemolytic and non-hemolytic SNPs.
Dynamic light scattering
Instead of large unilamellar vesicles with the size of about 100 nm, we have chosen small
unilamellar vesicles, with a size of about 30 nm. The reason for this choice was the discrimination
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in size. DLS allows a size discrimination if the diameters are three times bigger or smaller,
otherwise, it will simply display a polydisperse population. DLS results can be seen in 1 Figure 1
Figure 1. POPC SUVs into hemolytic SNP. This figure shows the size distribution of SUVs
alone (grey) and hemolytic SNP alone (second peak on Y-axis) by volume distribution. Different
weight ratios of lipid to HS are displayed along the Y-axis with an increasing ratio up to 0.36.
shows, that already upon a small hemolytic SNP to SUV ratio, heavy agglomeration is occurring.
The DLS results indicated that upon mixing hemolytic SNPs with SUVs, an agglomeration
process is starting at even low SUV concentration and there was no further size increase upon
addition of more SUVs.With increasing lipid content, a second population starts to show at 100
nm. This population may either be single SNPs or lipid membrane wrapped SNPs. The data is
volume-weighted in order not to overestimate the hemolytic SNP population.
Isothermal titration calorimetry (ITC)
Interaction of hemolytic and non-hemolytic SNPs with lipid membranes were monitored using
ITC technique. Figure 2 shows a calorimetric heat flow trace (Figure 2A and 2C) and the
corresponding titration curve (Figure 2B and 2D) obtained at 25 ◦C by titration of 0.5 mg/mL
hemolytic SNPs with 4 µL aliquots of POPC SUVs suspension (3.8 mg/mL). The integrated
heats in Figure 2C and 2D represent the net heats of each injection after correcting for the heats
of dilution of the POPC SUVs obtained in separate lipid-into-buffer titration. Figure 2 shows that
the reaction at 25 ◦C is exothermic. The reaction comes to an end after three injections when all
SNPs are bound to the injected lipid. The heat of reaction is given by ∑ hi / (CSNPs x Vcell) where
CSNPs is the SNPs concentration in the calorimeter cell. For the example given in Figure 2A the
cumulative heat released is ∑ hi = -22.8 µcal and the reaction enthalpy is δH0SNP = -0.026 cal/g.
From calorimetric trace the calculated amount of lipid which binds 1 mg of particles is 0.043 mg
(57.1 nmol). We have performed calorimetric titrations at different temperatures in the range of
15-45 ◦C and the reaction was exothermic at all temperature tested. However no temperature
dependence on the enthalpy of hemolytic particles binding to POPC was observed.
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Figure 2. Titration of POPC SUVs into SNPs at 25 ◦C. (A) Titration of 3.8 mg/mL POPC
SUVs into a suspension of hemolytic SNPs (0.5 mg/mL). Each peak corresponds to the injection
of 4 µL of lipid suspension into the cell. (B) Heats of reaction integrated from the calorimetric
trace (A) as a function of injection number. (C) Calorimetric trace obtained by titration of 7.6
mg/mL POPC SUVs into a suspension of non-hemolytic SNPs (1.0 mg/mL). Each peak
corresponds to the injection of 4 µL of lipid suspension into the calorimeter cell. (D) Heats of
reaction integrated from the calorimetric trace (C) as a function of injection number. Buffer: 10
mM phosphate, 150 mM NaCl, pH 7.4.
In contrast to hemolytic SNPs, very small heats in the range of control titration of lipids into
buffer were recorded for non-hemolytic SNPs. The integrated heats shown in Figure 2D are ∑hi
= -0.43 µcal and the enthalpy is almost hundredfold lower when compared to hemolytic SNPs
(-0.003 cal/g vs. -0.026 cal/g) indicating no interaction between non-hemolytic SNPs and neutral
lipid membrane. We have performed additional titration of POPC into non-hemolytic SNPs at
higher temperature to our results. Similar to the result obtained at 25 ◦C, calorimetric titration at
40 ◦C did not reveal any binding of non-hemolytic SNPs to POPC SUVs.
To probe whether electrostatic interactions are involved in the binding between hemolytic SNPs
and lipid membranes, we have performed titrations at lower salt concentration (50 mM NaCl).
The ITC titration pattern was identical to the titration performed at 150 mM NaCl and cumulative
heat released during the reaction was in the same range (∑hi = -23.4 µcal).
Solid state NMR
31P NMR studies on the silica nanoparticles-phospholipids interactions.
The phosphorus spectra of multilamellar lipid vesicles (MLVs) are characterized by a typical
shape with the chemical shielding anisotropy of -50 ppm determined from the distance between
low- and high-field shoulders of the spectrum. If molecules move rapidly in solution, isotropic
motions will produce a complete averaging of the phosphorus chemical shift anisotropy and
the spectrum consists of a single sharp line of about few Hz line width (Seelig, 1978). Figure
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Figure 3. 31P NMR of multilamellar phospholipid dispersions containing different amount of
silica nanoparticles. Twenty to 25 mg of phospholipid alone (E) or with different amounts of
SNPs (A, B, C, D) were suspended in 400 µL buffer. (A) non-hemolytic SNP/POPC weight
ratio of 0.15; (B) non-hemolytic SNP/POPC weight ratio of 1.0; (C) hemolytic SNP/POPC
weight ratio of 0.15; (D) hemolytic SNP/POPC weight ratio of 1.0; (E) POPC alone.
3 shows spectra obtained for multilamellar lipid dispersion composed of POPC in the absence
(Figure 3E) or presence of hemolytic and non-hemolytic SNPs (Figure 3A, 3B, 3C, 3D).
The 31P NMR spectrum of MLVs composed of POPC (Figure 3E) is a typical for a random
distribution of bilayer domains (so called powder-type spectrum) with the chemical shielding
anisotropy of -50 ppm. The addition of non-hemolytic SNPs to phospholipid dispersions did
not have any influence on the bilayer structure. Phospholipid spectra with non-hemolytic SNPs,
shown in Figure 3A and Figure 3B, exhibit the same pattern as the spectrum of phospholipid
alone. No changes in spectral shape were also observed for hemolytic SNPs nanoparticles mixed
with lipids at low weight ratios of hemolytic SNP/lipid weight ratio of 0.15 (Figure 3C). However
an isotropic component at 0 ppm appears in the powder spectrum when the amount of hemolytic
SNPs is increased to hemolytic SNP/POPC weight ratio of 1.0 (Figure 3E). Spectral simulation
(not shown) indicates that the isotropic component comprises about 20% of the overall spectral
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intensity. The presence of isotropic and bilayer component in the spectra indicates presence of
lipids which exhibit different motion environments such as a formation of smaller vesicles or
micelles.
Figure 4. 2H NMR spectra of multilamellar head group deuterium labeled phospholipid
dispersions containing different amount of SNPs. 25 mg of phospholipid alone (E) or with
different amounts of silica nanoparticles (A, B, C, D) were suspended in 400 µL buffer. (A)
non-hemolytic SNPs/POPC weight ratio of 0.15. (B) non-hemolytic SNPs/POPC weight ratio of
1.0. (C) hemolytic SNPs/POPC weight ratio of 0.15. (D) hemolytic SNPs/POPC weight ratio of
1.0. (E) POPC alone.
2H NMR measurements of the SNPs interactions with phospholipids.
To test whether there is direct interaction between the choline head group of the phospholipid
and hydroxyl group of the SNPs we have employed 2H NMR to monitor the head group region of
POPC perdeuterated at choline moiety (d4-POPC). Figure 4 shows 2H NMR spectra of d4-POPC
in the absence and upon addition of different amounts of hemolytic and non-hemolytic silica
nanoparticles. The measured quadrupole splitting of the head segment d4-POPC (in 10 mM
Hepes and 150 mM NaCl) is 5.5 kHz. Addition of hemolytic or modified non-hemolytic SNPs
did not change the quadrupole splitting of the head group segment. This result indicates that
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there is no confirmation change of the phosphocholine polar group, as depicted in Figure 4.
The measurements of the deuterium quadrupole splitting using selectively deuterated lipids
is a sensitive tool to directly monitor interaction of ions, small molecules and peptides with
the choline group of the phosphatidylcholine (Altenbach and Seelig, 1984; Akutsu and Seelig,
1981). Even the weak binding of Na+ could be detected and the changes in the quadrupole
splitting up to 9 kHz were observed (Akutsu and Seelig, 1981). Our results with SNPs and
d4-POPC showed that there are no direct electrostatic interactions between particles and choline
headgroup. In addition we have also performed solid state 2H NMR using lipids perdeuterated
at the hydrocarbon chain (d31-POPC). Upon addition of SNPs no changes in the quadrupole
splitting of the lipid chains were observed (data not shown).
Flow cytometry with MLVs
We first gated LUVs to find proper settings for the smaller species in the supernatant. hen we
separated the supernatant with the 550 nm laser to only have lipid vesicles and no SNPs in the
supernatant (although the samples was centrifuged prior to flow cytometry, the fluorescent signal
served as a control). Then again, these fluorescent species were plotted as forward scatter area
against sideward scatter area and a time dependent gating was set to count the lipid vesicles
in the supernatant. For the hemolytic SNPs 14’000 vesicles were counted, whereas for the
non-hemolytic non-hemolytic SNPs only 7000 were counted. This indicates that the faster
tumbling species from ssNMR could result in smaller vesicles.
DISCUSSION
One of the hypotheses for hemolytic mechanism of SNPs is a direct electrostatic interaction of
silanol groups with quaternary ammonium of phosphatidylcholine (Depasse and Warlus, 1976;
Slowing et al., 2009). We were interested exclusively in the interaction of the surface silanols
and the choline headgroups. Therefore, we have chosen POPC liposomes as model, since phos-
phatidylcholine lipid is the most abundant lipid in the outer leaflet of RBC membrane (Ziegler,
2008). This membrane model excludes other effects coming from membrane constituents or
additional factors like osmotic pressure.
The dye leakage assay with LUVs showed a 10% leakage with hemolytic SNPs in a 1:1 weight
ratio, whereas no leakage was observed for non-hemolytic SNPs. For strong hemolytic peptides
like melittin, a high leakage is already observed at low peptide to lipid ratio (Klocek et al., 2009).
However, a recent study has found similar % dye leakage for SNP of the same size (the primary
size of 15 nm increased up to 100 nm upon salt addition, which is comparable with our size)
(Mu et al., 2012). As different lipids might alter the interaction between SNPs and LUVs we
have performed leakage with mixed membranes. The composition of the membrane did not alter
the % of released dye. However, also for cell penetrating peptides like nona-arginine, no dye
leakage was observed, although they form pores in the membrane (Liu et al., 2013). For other
nanoparticles like gold nanoparticles (10 nm) or titanium dioxide (10 nm), it was shown that the
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dye leakage is depending on the surface groups, where positively charged groups exhibited a
time dependent release of carboxyfluorescein (Moghadam et al., 2012). However, comparison
is hampered by the size difference and the surface charge density. The authors observed a
time-dependent leakage, which was not the case for our particles (data not shown).
The DLS data showed a strong size increase when SUVs and hemolytic SNPs were mixed. This
happened already at a very low SUV to SNP ratio. Hence a strong agglomeration process is
present. A reason for this could be a locally high concentration which results in a stress of
the membrane. With ITC we monitored the interaction between SNPs and SUVs. Our data
support what was observed with DLS. Figure 2a shows a strong initial peak upon injection of
SUVs into SNPs suspension, but already for the second injection, the heat effect is decreasing
strongly. This initial peak suggests that all available binding partners are depleted after the first
injection of SUVs. However, the heat effect is rather small compared to melittin, where the
binding enthalpy to POPC LUVs is 2 cal/g (Que´batte, unpublished data), whereas for hemolytic
SNPs the binding enthalpy is -0.026 cal/g. However, the difference in binding enthalpy between
hemolytic and non-hemolytic SNP is also by a factor or 100 (non-hemolytic SNPs: (-0.003
cal/g), as stated in the results. Even if the effect is not comparable with cell penetrating peptides,
this difference is striking. However, we did not observe a temperature dependency in binding
enthalpy. Furthermore, no change was observed upon salt addition or abduction, which does not
support the evidence of an electrostatic interaction, as postulated in the literature (Slowing et al.,
2009).
Our adsorption data are in agreement with the literature, where adsorption of SNPs to a mono-
layer was shown. The adsorption interaction there was mainly driven by Van-der-Waals forces
(Vakurov et al., 2012). For the hemolytic SNPs to be attracted to DOPC monolayer, the surface
potential must be positive. This surface potential can arise only from fixed charges within the
phospholipid polar groups, namely, the N+ terminus of the P- -N+ dipole. The observation that
voltammetric peak suppression is independent of the solution pH and ionic strength clearly
negates any suggestion that the interaction is dominated by electrostatic forces. The ionic
strength and the pH change did not alter the results. This is indicative for van der Waals forces.
We further explored where the interaction between SNPs and lipid vesicles are located (head
region of the phospholipid or at its tail). Deuterium ssNMR of headgroup perdeuterated phos-
phatidylcholine showed no change in the quadrupole splitting indicating no direct interaction
with the phospholipid head group. This observation is in contrary to results obtained by Depasse
and Warlus who showed high affinity of SNPs to quaternary ammonium ions. However their
study has used tetraalkylammonium bromide and tetralkylammonium hydroxide as positively
charged constituents of the outer layer of the membrane (Depasse and Warlus, 1976). Phos-
phatidylcholine, the main lipid of the outer membrane of RBC (Ziegler, 2008) is a zwitter ion
due to presence of the negatively charged phosphate group. The phosphorous and the nitrogen
atom of the phosphatidylcholine headgroup are lying in the plane parallel to the surface of the
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membrane and the flexibility of the headgroup is limited (Seelig et al., 1977).
Using 31P NMR, we observed an isotropic peak in the presence of hemolytic SNPs. This
isotropic peak suggest that smaller lipid vesicles are formed. Brisebois et al. studied interaction
of fullerenol with DPPC/cholesterol membranes using 31P ssNMR (Brisebois et al., 2012). The
effect of fullerenol nanoparticles on the 31P was minor. 2H NMR with deuterated acyl chain lipids
also showed no change in signal after addition of fullerenol. These results were in agreement
with molecular dynamic simulations on fullerenol in DPPC bilayers, which suggest that the polar
nanoparticles would preferentially remain at the bilayer/water interface (D’Rozario et al., 2009).
From our data, we conclude that the direct interaction in the choline headgroup and the SNPs is
not very likely, since we would have observed a shift in the deuterium spectrum.
With flow cytometry, we gained insight into the smaller species that were formed upon addition
of hemolytic SNPs. For hemolytic SNPs we observed that 100% more smaller vesicles than for
the non-hemolytic SNPs. What remains also to be elucidated is whether a membrane wrapping
of SNPs was present. This means that the MLVs could spontaneously form a lipid bilayer
around the silica nanoparticles. This process is called supported lipid bilayer (SLB). It has
been reported that also neutrally charged or zwitter ionic phospholipids would be able to wrap
around SNPs (Mornet et al., 2005). Monet et al. found for liposomes with positive, neutral,
and low negative charge formed SLB around SNPs. The SNPs used in the study have the same
diameter. However, the liposomes used there were SUVs, where in our case they were present
as MLVs. The curvature of the surface may play a role in this case. Zhang et al. showed that
silica nanoparticles bigger than 78 nm caused membrane wrapping, followed by increase in lipid
lateral mobility and the eventual collapse of giant unilamellar vesicles (GUVs) composed of
DOPC Zhang et al. (2012b). However it should be noted that GUVs are very fragile structures
when compared to SUVs or LUVs Schwille (2011). Even though we centrifuged the SNP-MLV
mixture prior to flow cytometry experiments, membrane wrapping could still be present for
the centrifuged SNPs. Further experiments using cryo-TEM could give insight into membrane
wrapping process.
CONCLUSION
In this study we investigated the hemolytic effect by SNPs with biophysical methods. Our
findings suggest that the interaction of surface silanols and a model membrane composed of
phosphatidyl choline is rather low. ITC data showed no significant heat change at different tem-
peratures and salt concentrations, which would be present, if there is an electrostatic interaction.
Also ssNMR data indicated that an interaction with the choline headgroup is not prevalent, but
the phosphorus spectrum pointed towards formation of faster (i.e. smaller) tumbling species.
The presence of these species could be confirmed by flow cytometry. Even though the effects
measured were rather small, there was a clear difference between hemolytic and non-hemolytic
SNPs. Hemolysis may be partly explained by our data, however, more research needs to be
conducted, also involving membrane proteins and osmotic pressure.
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Abstract: Quantum dots (QDs) are highly fluorescent and stable probes for cellular and 
molecular imaging. However, poor intracellular delivery, stability, and toxicity of QDs in 
biological compartments hamper their use in cellular imaging. To overcome these limitations, 
we developed a simple and effective method to load QDs into polymersomes (Ps) made of 
poly(dimethylsiloxane)-poly(2-methyloxazoline) (PDMS-PMOXA) diblock copolymers without 
compromising the characteristics of the QDs. These Ps showed no cellular toxicity and QDs were 
successfully incorporated into the aqueous compartment of the Ps as confirmed by transmission 
electron microscopy, fluorescence spectroscopy, and fluorescence correlation spectroscopy. 
Ps containing QDs showed colloidal stability over a period of 6 weeks if stored in phosphate-
buffered saline (PBS) at physiological pH (7.4). Efficient intracellular delivery of Ps containing 
QDs was achieved in human liver carcinoma cells (HepG2) and was visualized by confocal laser 
scanning microscopy (CLSM). Ps containing QDs showed a time- and concentration-dependent 
uptake in HepG2 cells and exhibited better intracellular stability than liposomes. Our results 
suggest that Ps containing QDs can be used as nanoprobes for cellular imaging.
Keywords: quantum dots, polymersomes, cellular imaging, cellular uptake
Introduction
Development of highly sensitive and stable imaging probes is of considerable interest in 
many areas of biomedical research, ranging from cellular biology to molecular imaging 
and diagnostics. Fluorescent semiconductor quantum dots (QDs) are promising fluo-
rescent nanoprobes offering an alternative to conventional organic fluorophores due to 
their unique properties.1,2 QDs show superior optical and chemical properties, ie, broad 
spectral absorption with a narrow emission band, higher brightness of fluorescence 
despite a low quantum yield, high photostability, and resistance to photobleaching.3,4 
However, poor chemical stability, particle aggregation, and toxicity mediated by the 
cadmium semiconductor core limit the use of QDs in imaging.5–7 These limitations are 
of major concern in applications where cellular uptake of QDs is required to visualize 
intracellular compartments.
In cell culture media, QDs have low stability due to particle aggregation and 
surface degradation, which leads to minimal cellular uptake and difficulties with 
respect to the interpretation of cellular images.8 Therefore, attempts have been made 
to improve the stability and promote cellular uptake of QDs using surface chemistry 
modifications. This includes the functionalization of QDs with biomolecules such 
as antibodies,9 proteins,10 or peptides,11 as well as their coating with polymers or 
amphiphilic copolymers.12,13 However, modification of the QD surface may significantly 
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alter their  fluorescence properties.14 Once taken up by target 
cells, QDs often end up in the endolysosomal compartment 
or aggregate in intracellular regions.15 Earlier studies showed 
that QDs may disintegrate under acidic conditions in these 
compartments, leading to intracellular release of toxic heavy 
metals. This leads to oxidative stress, induction of apoptosis, 
and eventually, cell death.16 Recently, it was shown that 
polymer-coated QDs could be stabilized during cellular 
uptake. However, their coating dissociated in intracellular 
compartments such as lysosomes.17 Thus, new strategies 
are needed to improve both the uptake and the intracellular 
stability of QDs.
Amphiphilic block copolymers are known to self-
assemble into various supramolecular aggregates such as 
micelles, tubes, sheets, or vesicles in aqueous solutions.18 In 
particular, polymersomes (Ps; so-called polymeric vesicles) 
have gained increasing interest in recent years for various 
biomedical applications, including their use as drug and 
gene delivery nanocarriers, nanoreactors, and even artificial 
organelles.19 Ps are nanometer-sized hollow spheres with an 
aqueous cavity surrounded by a hydrophobic membrane and 
hydrophilic inner and outer surfaces. They are promising 
candidates for nanocarriers because many hydrophilic and 
hydrophobic molecules can be incorporated into their aque-
ous cavity or their membrane, respectively.20,21 Additionally, 
chemical surface modifications can be used to tailor their 
physicochemical and biological properties to improve the 
delivery of a wide range of therapeutics.22,23 Numerous types 
of Ps have been proposed as nanocarriers for encapsulat-
ing small drug molecules, larger therapeutic proteins, and 
other types of nanoparticles.24–26 Reports on the use of Ps 
as carriers of water-soluble nanoparticles such as QDs are 
scarce.27 Recently, Ps prepared from amphiphilic poly (D,L-
lactide)-poly(2-methacryloyl-oxy-ethylphosphorylcholine) 
(PLA-PMPC) diblock copolymers have been used to encap-
sulate phosphorylcholine-coated QDs. This coating confers 
hydrophilic properties to the QDs and also creates ion-pair 
interactions with PMPC, binding QDs to the inner and outer 
surfaces of Ps.27 However, this approach has limitations, since 
the presence of physiological buffer can destabilize the QDs 
and release them from the surface of the Ps.
The present study aimed to use a recent type of diblock 
copolymers composed of poly(dimethylsiloxane)-poly 
(2-methyloxazoline) (PDMS-PMOXA)28 to prepare Ps 
and to load them with QDs. The hydrophilic fraction and 
molecular weight of the PDMS-PMOXA were chosen to 
meet the prerequisites for diblock amphiphilic copoly-
mers to form vesicles.29 The neutral hydrophilic PMOXA 
outside the Ps thereby acts as a protein repellent, similar 
to conventional polyethylene glycol (PEG), to minimize 
interactions with phagocytic cells such as macrophages 
and monocytes.30,31 In this way, colloidal stability, cellular 
delivery, and intracellular stability needed for cellular 
imaging were improved. QDs were loaded into the aqueous 
cavity of Ps made of PDMS-PMOXA without altering the 
surface properties of Ps. Loading efficiency and colloidal 
stability in suspension were characterized by transmission 
electron microscopy (TEM), fluorescence spectroscopy 
(FS), zeta potential, and fluorescence correlation spec-
troscopy (FCS). The cellular toxicity of PDMS-PMOXA 
Ps was excluded by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Intracellular 
delivery of Ps containing QDs was investigated in human 
liver carcinoma (HepG2) cells. Concentration- and time-
dependent cellular uptake of Ps containing QDs in HepG2 
cells was analyzed using confocal laser scanning micro-
scopy (CLSM). Results were compared to those obtained 
for liposomes containing QDs.
Materials and methods
amphiphilic block copolymers
Poly (dimethylsiloxane)-poly (2-methyloxazoline) (PDMS
65
-
PMOXA
14
) was kindly provided by Prof Wolfgang Meier 
(Department of Chemistry, University of Basel, Basel, 
Switzerland). This amphiphilic diblock copolymer was 
synthesized as described elsewhere.28,31 An excess of pre-
activated PDMS was used to induce the polymerization of the 
hydrophilic PMOXA blocks. Unreacted PDMS was removed 
from the diblock copolymer by centrifugation.
Preparation of Ps
Ps were prepared using a f ilm rehydration method.32 
PDMS-PMOXA diblock copolymer (5 mg) was first dis-
solved in pure ethanol (1 mL). The polymeric solution was 
evaporated to dryness using a rotary evaporator (Rotavapor; 
BÜCHI Labortechnik AG, Flawil, Switzerland; 174 mbar, 
40°C, 80 rpm) to obtain a thin film. Residual humidity was 
removed in a vacuum oven (Vacutherm; Thermo Scientific, 
Wohlen, Switzerland) in high vacuum (0.3 mbar, 40°C, 
4 hours). Phosphate buffer solution (PBS; 1 mL, 0.1 mM) 
was added to the film for rehydration under vigorous stirring 
at room temperature for 6 hours. The resulting suspension 
was extruded (Mini extruder; Avanti Polar Lipids, Alabaster, 
AL, USA) eleven times through a polycarbonate filter with 
an average pore diameter of 0.4 µm, followed by eleven 
extrusions through a filter with an average pore diameter of 
3.4. POLYMERSOMES CONTAINING QUANTUM DOTS
87
International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2289
Polymersomes containing quantum dots
0.2 µm (Nucleopores; Whatman, VWR International AG, 
Dietikon, Switzerland).
loading of QDs
An aliquot (100 µL) of QDs solution (8 µM solution in 50 mM 
borate, pH 9) with a maximum red fluorescence emission of 
625 nm (Qdot® ITK™ carboxyl quantum dots, cadmium–
 selenium core; Invitrogen, Life technologies, Lucerne, 
 Switzerland) was mixed with PBS (900 µL, 1 mM) to obtain 
a final QDs concentration of 200 nM. The photoluminescence 
yield of CdSe QDs was previously reported to be negligible for 
emission wavelengths in the red spectral range.33 This suspension 
was added to a dry polymer film and stirred for 6 hours at room 
temperature and protected from light. QDs were encapsulated 
in Ps during the self-assembly process. After extrusion (as 
described in paragraph Preparation of PS), non-encapsulated 
QDs were removed by size-exclusion chromatography using 
a  Sepharose 2B column (Sigma Aldrich, Buchs, Switzerland) 
eluted with PBS (0.1 mM). The first fraction corresponding to the 
Ps-containing QDs was detected by UV absorption at 280 nm. 
It should be noted that free QDs cannot be separated from the 
suspension by dialysis due to their big molecular size.
Dynamic light scattering
Suspensions of empty Ps and Ps-containing QDs were 
 measured for average size and size distribution using dynamic 
light scattering (DLS) with a Delsa™ Nano C (Beckman 
Coulter, Inc., Nyon, Switzerland) equipped with Dual 30 mW 
laser diodes (wavelength lambda: 632.8 nm). Data were ana-
lyzed using the CONTIN program34 (DelsaNano UI software 
version 3.73/2.30, Beckman Coulter, Inc.).
surface charge – zeta potential
Suspensions of free QDs, empty Ps, and  Ps-containing 
QDs were measured for zeta potential determination 
using  electrophoretic light scattering in a Delsa™ 
Nano C.  Suspensions were measured in a flow cell using 
PBS as buffer. Data were converted with the Smoluchowski 
equation (DelsaNano UI software, Beckman Coulter, Inc.).
Transmission electron microscopy
Samples for transmission electron microscopy (TEM) 
were prepared using an aliquot (5 µL) of suspension of 
empty Ps and Ps-containing QDs on a carbon-coated grid. 
Samples were negatively stained with freshly prepared 
2% uranyl acetate. The grids were air-dried overnight 
before TEM analysis (CM-100; Philips, Eindhoven, the 
Netherlands).
Fluorescence spectroscopy
A microplate fluorescence spectrometer (SpectraMax M2e, 
Molecular Device, Biberach an der Riss, Germany) was 
used to analyze the efficiency of loading QDs into Ps. All 
samples (free QDs, empty Ps, and Ps-containing QDs) 
were excited at 405 nm, and continuous emission spectra 
were recorded from 500 to 700 nm. All measurements were 
performed in a  polystyrene 96-well microplate (Greiner-bio 
one,  Frickenhausen, Germany). Fluorescence intensity of 
QDs changes over time. Therefore, fluorescence signals are 
represented in relative fluorescent units.
Fcs
FCS measurements were performed on the surface of a cover 
glass using a Zeiss 510-META/Confocor2 laser-scanning 
microscope (Carl Zeiss AG, Feldbach, Switzerland) equipped 
with an argon laser (477 nm) in the FCS mode. Fluctua-
tions of fluorescence intensity were processed by means of 
an autocorrelation  function. FCS was used to analyze the 
loading of QDs into Ps and to determine quantitatively the 
number of QDs in each polymersome.35 Diffusion times of 
free QDs determined  independently were included in the 
fitting procedure. All results represent the average of ten 
measurements. For stability  determinations, Ps-containing 
QDs were analyzed regularly over a period of 6 weeks.
cell culture
HepG2 cells (ATCC HB-8065) were kindly provided by 
Prof Dietrich von Schweinitz (University Hospital Basel, 
Basel, Switzerland). Cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with low 
glucose (1 g/L), 10% fetal bovine serum (FBS), 0.1 mM 
non-essential amino acids (NEAA), 2 mM GlutaMAX™, and 
10 mM HEPES (all obtained from Gibco, Life Technologies, 
Lucerne, Switzerland) at 37°C under 5% CO
2
 and saturated 
humidity. Cells were confirmed to be free of mycoplasma 
(MycoAlert™; Lonza, Visp, Switzerland).
MTT cellular toxicity assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was used with some modifications as 
described elsewhere.36 The MTT stock solution (Roth AG, 
Arlesheim, Switzerland) was prepared by dissolving 5 mg 
MTT/mL PBS, sterile-filtered, and stored at 4°C. Briefly, 
HepG2 cells were seeded at a density of 2.5 × 104 cells/well in 
a 96-well plate. After 24 hours, the medium was removed and 
100 µL aliquots containing the corresponding  concentration 
of Ps were added. A blank medium served as a negative 
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control. After 24 hours, the medium was replaced by blank 
medium containing 10% MTT solution. The plates were 
incubated for 2 hours at 37°C, and the resultant formazan 
crystals were dissolved by adding 3% soduim dodecyl sulfate 
(20 µL) and 40 mM HCl (100 µL) in isopropanol. Optical 
density was measured at 550 nm using a spectrophotometer 
( SpectraMax M2e; Molecular Device). Test substances 
showed no absorbance overlapping with the signal of MTT. 
Unspecific background signal was determined at 680 nm and 
subtracted to reduce artifacts.
cellular uptake of Ps-containing QDs
We analyzed the cellular uptake of Ps-containing QDs in 
HepG2 liver cancer cells using CLSM. HepG2 cells were 
cultured on poly-D-lysine–coated cover slips (#1.5; Menzel 
Glasbearbeitungswerk GmbH & Co, KG,  Braunschweig, 
Germany). Cells were incubated at 37°C with Ps 
(100–500 µg/mL) or liposomes (0.14 mM of  phospholipids) 
loaded with QDs. Nucleus counterstaining was performed 
by adding Hoechst 33342 dye (1 µg/mL) to the cells 
5 minutes before the completion of the uptake assay. Cells 
were washed three times with cold D-PBS (Dulbecco’s PBS) 
and fixed for 15 minutes with 2% paraformaldehyde at 4°C. 
After an additional wash, slides were embedded in Prolong 
Gold antifade reagent (Gibco) and sealed with nail polish 
after  drying. Samples were analyzed with an  Olympus 
FV-1000 inverted confocal laser scanning microscope 
 (Olympus, Le  Mont-sur-Lausanne,  Switzerland), using 
a 60× Plan Apo N oil-immersion objective  (numerical 
aperture 1.40), and images were processed using either 
the Olympus  FluoView software (v3.1,  Olympus) or Gimp 
software (v2.8; GNU image manipulation program, http://
www.gimp.org).  Intracellular QDs were activated by light-
emitting diodes (LEDs) with a wavelength of 400 nm 
(210 mW/cm2) or 490 nm (190 mW/cm2),37 using a pE-2 
LED (CoolLED Limited, Andover, UK) excitation system. 
For activation, samples were exposed to a wavelength of 
490 nm for 1 minute prior to analysis.
Results and discussion
characterization of Ps
These last years, the development of Ps for technical or phar-
maceutical applications is increasing. In this study, we have 
formulated Ps with a PDMS-PMOXA diblock copolymer, 
composed of 65 siloxane and 14 2-methyloxazoline units 
(Figure 1B),28,31 as nanosized carriers for QDs.
Size and morphology of extruded PDMS-PMOXA Ps 
were determined by DLS and TEM (Figure 1). The mean 
hydrodynamic diameter was approximately 205 nm for empty 
Ps and 223 nm for Ps-containing QDs (Figure 1A). Table 1 
shows the polydispersity index (PDI) of free QDs, empty Ps, 
and Ps-containing QDs. The very low PDI values for both 
Ps preparations indicated a homogeneous population with a 
very narrow size distribution range.
However, the absence of a significant difference in 
average diameters of the two Ps preparations suggests that 
encapsulation of high-molecular weight QD nanoparticles 
did not affect the molecular self-assembly of PDMS-
PMOXA copolymers into Ps. In TEM investigations, we 
observed spherical vesicles with a diameter of approxi-
mately 200 nm, confirming the formation of Ps. Collapsed 
Ps revealed a hollow vesicular structure (Figure 1C). 
A recent report on self-assembly of a similar molecular 
composition of PDMS-PMOXA into vesicular structures 
supports our findings.28
loading of QDs into Ps
TEM investigations showed the presence of monodispersed 
QDs inside the Ps. QDs incorporated into Ps had the same 
appearance as free QDs in suspension, confirming that QDs 
were located in the aqueous compartment of the Ps without 
any aggregations. The morphology of empty Ps and Ps loaded 
with QDs remained the same (Figure 1D), confirming that 
encapsulation of QDs did not affect the formation of Ps. 
The number of QDs per Ps ranged from a single QD to tens 
of QDs, according to the statistical probability of available 
QDs in close proximity (for loading) during Ps formation. 
The stabilizing effect of the Ps provides indirect evidence 
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Figure 1 chemical composition, size, and morphology of PDMs-PMOXa Ps-
containing QDs. (A) size distribution of Ps determined by Dls. average diameter 
of Ps was 200 nm (dashed line: empty Ps, dot-dashed line: Ps-containing QDs); 
(B) chemical structure of PDMs-PMOXa amphiphilic block copolymers; (C) TeM 
analysis of Ps; (D) TeM analysis of Ps-containing QDs.
Note: The scale bars represent 100 nm.
Abbreviations: Dls, dynamic light scattering; PDMs-PMOXa, poly(dimethylsilo-
xane)-poly(2-methyloxazoline); Ps, polymersomes; QDs, quantum dots; TeM, trans-
mission electron microscopy.
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that the QDs are contained inside the Ps, and are not just 
loosely attached to the outer surface of the Ps membrane. 
Figure 2A shows characteristic emission spectra of free 
QDs, empty Ps, and Ps-containing QDs at the excitation 
wavelength of 405 nm. The appearance of the characteristic 
emission of QDs without any shift in the Em
max
 (625 nm) in 
Ps-containing QDs and the absence of this emission peak 
in empty Ps demonstrated the loading of QDs in Ps without 
alteration of the fluorescent properties of QDs. Thus, QDs 
can be incorporated into Ps without aggregation and with-
out affecting the fluorescence properties of QDs. The main 
advantage of QDs is not their high quantum yield, which is 
often lower than that of many organic dyes. However, their 
high absorption rate and increased photostability finally 
result in a brighter fluorescence signal. Moreover, the Stokes 
shift leads to a very low background signal. In Figure 2A, 
fluorescence signals obtained from Ps-containing QDs are 
lower than from free QDs. This can be explained by the fact 
that QDs are encapsulated within Ps, which absorbs some of 
the excitation light. In addition, not all QDs were entrapped 
within the Ps during their preparation and were thus lost 
during the consecutive purification steps. However, this 
reduced fluorescence intensity of encapsulated QDs can be 
easily compensated by an increased excitation light intensity 
since there is no risk of photobleaching.
Free QDs are characterized by a negative surface charge 
(zeta potential: −25 mV; Table 1). After loading into Ps, the 
zeta potential increases to 9 mV. This positive value is very 
similar to the zeta potential of empty Ps. Thus, masking of the 
surface charge of QDs after loading into Ps is an indication 
of their presence within the Ps as opposed to a mere binding 
to the outer surface of the Ps.
FCS analyzes the intensity fluctuations of molecules 
in a defined confocal volume. These signals can be cor-
related to the diffusion time of molecules (τ
D
). We deter-
mined that τ
D
=4,000 µs for freely diffusing QDs and 
τ
D
=15,000–17,000 µs for QDs loaded into Ps (Figure 2B). 
This is in agreement with the reported diffusion time of 
Ps of a similar size based on the PDMS-PMOXA block 
copolymer.28
Molecular brightness measurements have been used to 
calculate the number of fluorescent molecules encapsulated 
inside each polymersome.25,38 We estimated the average 
number of QDs per polymersome based on brightness 
obtained from the count rate per molecule (cpm, kHz). We 
calculated an average of four QDs/polymersome based on 
the brightness of free QDs and QDs encapsulated in Ps. The 
loading efficiency of Ps in our study was comparable with 
the reported loading efficiency of liposomes (ie, three QDs/
liposome on average).39,40 However, we aimed to improve the 
loading efficiency by introducing 5% amine-functionalized 
PDMS-PMOXA copolymers in hydroxyl-functionalized 
PDMS-PMOXA copolymers to generate charges in the copo-
lymer system (Figures S1–S4 in supplementary material). We 
calculated an average of eight QDs/Ps based on brightness 
measurements. This was clearly superior to the loading of 
purely hydroxyl-functionalized copolymers (neutral charge). 
Our results suggest that introducing a small amount of amine-
functionalized monomers to the copolymer system causes 
favorable electrostatic interactions leading to improved 
loading efficiency. Geometric considerations and analysis 
of TEM images suggest that much higher loading efficiency 
can be achieved up to a theoretical maximal up-loading con-
tent of 4,900 QDs per polymersome. However, the achieved 
accumulation of QDs at picomolar concentrations within 
individual Ps is sufficient to induce a bright fluorescence 
signal suitable for cellular imaging (see below).
stability of Ps-containing QDs
The stability of Ps-containing QDs was investigated using 
size measurements by DLS, morphology analysis by TEM, 
Table 1 size, PDI, and surface charge of QDs and Ps
Sample Diameter  
(nm)
PDI Zeta potential 
(mV)
Free QDs 7–10a nd −24.18
empty Ps 205±7 0.075 5.62
Ps-containing QDs 223.9±9 0.053 9.69
Note: asize according to data provided by the manufacturer for ITK™ carboxyl 
quantum dots (Invitrogen, life Technologies, lucerne, switzerland).
Abbreviations: nd, no data; PDI, polydispersity index; Ps, polymersomes; QDs, 
quantum dots.
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Figure 2 Analysis of QDs loading efficacy by fluorescence spectroscopy and FCS. 
(A) Emission fluorescence spectra of free QDs (dotted-lines), Ps-containing QDs 
(dot-dashed lines), and empty Ps (dashed lines), excitation wavelength 405 nm; 
(B) FCS auto-correlation curves, experimental (solid lines) and fitted (dashed-lines) 
of free QDs (dotted-lines) and Ps-containing QDs (dot-dashed lines).
Abbreviations: Fcs, fluorescence correlation spectroscopy; Ps, polymersomes; 
QDs, quantum dots; RFU, relative fluorescent units.
CHAPTER 3. PUBLISHED AND SUBMITTED RESULTS
90
International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2292
camblin et al
and FCS analysis yielding release profiles of QDs from Ps. 
These tests were carried out over a period of 6 weeks at regu-
lar intervals (Figure 3). We did not observe any significant 
changes in size (∼200 nm) or size distribution, suggesting 
that Ps were highly stable and remained intact (Figure 3D). 
In addition, TEM showed the presence of QDs inside the Ps 
(∼200 nm), with no free QDs outside the Ps between day 1 
and week 6 (Figure 3B and C).
For stability analysis, auto-correlation curves obtained 
with FCS were f itted with a two components model. 
 Diffusion times of free QDs were determined independently 
and were included in the fitting procedure. The majority of 
the particle population (99.9%) represented QDs encapsu-
lated in Ps, as confirmed by corresponding diffusion times 
(τ
D
=15,000–17,000 µs), that were similar to those of freshly 
prepared Ps loaded with QDs (Figure 3A). This finding 
confirms that QDs were not released from the Ps even after 
6 weeks, due to the robust impermeable membrane of the Ps 
(∼15 nm).28 In addition, passive transmembrane diffusion is 
unlikely due to the high molecular weight of the QDs. Thus, 
DLS, TEM, and FCS experiments clearly indicated that Ps 
were highly stable. They retained their size and shape and 
entrapped the QDs for a long period of time.
cellular viability (MTT) assay
Various types of PMOXA-PDMS-PMOXA tri-block copo-
lymers were previously suggested to be non-toxic and non-
immunogenic.30,31 The PDMS-PMOXA diblock copolymer 
used in the present study showed no cellular toxicity in a 
HepG2 human liver carcinoma cell line (Figure 4). There 
was no loss of viability in HepG2 cells after 24 hours of 
incubation with PDMS-PMOXA Ps at concentrations up to 
300 µg/mL.
cellular uptake of Ps-containing QDs
Time-and dose-dependent uptake kinetics of Ps- 
containing QDs were studied using incubation times 
of 1, 7, and 24 hours and different polymer concentrations 
B
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Figure 3 long-term stability of Ps-containing QDs.
Notes: (A) Fcs auto-correlation curve of Ps-containing QDs at day 1 (dot-dashed lines) and Ps-containing QDs at week 6 (double dot-long dashed lines); (B) average particle 
size determined by Dls over 6 weeks (C) TeM analysis of Ps-containing QDs at day 1 (week 0); (D) TeM micrograph analysis of Ps-containing QDs at week 6; (E) TeM 
micrograph analysis of Ps-containing QDs after 1 year of storage at 4°c. average size determined by Dls for the Ps-containing QDs after of 1 year storage was 221.1 nm 
(PDI =0.068). scale bar represents 100 nm.
Abbreviations: Dls, dynamic light scattering; FCS, fluorescence correlation spectroscopy; PDI, polydispersity index; Ps, polymersomes; QDs, quantum dots; TEM, trans-
mission electron microscopy.
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(100 µg/mL, 300 µg/mL, 500 µg/mL). While no uptake was 
observed for any concentrations after 1 hour of incubation, 
the uptake rate increased linearly from 7 hours to 24 hours, 
indicating the time-dependent uptake of Ps-containing QDs. 
Simultaneously, we observed a gradual increase in the uptake 
rate between the low concentration (100 µg/mL) to higher 
concentration (300 µg/mL), suggesting dose-dependent 
uptake (Figure 5). The appearance of red fluorescent sig-
nals, mainly in the perinuclear regions, was indicative of the 
intracellular accumulation of Ps-containing QDs in HepG2 
cells. Concentrations of Ps used for imaging purposes rarely 
exceed 100 µg/mL. Under these conditions, cellular uptake 
is  minimal. Free QDs are rapidly taken up by living cells. 
 However, this process is not specific, and therefore QDs 
cannot be used to label defined tissues or sub-populations of 
cells within tissues. In addition, free Cd/Se QDs are cytotoxic 
because of their heavy metal core. In contrast, Ps-containing 
QDs were demonstrated in our work to be non-cytotoxic. 
Their cellular uptake is negligible. This absence of unspecific 
cellular interactions is a mandatory prerequisite for their 
use to implement specific targeting strategies. For this latter 
purpose (ie, to promote cellular targeting and uptake), Ps 
can be modified by covalent modification of their surfaces 
using, for example, receptor-specific targeting ligands. 
Thus, surface-modified, polymer-based nanoparticles can 
be conveniently labeled with stabilized QDs to study and 
visualize their cellular interactions.41 The low uptake between 
1 hour and 7 hours suggests that the PMOXA block acts as 
a protein repellent, reducing cellular interactions of Ps. This 
property has previously been described for other types of 
nanoparticles such as PEGylated liposomes,41 and is a pre-
requisite for in vivo implementation of targeting strategies. 
Thus, prolonged incubation (24 hours) was needed to induce 
forced uptake by HepG2 cells. We presume that  cellular 
1 hour
10
0 
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/m
L
30
0 
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/m
L
7 hours 24 hours
Figure 5 Dose- and time-dependent uptake of Ps-containing QDs in hepg2 cells. Ps concentrations incubated with hepg2 cells were 100 µg/ml (upper row, recommended 
concentration) to 300 µg/ml (lower row). Incubation times were 1 hour (left column), 7 hours (center column), and 24 hours (right column, condition of forced uptake). 
QDs were photo-activated at a wavelength of 490 nm for 1 minute. Red fluorescence: Ps-containing QDs, blue fluorescence: nuclei stained with Hoechst 33342.
Note: scale bars represent 10 µm.
Abbreviations: Ps, polymersomes; QDs, quantum dots; hepg2, human liver carcinoma cells.
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Figure 4 Viability of hepg2 cells incubated with Ps (MTT assay). hepg2 cells 
showed no loss of viability after 24 hours of incubation with different concentrations 
of Ps (50–300 µg/ml).
Note: Data are means ± sD, n=3.
Abbreviations: Ps, polymersomes; hepg2, human liver carcinoma cells.
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uptake can be further increased by surface modifications of 
the Ps, such as, for example, cationization or coupling of 
specific receptor ligands.41 Previous publications suggest that 
cellular uptake of nanoparticles is a prerequisite to induce 
cellular toxicity.42 In order to explore the potential toxic 
effect of the Ps, the concentration in medium was increased 
to 300 µg/mL. A long incubation time (24 hours) under these 
conditions led to cellular uptake. However, the MTT assay 
demonstrated an absence of toxicity under these conditions of 
forced uptake. Therefore, we recommend to limit incubation 
times with Ps-containing QDs to 24 hours and not to exceed 
a polymer concentration of 100 µg/mL.
Intracellular stability  
of Ps-containing QDs
QDs encapsulated in Ps or liposomes can be photoactivated by 
UV irradiation at 405 nm. This is a widely used technique to 
enhanced fluorescence signals of QDs in suspension or cells.43 
Photoactivation was made evident by a blue-shift of cellular 
emission fluorescence signals by 10 nm (Ps) or 15 nm (lipo-
somes), as compared to free QDs (Figure 6C). This is indicative 
of the slow degradation of the QD core under these conditions. 
In liposomes, photoactivation of encapsulated QDs resulted in a 
blurred and unspecific staining of the whole cell cytoplasm (data 
not shown, preparation of liposomes containing QDs can be 
found in supplementary material). However, photoactivation of 
QDs in Ps resulted in a sharp and punctuated intracellular stain-
ing pattern (Figure 6A and B). These results suggest that QDs 
encapsulated in Ps were retained in the intact polymer vesicles, 
whereas QDs encapsulated in liposomes were released into the 
cytoplasm due to degradation of the liposomal carrier.
In living cells, photoactivation of QDs is caused by the 
generation of reactive oxygen species (ROS) within the target 
cell.43 In view of the pronounced intracellular stability of Ps, 
the question arises how oxidation of QDs within Ps can be 
induced by cellular ROS. It was recently proposed that the 
membranes of Ps are permeable to ROS, such as superoxide 
or singlet oxygen, which are major contributors to the deg-
radation of the QD surface.43,44
For a similar type of Ps made of PMOXA-PDMS-
PMOXA, ROS were reported to permeate the polymer 
membrane. Ps remained stable inside cells after having 
escaped from  endosomes without releasing the encapsu-
lated compounds.24,25,45 Therefore, it is possible that in our 
experiments, QDs were partially degraded inside the Ps 
without being released. Due to the stability of Ps in cellular 
conditions, degradation of QDs and background signals 
were dramatically lower in Ps than in liposomes. Similarly, 
increased photo-enhancement of QDs embedded in silica 
colloids have been reported in living cells, due to partial deg-
radation mediated by oxidation with minimal  aggregation.46 
Results suggested that Ps protect QDs from biological inter-
actions in cell compartments, thus improving the quality of 
cellular imaging.
Conclusion
QDs are a promising tool for a variety of bio-imaging 
 applications. However, their use in biological systems is 
limited by their chemical instability and toxicity. We dem-
onstrated that loading of QDs into Ps made of the diblock 
copolymer PDMS-PMOXA may overcome these problems. 
In particular, Ps-containing QDs were stable for a prolonged 
time upon storage and had improved optical properties after 
cellular uptake.
The implications of these findings are two-fold. First, 
 stabilization of QDs by a protective shell of diblock 
 copolymers may facilitate their preparation, storage, and use 
in biological systems. Second, chemical modification of the 
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Figure 6 Fluorescence activities of QDs loaded into Ps under intracellular conditions.
Notes: hepg2 cells were incubated with Ps-containing QDs (red signal) and were analyzed before (A) and after (B) photo-activation at a wavelength of 400 nm for 
15 seconds. (C) emission peak of a lambda scan of intracellular QDs in Ps (solid lines) and in liposomes (dashed-lines) compared with free QDs (dotted-lines). Nuclei were 
stained with hoechst 33342 (blue signal).
Abbreviations: Ps, polymersomes; QDs, quantum dots; hepg2, human liver carcinoma cells.
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Ps surface may improve their recognition and uptake by target 
cells. Therefore, design of such targeted Ps offers the pos-
sibility to deliver QDs to specific cellular targets within the 
organism for diagnostic purposes or imaging applications.
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Supplementary material
Materials and methods
Preparation of liposomes containing QDs
A mixture of lipids of disuccinatocisplatin (DSPC; 5.5 µmol), 
cholesterol (4.5 µmol), and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-poly(ethylene glycol) (DSPE-
PEG; 0.27 µmol), were dissolved in chloroform/methanol 
(2:1, volume/volume). The solution was evaporated by vacuum 
in a water bath at 60°C for 1 hour to form a homogenous lipid 
film using a rotary evaporator (Rotavapor, BÜCHI Labortech-
nik AG, Flawil, Switzerland). The lipid film was hydrated for 
10  minutes in 1 mL in a 100 nM solution of QDs (Qdot® ITK™ 
carboxyl quantum dots; Invitrogen, Life  Technologies, Lucerne, 
 Switzerland) in 0.1 M phosphate buffer solution (PBS) contain-
ing 1 mM EDTA, pH 7.2;  extrusion was performed five times 
through a polycarbonate filter with an average pore diameter 
of 0.2 µm, followed by nine extrusions through a filter with 
an average pore diameter of 0.08 µm (Nucleopores, Whatman, 
VWR International AG, Dietikon, Switzerland).
Liposomes containing QDs were purified by size exclu-
sion chromatography using a Superose 6 prep column 
(1.6 × 20 cm), (GE Healthcare, Cleveland, OH, USA) eluting 
with 0.01 M PBS, pH 7.2.
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Figure S3 Analysis of QDs loading efficacy by fluorescence spectroscopy. Emission 
fluorescence spectra of free QDs (dotted-lines), Ps with 5% amine function containing 
QDs (long-dashed lines), and empty Ps (dashed lines), excitation wavelength 405 nm.
Abbreviations: Ps, polymersomes; QDs, quantum dots; RFU, relative fluorescent 
units.
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Figure S1 Size of Ps made of PDMS-PMOXA with 5% amine function (long-dashed 
lines), loaded with QDs. average diameter of Ps was 210 nm.
Abbreviations: PDMs-PMOXa, poly(dimethylsiloxane)-poly(2-methyloxazoline); 
Ps, polymersomes; QDs, quantum dots.
Figure S2 TEM morphology analysis of Ps made of PDMS-PMOXA with 5% amine 
function, loaded with QDs.
Note: scale bar represents 100 nm.
Abbreviations: PDMs-PMOXa, poly(dimethylsiloxane)-poly(2-methyloxazoline); 
Ps, polymersomes; QDs, quantum dots; TeM, transmission electron microscopy.
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a b s t r a c t
Drug-induced toxicity is of considerable concern in drug discovery and development, placing emphasis
on the need for predictive in vitro technologies that identify potential cytotoxic side effects of drugs.
A label-free, real-time, multiparametric cytosensor system has therefore been established for in vitro
assessment of drug-induced toxicity. The system is based on monitoring cellular oxygen consumption,
acidification and impedance of human hepatocarcinoma-derived HepG2 cells. The read-out derived from
the multiparametric cytosensor system has been optimised and permits sensitive, reliable, and simulta-
neous recording of cell physiological signals, such as metabolic activity, cellular respiration and morpho-
logical changes and cell adhesion upon exposure to a drug.
Analysis of eight prototypic reference drugs revealed distinct patterns of drug-induced physiological
signals. Effects proved to be rigidly concentration-dependent. Based on signal patterns and reversibility
of the observed effects, compounds could be classified based as triggering mechanisms of respiratory or
metabolic stress or conditions leading to cell death (necrosis-like and apoptosis-like). A test-flag-risk mit-
igation strategy is proposed to address potential risks for drug-induced cytotoxicity.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
The prediction of chemically induced toxicity in animals or hu-
mans remains a challenge. Biochemical or cell based in vitro test sys-
tems often fall short in predicting toxicities involving multiple
organs, such as inflammation or immune-mediated adverse reac-
tions, or events associated with adaptation to chronic chemical
exposure. However, such models have nevertheless been proven to
provide valuable insight into molecular mechanisms of toxicity on
a cellular level. This is in particular true for organotypic liver cell cul-
ture models, whichmay be applied in situations where biotransfor-
mation and bioactivation of chemicals contribute to their toxicity
(LeCluyse et al., 2012). In the field of clinical toxicology, drug-in-
duced liver injury (DILI) is a prime example of a chemically induced
liver injury, which in 80% of all cases is caused by direct concentra-
tion-dependent toxicity of an administered drug or its metabolites
(Smith and Schmid, 2006). Drugs that exhibit such chemical (direct)
hepatotoxicity have predictable dose–response curves and well
characterised mechanisms of toxicity. Examples include promotion
of dysfunctionof physiological pathways andfinally cell deathbydi-
rect insult by chemically reactive compounds, induction of an apop-
totic process or infliction of cellular stress (David and Hamilton,
2010). The latterphenomenon isoftenobserved in thecontextof oxi-
dative or metabolic stress, where inhibition of the mitochondrial
respiratory chain results in a release of reactive oxygen species
(ROS) to an excessive level and depletion of adenosine triphosphate
(ATP) (Berson et al., 1996; Fromenty and Pessayre, 1995; Jaeschke
et al., 2002). Furthermore, certain drugs influence mitochondrial
activity by inhibiting fatty acid b-oxidation (Fromenty and Pessayre,
1995), impairingmitochondrial DNA replication (Setzer et al., 2008)
or opening themitochondrial permeability transition pore, which is
implacably associated with cell death (Lee and Farrell, 2001). All of
the physiological dysfunctions mentioned above ultimately lead to
hepatic tissue damage. If energy is available in the form of ATP, in-
jured cells enter programmed cell death (apoptosis). If ATP sources
are exhausted, cells follow the necrosis pathway, enhancing hepatic
inflammation (Leist et al., 1997).
0887-2333/$ - see front matter  2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.tiv.2013.02.001
Abbreviations: ATP, adenosine triphosphate; DMSO, dimethyl sulfoxide; GSH,
glutathione; IU, international unit; NAPQI, N-acetyl-p-benzoquinone imine; ROS,
reactive oxygen species.
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Drug-induced toxicities leading to organ dysfunction are gener-
ally paralleled by a rise in biochemical markers such as liver-spe-
cific alanine aminotransferase or alkaline phosphatase (Liss and
Lewis, 2009). These initial indicators of cell damage, when ob-
served during the drug discovery and development process, call
for alert and necessitate mechanistic follow-up studies. Such stud-
ies are ideally based on the use of additional biomarkers as predic-
tors and are time consuming and costly if performed in
experimental animals (Liss et al., 2010). However, in view of the
poor correlation between clinical findings of toxicity and standard
preclinical animal studies, such efforts remain a challenge and are
in some cases a source of concern for investigators and regulatory
authorities. Ongoing efforts are therefore directed towards the
development of predictive in silico or in vitro models to gain better
insight into mechanisms leading to cytotoxicity. One strategy is the
use of cytosensor systems, where a silica-based sensor system al-
lows online-monitoring of metabolic activity in target cells in the
presence of potentially toxic chemicals (Twiner et al., 1998). Re-
cently, we used a multiparametric, chip-based sensor system to
determine extracellular acidification, and cell respiration and
adhesion in a cell line overexpressing the drug efflux transporter
P-glycoprotein (P-gp) (Seeland et al., 2011). In light of the sensitiv-
ity of such cytosensor systems to deviations in the metabolic bal-
ance between glycolysis and mitochondrial respiration, the
question arises as to whether this approach might be adapted to
monitor the early onset of drug-induced cellular damage in vitro.
The aim of the present study was therefore to implement and
validate a cell-based multiparametric sensor system to character-
ise drug induced cytotoxicity. For this approach, eight prototypic
drugs known to be hepatotoxic in therapeutic use were investi-
gated with respect to their toxicological potential on human hepa-
tocarcinoma-derived HepG2 cells. The distinct difference in the
mechanisms of toxicity and liver pathology were considered dur-
ing the selection of theses eight drugs. The HepG2 cell line is fre-
quently used as a model system because these cells are adherent,
well established and characterised by a limited potential to metab-
olise drugs in terms of cytochrome P450 monooxygenase metabo-
lism. Emphasis was placed on the assessment of mitochondrial
respiration, glycolytic (catabolic) activity and/or morphological
changes and cell adhesion as major cellular markers for toxicity.
Based on the nature of cellular response, different types of effects,
including necrosis-like, apoptosis-like and metabolic or respiratory
stress, were discriminated.
2. Material and methods
2.1. Compounds
All chemicals were purchased from Sigma (Buchs, Switzerland)
if not otherwise indicated. Amiodarone, cyclosporine A, doxorubi-
cin, isoniazide, and methotrexate were used as stock solutions dis-
solved in either water or dimethyl sulfoxide (DMSO). DMSO
concentrations in none of the experiments exceeded 1% (v/v). Acet-
aminophen, D-sorbitol and valproic acid were directly dissolved in
assay medium. The pH of solutions was adjusted to pH 7.4 prior to
the experiment. The MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) stock solution was prepared in
phosphate buffered saline at a concentration of 5 mg/mL, then
was sterile-filtered and stored at 4 C in the dark.
2.2. Cell culture
The human epithelial hepatocarcinoma-derived cell line HepG2
was obtained from the American Type Culture Collection (ATCC,
Rockville, MD, US) and was maintained under standard cell culture
conditions as described previously (Van Summeren et al., 2011). In
brief, cells were cultivated at passage numbers 3–15 in modified
Eagle medium (MEM) with 1 g/L glucose and 2 mM GlutaMAX™
(Life Technologies, Carlsbad, CA, US) supplemented with 1 mM so-
dium pyruvate, 1% (v/v) non-essential amino acids, 50 IU/mL pen-
icillin, 50 lg/mL streptomycin and 10% (v/v) heat-inactivated
foetal bovine serum (PAA Laboratories, Pasching, Austria) in a
humidified atmosphere containing 5% carbon dioxide. Prior to
the experiment, HepG2 cells were detached by trypsination, viabil-
ity determined by a Vi-cell XR analyser (Beckman Coulter, Krefeld,
Germany) and seeded onto pre-warmed, non-coated metabolic
sensor chips at a density of 2  105 cells/chip. Seeded cells were
incubated for at least 20 h prior to use. Integrity of the cell mono-
layer covering the surface of the cytosensor chip was verified using
a Motic DM-39C reflected-light microscope (Motic Group Ltd.,
Hong Kong, China). Cell monolayers with a cellular confluence be-
low 80% were rejected for use. It should be noted that expression of
drug transporters such as P-glycoprotein by HepG2 cells (Hilgen-
dorf et al., 2007) may influence drug uptake by this cell line and
thereby modulate its response towards toxic insults. The mRNA
expression level of MDR1 in primary human hepatocytes is in the
range of the one of HepG2 cells (Le Vee et al., 2006) and below
the level of human liver tissue (Hilgendorf et al., 2007).
2.3. Cytosensor experiments
A Bionas2500 cytosensor system (Bionas, Rostock, Germany)
was used to record cell physiological parameters continuously.
The system consists of six metabolic sensor chips SC1000 working
in parallel and containing ion-sensitive field effect transistor- (IS-
FET) and Clark-type sensors for the measurement of changes of
acidification and oxygen consumption. Cell adhesion, morphologi-
cal changes, and membrane functionality were monitored by
means of impedance measurements. The cytosensor system was
used as described previously (Seeland et al., 2011) with the follow-
ing modifications: a flow head with 200 lm spacers (as deter-
mined by the distance between the flow head and the sensor
chip surface) was used (Fig. 1) leading to an effective chamber vol-
ume of 5.7 lL. The assay mediumwas prepared from a 10-fold con-
centrated, modified Eagle medium (Life Technologies, Basel,
Switzerland) supplemented with 2 mM GlutaMAX, 1 mM sodium
pyruvate, 1% (v/v) non-essential amino acids, 25 IU/mL penicillin,
25 lg/mL streptomycin, and 0.1% (v/v) heat-inactivated foetal bo-
vine serum. The assay medium contained neither Hepes nor so-
dium bicarbonate and was adjusted to pH 7.4 using sodium
hydroxide. During analysis, the assay medium was delivered to
the cells at a constant flow rate of 56 lL/min and interrupted peri-
odically (stop phases and pump phase lasted 3 min each) as de-
scribed previously (Seeland et al., 2011). Raw data were recorded
by all sensors at intervals of 10 s to obtain 18 raw data points
per cycle. A linear regression analysis was performed to determine
initial rates of extracellular acidification and respiration. Rates
were calculated based on datapoints recorded during the stop
phases of the experiment. The Bionas data analyser software (ver-
sion 1.66) was used for data evaluation. Impedance measurements
were carried out continuously to monitor cell adhesion and thus
cell morphology and membrane functionality (Ehret et al., 1998).
Signals were normalised to a reference value, which represented
the baseline signal of a cell-coated chip prior to treatment with
the compound. At the end of each experiment, 0.2% (v/v) Triton
X-100 was added to the cells to detach cells from the surface of
the sensor chip. The signal that was generated under these condi-
tions was used to provide a reference signal from the cell-free sen-
sor surface (0% baseline value). Data from the metabolic sensor
chip were recorded after a stabilisation phase of 3 h, which re-
sulted in a constant baseline signal from the different sensors. Cells
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were incubated for 19 h with the test compounds (Table 1). For
those compounds whose stock solutions were prepared in other
media, an equivalent amount of DMSO was added to the incuba-
tion medium. DMSO concentrations were below 1% (v/v) in all
experiments. The drug treatment phase was followed by a 2 h
wash-out period to detect cell recovery processes if occur.
2.4. MTT cell viability assay
HepG2 cells were seeded in 96-well plates at a density of
5  104 cells/well and were cultured as described above. Twenty-
four hours after seeding, medium was removed and 100 lL ali-
quots of cell culture medium containing the test compounds were
added to each well in triplicate. Control cells were incubated in the
presence of 1% (v/v) DMSO (100% viability control). After 24 h, cell
culture medium was replaced by 100 lL cell culture medium con-
taining 10% (v/v) MTT stock solution. Cells were incubated for
additional 2 h at 37 C. In a final step, the cell culture medium
was discarded and reduced MTT, which is present as water-insolu-
ble formazan dye crystals, was dissolved by adding 20 lL of 3% (v/
v) sodium dodecylsulphate solution in water, and 100 lL of a
40 mM hydrochloric acid in isopropanol. Optical density was mea-
sured at 550 nm using a Spectramax M2 plate reader (Molecular
Devices, Sunnyvale, CA, US). The 24 h incubation in the MTT assay
is comparable to the 24 h total duration of the cytosensor assay
considering a 19 h incubation time with test compound and a 5 h
pre- and post-conditioning phase.
2.5. Data analysis and statistics
The calculation of the standard rates was done with the Bionas
2500 Data Analyzer software (Version 1.66, Bionas, Rostock, Ger-
many). The control (running medium without drug) was norma-
lised to 100% and was used for better visualisation. The
evaluation and interpretation of the multiparametric cytosensor
system data was performed using GraphPad Prism software (Ver-
sion 5.04, GraphPad Software Inc., La Jolla, CA, USA). Each experi-
ment was performed at least in triplicates. MTT test was
performed two times in quadruplicate samples. The calculations
for the MTT were performed using Microsoft Excel and the results
are expressed as the mean ± SD, where SD is the standard
deviation.
3. Results
3.1. Experimental setup using a multiparametric cytosensor system
Changes in three cellular parameters (i.e. extracellular acidifi-
cation, oxygen consumption and impedance) were monitored in
real-time using a multiparametric cytosensor system. The experi-
mental set-up was optimised to achieve maximal sensitivity to
physiological alterations (Fig. 1). Important assay parameters in-
cluded the use of an assay medium (see section cytosensor exper-
iments) with a low buffer capacity which was additionally
supplemented with 0.1% (v/v) heat-inactivated foetal bovine serum
albumin. Optimal cell density was determined as 2  105 viable
HepG2 cells per chip. Minimal required cell viability, estimated
by a trypan blue dye exclusion test, was 90%. The effective volume
of the incubation chamber, i.e. the volume of the space between
the surface of the sensor chip and the chamber lid, was 5.7 lL
and was determined by the distance (200 lm) between the flow
head and the sensor chip surface (Fig. 1). This minimal volume en-
hances the responsiveness of the systemwith respect to alterations
in pH and oxygen partial pressure. Signals from cell respiration,
acidification, and impedance were recorded after an initial stabili-
sation phase of 3 h. Subsequently, cells were exposed to test com-
pounds for 19 h followed by a drug wash-out period of 2 h to
detect cell recovery. After the experiment, baseline signals of the
cell-free cytosensor chips (i.e. 0% reference signal) were recorded
after solubilisation of cells using a non-ionic detergent (Triton X-
100). Cellular adhesion was monitored continuously by measure-
ments of cellular impedance. Thus, signals from the three sensor
types were recorded relative to initial conditions (100% reference
signal) and 0% background signal. Eight marketed drugs were used
at, above, and below their clinically relevant plasma concentra-
tions to study hepatotoxic effects in vitro (Table 1). In control
experiments, the metabolic activity of HepG2 cells was assessed
by 19 h incubations of acetaminophen and amiodarone (20 lM
each, data not shown). Metabolites were detected using high-reso-
lution liquid chromatography coupled with mass spectrometry in
positive ion mode. Acetaminophen incubations with HepG2 cells
resulted in formation of an oxidised metabolite (m/z 168,
0.1 lM), N-acetyl-p-benzoquinone imine (NAPQI) (m/z 150,
0.6 lM), and two phase II metabolites (a cysteine adduct at m/
z 271, 5.0 lM and a glucuronic acid conjugate at m/z 328,
4.4 lM). In incubations with amiodarone, the major metabolite
was desethylamiodarone (m/z 618, 1.0 lM) accompanied by a hy-
drated- (m/z 648, 0.1 lM), a dehydrated- (m/z 644, 0.1 lM) and an
oxidised metabolite (m/z 662, 0.1 lM). These results are in line
with previous reports suggesting residual metabolic phase I activ-
ity and intact phase II metabolism in HepG2 cells (Roe et al., 1993;
Westerink and Schoonen, 2007a,b).
3.2. Effect of D-sorbitol on HepG2 cells
D-sorbitol, known to be well tolerated even at high concentra-
tions and non-toxic, was used as a negative control (Lederle,
1995). D-sorbitol (Fig. 2) showed no relevant effects in the multi-
parametric cytosensor system at concentrations from 0.001 mM
to 5.0 mM. A small but continuous increase in cellular oxygen con-
sumption, reaching 110–120% of the control values, was detected
at all concentrations.
Fig. 1. Schematic diagram of the experimental setup of the multiparametric
cytosensor system. Incubation volumes, flow rates, and dimensions of the perfusion
chamber are shown. The direction of the flow of incubation medium is indicated by
arrows. The core of the system consists of a sensor chip with a surface area of
75 mm2.
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3.3. Effect of acetaminophen on HepG2 cells
Acetaminophen was used in a concentration range of 0.01–
10 mM (Fig. 2) and induced concentration-dependent effects in
the multiparametric cytosensor system at all considered parame-
ters over a 19 hour incubation period. The change in impedance
was indicative of shrinking and retraction of cells reflected by a
maximal drop to 80% from baseline values at 10 mM acetamino-
phen within the first 70 min after addition of the compound. It
then remained at around 80–90% for the remaining incubation
time. Impedance was reversible in the recovery phase, reaching
baseline levels similar to the initial values prior to acetaminophen
treatment. The osmolality of control assay medium and assay
medium containing 10 mM acetaminophen were 272 mmol/kg
and 280 mmol/kg, respectively, as determined by the freeze point
depression method. This is within the physiological range of
osmolalities of human plasma (i.e. 276–295 mmol/kg) (Glasser
et al., 1973). Reduction of cellular oxygen consumption was de-
tected immediately after acetaminophen application. Maximal
reduction was observed at 20 min after drug application reaching
40% of baseline values and was constant until the end of drug
treatment. Conversely, at the same time, extracellular acidity in-
creased in a concentration-dependent manner up to 130%
(10 mM) and remained constant at this level over six hours before
it returned to initial baseline levels. These effects were partially
reversible during the recovery phase, reaching values equal to
those prior to drug treatment. In the MTT test, cell viability was
significantly decreased (Table 2) showing a reduction to 80%
and 62% in cell viability at 1 mM and 10 mM acetaminophen,
respectively.
3.4. Effect of amiodarone on HepG2 cells
Amiodarone caused intense changes in the multiparametric
cytosensor system experiments (Fig. 2). These changes were pro-
portional to the concentrations used, which covered a range of
1.0–30 lM. Concentrations below 10 lM amiodarone did not influ-
ence cellular physiology. However, pronounced effects were ob-
served at concentrations equal to and above 10 lM. Three hours
after amiodarone application, dying cells were released from the
sensor chip resulting in a persistent decrease in cell impedance.
At the end of the drug treatment period, only 16% (approx.
32,000 cells) of the initial cell number remained. At concentrations
of 10 lM and above, amiodarone affected mitochondrial respira-
tion and metabolic activity non-reversibly. The oxygen consump-
tion at 30 lM amiodarone described a steep drop until 280 min
post-treatment with 30% residual cell respiration, followed by a
levelling-off to 15% at the end of the incubation period. The extra-
cellular acidification at 15 lM and 30 lM amiodarone increased
with a maximal amplitude of 150% at 400 min post-treatment. At
30 lM amiodarone, this boost in metabolic activity changed into
a sustained reduction until the end of the drug-treatment with
only 7% metabolic activity left. In the MTT assay, amiodarone had
no statistical significant effect on HepG2 cell viability at all concen-
trations of the MTT assay (Table 2).
3.5. Effect of cyclosporine A on HepG2 cells
Cyclosporine A was analysed at concentrations up to 60 lM and
showed no obvious effects with respect to cell impedance (Fig. 2).
In cell respiration, concentrations below 30 lM showed no obvious
Table 1
Characteristics and toxicological profiles of reference drugs used in the present study.
Drug Indication (Cmax, range of
therapeutic plasma
concentration)
Mechanism of toxicity Reactive
metabolites
Liver pathology
Acetaminophen
NSAIDa 0.13 mM (el-Azab et al.,
1996; Stocker and Montgomery,
2001)
GSH depletion, mitochondrial toxicity (Zhou et al.,
2005; Leung et al., 2011; Kumari and Kakkar, 2012b)
N-acetyl-p-
benzoquinone
imine (NAPQI),
other quinones
Hepatocellular
degeneration
Amiodarone
Antiarrythmic 2.1 lM (Meng
et al., 2001)
ROS formation, mitochondrial toxicity (Fromenty et al.,
1990a,b; Kim et al., 2011)
Desethyl-
amiodarone
Steatosis,
hepatocellular
death
Cyclosporine A
Immunosuppresant 1.5 lM
(Grant et al., 1999)
Covalent binding to microsomal proteins, ROS
formation, oxidative stress (Zhou et al., 2005)
Reactive
metabolites
Cholestasis
Doxorubicin
Anticancer 1.9 lM (Speth et al.,
1988)
DNA intercalation, ROS formation, oxidative
stress,mitochondrial toxicity(King and Perry, 2001; Ye
et al., 2007)
Semiquinone
radical
Hepatocellular
death
Isoniazide
Antibacterial 0.11 mM
(McIlleron et al., 2006)
Oxidative stress, GSH depletion (Woo et al., 1992;
Zhou et al., 2005; Chowdhury et al., 2006; Bhadauria
et al., 2007, 2010)
Hydrazine,
reactive acetyl
species
Steatosis,
necrosis,
hepatocyte and
vasculature
damage
Methotrexate
Anticancer up to 1200 lM
Immunosuppressant 0.4 lM
(Comandone et al., 2005;
Shiozawa et al., 2005)
Inhibition of biosynthetic pathways, metabolic stress
(Kaminskas and Nussey, 1978; Kevat et al., 1988;
West, 1997; Cetin et al., 2008)
Polyglutamated
methotrexate
Fatty infiltration,
fibrosis, cirrhosis
D-Sorbitol
Laxative 70 lM (Hubinont et al.,
1981)
None None None
Valproic acid
Anticonvulsant 0.62 mM (Fisher
and Broderick, 2003)
Oxidative stress, altered mitochondrial b-oxidation
and oxidative phosphorylation, GSH/NACb depletion
(Fromenty and Pessayre, 1995; Tong et al., 2005b;
Zhou et al., 2005; Ji et al., 2010)
Acyl
glucuronides, 2-
N-propyl-4-
pentenoic acid
Necrosis,
steatosis,
cholestasis
a Non-steroidal anti-inflammatory drug.
b N-acetylcysteine.
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effects in the first 400 min of treatment, followed by a small in-
crease in oxygen consumption to 110% of baseline values. A de-
crease to 60% was monitored within the first 400 min after
application of 30 lM and 60 lM cyclosporine A, followed by a
nearly complete recovery of respiratory activity (90%) at the end
of the treatment period. The decrease in respiration at 30 lM
and 60 lMwas paralleled by an increase in extracellular acidificat-
ion up to 110%. Along the time course, this metabolic activity was
continually reduced to 90% at the end of the cyclosporine A incuba-
tion. The MTT assay showed a statistically significant reduction of
18% in cell viability at the highest concentration of 60 lM (Table 2).
No effects were observed in the MTT assay at concentrations below
60 lM.
3.6. Effect of doxorubicin on HepG2 cells
Cells treated with up to 25 lM doxorubicin were found to have
stable impedance during the experiments (Fig. 2). In contrast, oxy-
gen consumption was directly affected and reacted with a sudden,
concentration-dependent drop after drug application. At 25 lM
doxorubicin, cell respiration diminished to 46% within 230 min,
followed by a constant and non-reversible reduction to 30% during
the remaining incubation period. Simultaneously, extracellular
acidification was reduced in a concentration-dependent and non-
reversible manner. Doxorubicin initiated a sustained decrease of
this metabolic activity at 390 min post-application. At the end of
the incubation period, the extracellular acidification was in the
Fig. 2. (a) and (b) Representative patterns of cytosensor signals upon stimulation of HepG2 cells with selected drugs. Cells were incubated with the indicated concentrations
of reference drugs. Using the multiparametric sensor system, three physiological parameters were monitored on-line: cell impedance being an indicator for cell morphology/
adhesion, cellular respiration based on oxygen consumption and metabolic activity resulting in extracellular acidification. The grey areas indicate the initial stabilisation and
final recovery periods, which are carried out in the absence of a test compound. Depict are the mean patterns of nP 3 experiments.
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range of 75% and 90% for doxorubicin concentrations equal to and
above 5 lM and 1 lM, respectively. The 24 h incubations of doxo-
rubicin in the MTT assay indicate an impairment of cell viability
(Table 2) showing a 61% and 54% reduction in viability for 10 lM
and 25 lM doxorubicin, respectively.
3.7. Effect of isoniazide on HepG2 cells
Isoniazide was used in a concentration from 0.1 mM to 5.0 mM.
After applying isoniazide to HepG2 cells, a non-reversible and sus-
tained reduction to 90% in impedance was observed until the end
of the incubation period. An initial increase in cell impedance
was detected at the highest concentration (5.0 mM), reaching a
maximum of 110% at 400 min post-application (Fig. 2). Immedi-
ately after drug application, oxygen consumption decreased con-
tinually during the entire incubation period and remained at
levels of 60–80% for all concentrations used. Extracellular acidifi-
cation was not affected and remained stable during all experi-
ments. There was also no impact on cell viability as determined
by the MTT assay (Table 2), with a viability of 103% at 5.0 mM
isoniazide.
3.8. Effect of methotrexate on HepG2 cells
Methotrexate was investigated at concentrations from 1.0 lM
to 200 lM. The two highest concentrations of methotrexate
(100 lM and 200 lM) initiated a reduction of impedance at
80 min post-application, described by a sustained decrease to
86% of baseline values at the end of the incubation (Fig. 2). This
reduction was not reversible during the recovery phase, which
Fig. 2. (continued)
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indicates cell death and was corroborated by observations in the
MTT assay, where cellular viability was reduced to 79% at
200 lM (Table 2). The oxygen consumption curves at the two high-
est concentrations described an initial decrease to 78% during the
first 320 min after application, followed by a persistent increase,
reaching 125% at the end of the incubation. With the exception
of the initial decrease, treatment with 50 lM methotrexate
showed similar curves, reaching 145% of this cell respiration signal
at the end of the incubation. Extracellular acidification was inhib-
ited in a concentration-dependent manner 30 min after drug treat-
ment, with a maximal reduction to 70% at 200 lM and was
subsequent maintained at levels between 60% and 80%. In contrast
to oxygen consumption, extracellular acidification was restored
after the removal of the drug, reaching levels of around 90%.
3.9. Effect of valproic acid on HepG2 cells
Valproic acid was used in the concentration range of 0.5–
10 mM. An increase to 112% in cellular impedance was observed
during the first six hours of treatment with 10 mM valproic acid
(Fig. 2). After 640 min of treatment with 3–10 mM valproic acid,
dying cells detached from the sensor chip, indicated by a constant
decrease in cell impedance. Half of the initial cell amount
(1  105 cells) remained on the sensor chip at the end of the incu-
bation period with 10 mM valproic acid. Signals reflecting oxygen
consumption were concentration-dependent. The respiration
curve described a sudden steep drop to 52% at 10 mM valproic acid,
followed by a bell-shaped curve with maximal amplitude of 153%
at 820 min post-application. At the end of drug incubation period,
the cell respiration was 130% at 10 mM valproic acid. Extracellular
acidification and cell respiration were reciprocally related. Simul-
taneous to the reduction of cell respiration, the acidification in-
creased to equal extents, reaching levels up to 145%. This
amplification levelled off until the end of treatment, with residual
extracellular acidification rate of 82% at 10 mM valproic acid. Nei-
ther cell respiration nor extracellular acidification was reversible in
the recovery phase. The MTT assay indicated a statistically signifi-
cant trend towards decreased HepG2 cell viability at 10 mM and
1 mM, showing 85% and 89% remaining viability, respectively
(Table 2).
4. Discussion
Identifying cytotoxic effects of potential drug candidates re-
mains a challenge. Standard preclinical animal models do not reli-
ably predict human toxicity (animal concordance of 55%) (Olson
et al., 2000). To improve predictability, specialised animal models
can be combined with, for example, in silico, in vitro (endpoint as-
says) or toxicogenomic approaches (Liu et al., 2011). In this con-
text, it was proposed that cytosensor systems be used to monitor
reduction in metabolic rates as an indicator of cell death (Cao
et al., 1997). Due to technical limitations, measurements were lim-
ited to measuring cellular acidification rates. Only recently have
novel, multiparametric sensor chips become available that can be
used for the simultaneous determination of three parameters,
namely cellular impedance as a measure of cell morphology and
adherence, oxygen consumption as a measure of mitochondrial
respiration, and extracellular acidification as a measure of cellular
metabolism. Changes in extracellular pH are thereby caused by re-
lease of metabolic breakdown products such as lactate and carbon-
ate (Seeland et al., 2011). It should be noted that a reduction of
impedance is an indication for cellular detachment from the sur-
face of the cytosensor chip. This process is not necessarily associ-
ated with cellular viability. Consequently, changes in impedance
are not always associated with cell viability as determined in the
MTT assay. Furthermore, the reduction of MTT to the assessed
water-insoluble formazan dye is rather related to the mitochon-
drial succinat dehydrogenase activity than to the pyridine contain-
ing reduction equivalent NADH and NADPH. As the succinat
dehydrogenase only partly contributes, the MTT assay reflects a
mixed pattern of glycolytic activity and mitochondrial respiration
(Berridge et al., 1996). In the present study, high sensitivity and
responsiveness of the multiparametric cytosensor system was
achieved by combining an assay medium with low buffer capacity
and a minimal inner volume of the perfusion chamber (Fig. 1). The
system therefore permitted real-time monitoring of physiological
changes resulting from toxicological insult over a 24-h period in
human hepatocarcinoma-derived HepG2 cells.
To validate the cytosensor approach, eight well characterised
reference drugs known to be cytotoxic at certain concentrations
(Table 1) were selected. They exhibit different hepatotoxic mecha-
nism and liver pathological patterns. The drugs are structurally di-
verse, are used for different clinical indications, and the selection
included the intrinsically cytotoxic drugs doxorubicin and metho-
trexate used to treat cancer. D-sorbitol, known to be non-toxic and
well tolerated even at high concentrations, was used as a negative
control (Lederle, 1995). Assay concentrations were comparable to
clinically relevant plasma concentrations, covering a nanomolar
to millimolar range.
The test compounds have been reported to have different mech-
anisms of toxicity (Table 1). Cellular viability was measured by the
MTT assay, which responded in statistically significant way to the
antineoplastic drugs, acetaminophen, cyclosporine A and valproic
acid (Table 2). Methotrexate and doxorubicin thereby used at clin-
ical plasma concentrations observed in human cancer treatment.
Clinical plasma concentrations of methotrexate and doxorubicin
are in the range of 1150 lM (Comandone et al., 2005) and
1.9 lM (Speth et al., 1988), respectively. All other drugs investi-
gated in the MTT viability assay reduced cell viability only at con-
centrations clearly above the clinical relevant human plasma
concentrations. Interestingly, all analysed compounds known to
cause DILI in humans also responded with very distinct and char-
acteristic signal patterns in the multiparametric cytosensor assay
(Fig. 2). All observed effects were rigidly concentration-dependent.
This result was unexpected, because reactive metabolites (and not
the parent compound alone) are often suspected sources of adverse
Table 2
Cellular viability of HepG2 cells determined after a 24 h incubation by the MTT assay.
Compound % Viability Concentration
Acetaminophen 80.3 ± 0.5*** 1.0 mM
61.8 ± 0.5*** 10 mM
Amiodarone 95.7 ± 1.1 10 lM
108 ± 10.2 30 lM
Cyclosporine A 101 ± 1.4 10 lM
81.8 ± 4.5** 60 lM
Doxorubicin 61.3 ± 2.1*** 10 lM
53.5 ± 3.2*** 25 lM
Isoniazide 99.5 ± 3.1 1.0 mM
103 ± 1.4 5.0 mM
Methotrexate 70.3 ± 4.3*** 50 lM
79.3 ± 1.3*** 200 lM
Valproic acid 89.0 ± 2.4** 3.0 mM
85.2 ± 3.1** 10 mM
Terfenadine (control) 98.9 ± 10.9 5.0 lM
1.4 ± 0.4*** 25 lM
Values are means ± SD (n = 3 independent sets of experiments) as compared to
untreated control cells (100% viability). The two highest concentrations are shown.
Level of significance (Student’s t-test as compared to 100% control).
** p 6 0.01.
*** p 6 0.001.
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effects (Table 1). Thus, in liver tissue, hepatotoxicity is frequently
linked to accumulation of the parent drug in combination with
its metabolites, initiating pathological effects, and/or an altered
cellular defence mechanism, such as the depletion of glutathione
(GSH), formation of ROS or the inhibition of metabolising enzymes.
In the present study, the human hepatocarcinoma-derived HepG2
cell line was used. As opposed to primary human hepatocytes,
HepG2 cells are characterised by a defined but low expression level
of cytochrome P450 monooxygenases (Roe et al., 1993). In contrast
expression levels of most phase II enzymes seem to be normal
(Westerink and Schoonen, 2007a,b). Our results suggest that pha-
se II metabolic enzymes in combination with residual phase I met-
abolic enzymes (e.g. cytochrome P450) activity may generate
adequate levels of intracellular metabolites to trigger cytotoxic
reactions. HepG2 cells therefore seem to be a convenient, stable,
economic, and relatively easy to handle alternative to hepatocytes
for cytosensor-based toxicological investigations. This view was
supported by control experiments where amiodarone and acetami-
nophen were used to assess the phase I and phase II metabolising
enzymes (see above).
Analysis of the reference drugs in the multiparametric cytosen-
sor system revealed distinct signal patterns that allowed for classi-
fication according to six distinct cytotoxic reaction types (Table 3,
Fig. 3). Type 1 is represented by D-sorbitol, a well tolerated and safe
compound (Lederle, 1995), as confirmed in the present study
(Fig. 3). The slight increase in cell respiration of 20% at 5 mM dur-
ing the 24 h of the experiment was attributed to active compensa-
tion of the osmotic effect of D-sorbitol to cells.
Type 2 signal patterns are represented by valproic acid (Fig. 3).
This compound is one of the most widely used antiepileptic drugs,
with a black box warning for hepatoxicity. Oxidative stress, GSH
depletion, as well as mitochondrial dysfunction and necrosis have
been associated with valproic acid treatment (Tong et al.,
2005a,b,c; Kiang et al., 2010). Recently, Ji et al. reported toxicolog-
ical effects due to valproic acid and its reactive metabolites, sug-
gesting an ability to damage liver cell plasma membranes and
resulting in leakage of intracellular enzymes and finally cell death
via necrotic or apoptotic pathways (Ji et al., 2010). These findings
were confirmed in the cytosensor assay: an irreversible decrease
of 50%, at 10 mM, of the impedance value over time, which indi-
cated cell death. This effect was preceded by a short and transient
period of water influx resulting in transient cell swelling (i.e. in-
creased impedance), as described recently (Noch and Khalili,
2009). A sudden drop in respiration was observed after the addi-
tion of valproic acid in the first 20 min of incubation, apparently
indicating reduced oxidative phosphorylation and hence reduced
ATP generation. The reduced cell respiration was compensated by
an increase in metabolic activity for a similar time range. The ob-
served reduction of intracellular concentration of ATP led to strong
respiratory and metabolic stress and caused an initiation of en-
ergy-independent necrotic-like pathways, which was detected in
a previous study (Bown et al., 2000). Consequently, metabolic
activity levelled off to 82% over the entire experiment. The changes
in pH, observed in the experimental system, are transient and lim-
ited to the 3 min stop phases during the assay. In addition, pH
changes are very small and cover a range of 0.4 pH units only over
24 h. Under these conditions, induction of toxic effects by pH
changes is unlikely. This assumption is corroborated by the lack
of correlation between changes of pH and changes in respiration
or impedance (Table 3).
Amiodarone was used as a second drug with a black box warn-
ing for hepatoxicity and it is known to generate liver steatosis and
hepatocellular death (Van Summeren et al., 2011). In the multipa-
rameter cytosensor system, the strong tendency of amiodarone to
damage cells was confirmed (i.e. irreversible decrease in imped-
ance) and was classified by us as type 3 (Fig. 3), representing drugs
causing apoptotic-like cell death. Amiodarone showed the most
distinct concentration-dependent cytotoxic behaviour of all drugs
analysed in this study. After 9 h of amiodarone treatment (15 lM
and 30 lM), only 50% of the initial cells remained on the sensor
chip. Higher concentrations of amiodarone showed almost com-
plete inhibition of cellular respiration (15% of control), correlating
with a continuous release of dying cells from the sensor chip. It is
interesting to note that these concentrations of amiodarone can
also be reached in human plasma (Table 1). Mitochondrial toxicity
induced an amplification of metabolic activity as a compensatory
but transient means of ATP regeneration. This compensatory
mechanism failed after approx. 6–8 h and amplified metabolic
stress, as previously described (Kim et al., 2011) and demonstrated
by the steep drop of the acidification curve down to 7%. Amioda-
rone showed no recovery of signals, thus identifying amiodarone
as a potent hazard to liver cells at elevated levels in tissue, without
the possibility of regeneration. Furthermore, the observed effects
support the previous findings of the production of reactive oxygen
species, induced mitochondrial damage, and promoted apoptosis
in HepG2 cells (Zahno et al., 2011). It is still unclear whether ami-
odarone, its postulated reactive metabolite (desethylamiodarone)
or both cause toxicity (Zhou et al., 2005). However, the findings
showed the significant potential of amiodarone to damage the li-
ver, which was in good agreement with the black box warning
for hepatoxicity on this drug.
In contrast to drugs that induce cell death (i.e. type 2 and type 3
cytotoxicity), several drugs were identified that caused cellular
stress only but no changes in cellular impedance. Three out of eight
compounds in this study were identified as inducing respiratory
stress in HepG2 cells (type 4, acetaminophen, cyclosporine A, and
isonidazide). Acetaminophen induces mitochondrial stress upon
formation of its reactive metabolites as a consequence of depletion
of GSH. Acetaminophen is widely used as an analgesic and antipy-
retic compound, and is classified as a non-steroidal anti-inflamma-
tory drug. The first hours of the treatment phase showed slight and
reversible shrinking of the cells, reflected by reduced impedance
values of 70–80%, followed by an apparent recovery period
(Fig. 3) during which the impedance was maintained at around
80%. This apparent recovery is most likely linked to the disturbance
of mitochondrial Ca2+ homeostasis (Moore et al., 1985), character-
Table 3
Classification of toxic effects based on multiparametric cytosensor signal patterns.
Type Classification Endpoint Impedance Acidification Respiration Example
1 No toxicity No effect s s s/+ D-sorbitol
2 Necrosis-like Cell death – s/+ + Valproic acid
3 Apoptosis-like Cell death – s/+ – Amiodarone
4 Respiratory stress Cell stress s s/+ – Acetaminophen
5 Metabolic stress Cell stress s – + Methotrexate
6 Respiratory and metabolic stress Cell stress s – – Doxorubicin
Physiological parameters were monitored online in HepG2 cells and included metabolic activity (acidification), respiration (oxygen consumption) and cell morphology and
adhesion (increased by swelling of cells or decreased by cell detachment or shrinking). Signals were stable over time (s), increasing in intensity (+) or decreasing (). Typical
signal patterns of representative drugs are shown in Fig. 3.
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ised by a phenotypic blebbing of the cell surface. The osmolality of
10 mM acetaminophen was determined to be comparable to the
osmolality of human plasma (Glasser et al., 1973). Induction of
shrinking effects due to hyper-osmotic medium is therefore unli-
kely. Cellular respiration was intensely affected in a concentra-
tion-dependent manner and inhibited the respiration to 40% at
10 mM, indicating severe respiratory stress on the cell respiratory
system, the formation of toxic benzoquinone metabolites, and the
linked depletion of GSH, as previously described (Kumari and Kak-
kar, 2012a,b). The intense impairment of respiration and the conse-
quent deficit of oxidative phosphorylation results in an apparent
lack of ATP generation. In such events, the cells typically compen-
sate the lack of energy generation by enhancing ATP generation via
glycolysis, which is confirmed by the increase in metabolic activity
to 130% at 10 mM. During the drug wash-out period, the signals of
impedance and cell respiration almost recovered to initial baseline
values prior to acetaminophen treatment. Wash-out of the drug
reactivated the formation of ATP via oxidative respiration leading
to a decrease in metabolic activity, as the generation of ATP via gly-
colysis was no longer in demand. A study by Roe et al. (1993) con-
firmed the formation of the reactive metabolite (NAPQI) and
phase 2 conjugation products in HepG2 cells, among others (e.g.
benzoquinone) that were also responsible for adverse effects
(Roe et al., 1993). Cyclosporine A showed similar effects (Fig. 2)
in all three physiological parameters. This potent immunosuppres-
sive agent prolongs survival of allergenic transplants by suppress-
ing humoral immunity and, to a greater extent, cell-mediated
immune reactions such as allograft rejection and delayed hyper-
sensitivity. Unfortunately, cyclosporine A is associated with toxic
effects to several organs, mainly the kidney but also the liver,
which is confirmed in our experiments. Respiratory stress was in-
duced in HepG2 cells particular at concentrations equal to and
above 30 lM followed by a recovery phase and a slight compensa-
tory amplification of the metabolic activity. It should be noted that
the observed effects were apparent at concentrations that were
40 times higher than clinically relevant plasma concentrations of
cyclosporine A and therefore of no direct clinical relevance. Addi-
tional cyclosporine A exemplified the limitations of the HepG2
cells, because the hepatoxicity of cyclosporine A is accompanied
by the ability to inhibit hepatic bile-salt export transporters (e.g.
ABCB11) (Kullak-Ublick et al., 2000). These pumps are responsible
for the secretion of bile components into the bile canaliculi. A block
of these bile-salt export pumps results in an intracellular accumu-
lation of bile salts and thus cholestasis (Bohme et al., 1994; Van
Summeren et al., 2011). HepG2 cells are a common in vitro model
to analyse toxic effects to the liver (Lin and Will, 2012). However,
in previous studies, HepG2 cells showed impaired bile-salt trans-
porter levels (Cooper et al., 1994) and therefore HepG2 seems
not to be the most appropriate model for studying such specific
effects. An alternative to indicate toxicological effects linked
with these efflux transporters would be the use of primary
hepatocytes.
Isoniazide, another example of a drug that induces respiratory
stress, is associated with mild to severe liver toxicity in 2% of pa-
tients (Sarich et al., 1999). Its metabolism is characterised by the
formation of hydrazine (H2NNH2) and an additional toxic interme-
diate, isonicotinic acid. Hydrazine is a well-characterised hepato-
toxin (Patrick and Back, 1965; Gent et al., 1992). Hydrazine can
be formed directly by amidohydrolase or indirectly via the isoni-
cotinic acid pathway (N-acetyltranferase) to form acetylhydrazine
and then hydrazine. Histopathological observations of isoniazide-
induced liver toxicity reveal inflammatory processes and cell death
(Sarich et al., 1999). In our experiments (Fig. 2), cellular respiration
was affected in a concentration-dependent manner and was max-
imally reduced to 60%, indicative of previously described observa-
tions of respiratory stress to cells after isoniazide treatment
(Bhadauria et al., 2007, 2010).
Methotrexate is a compound that induces metabolic stress to
cells (type 5, Fig. 3). This drug is a folic acid antagonist used at high
doses in cancer therapy. The intrinsic toxicity of methotrexate was
evident in the MTT assay, showing reductions to 70% and 79% of
cell viability at 50 lM and 200 lM, respectively. The mechanism
of liver injury is poorly understood (West, 1997). The pathological
pattern of methotrexate-induced liver injury varies from mild liver
enzyme elevations to severe fibrosis and cirrhosis. Methotrexate
enters the cell via a folate transporter and is retained within the
Fig. 3. Classification of cytotoxic effects based on cytosensor signal patterns. Incubation of HepG2 cells with elevated concentrations of hepatotoxic drugs has an impact on
cell morphology/adhesion (impedance, black line), metabolic activity (acidification, red line), and cellular respiration (oxygen consumption, green line). Cellular responses
and cytotoxic effects can be classified according to six typical signal patterns (Table 3). Representative examples of experiments are shown where treatment of HepG2 cells
resulted in cytotoxicity and cell death (toxicological effects type 2 and 3) or cellular stress (effects of type 4–6). D-sorbitol served as a negative control (no cytotoxicity type l).
Effects are considered reversible if baseline levels of signals are re-established after wash-out of drug (grey areas, absence of test compound). Depict are the mean patterns of
nP 3 experiments.
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cell as a polyglutamate (Kevat et al., 1988). The drug inhibits the
enzymes required for the synthesis of purines and pyrimidines
(Aithal, 2011). It additionally blocks the conversion of homocyste-
ine to methionine. High levels of homocysteine cause metabolic
stress, with the above-described consequences, i.e. impaired meta-
bolic activity (Mato and Lu, 2005; Basseri and Austin, 2008). Met-
abolic stress was clearly observed using the multiparametric
sensor system, by a metabolic inhibition to a maximum of 60% of
baseline values at 200 lM. The highest concentration (200 lM)
investigated was 6-fold below the detected clinical plasma concen-
trations in humans receiving methotrexate at high doses for anti-
cancer therapy (P1150 lM, see above). Therefore methotrexate
was a prime example of a drug that is intrinsically toxic, intensely
inhibits metabolic activity and induces metabolic stress in HepG2
cells, which was previously described (Kaminskas and Nussey,
1978). The amplified cellular respiration agreed well with the
apparent impaired glycolytic activity, which represents a compen-
satory mechanism to generate ATP.
Doxorubicin indicates a combined pattern of respiratory and
metabolic stress (type 6, Fig. 3). Doxorubicin is an anthracycline
derivate, commonly used in the treatment of a wide range of can-
cers, including hematological malignancies, many types of carcino-
mas, and soft tissue sarcomas. The MTT assay reflects the intrinsic
cytotoxicity of the drug (54% viability at 25 lM), even at concen-
trations below the human plasma concentrations, which is
1.9 lM (see above). The MTT assay at 1.0 lM doxorubicin showed
a statistical significant decrease in cell viability of 30% (data not
shown) on HepG2 cells after 24 h treatment. During its metabo-
lism, doxorubicin undergoes a one-electron reduction by different
oxidoreductases to form a doxorubicin-semiquinone radical
(Minotti, 1989). The re-oxidation of the radical back to the parent
drug leads to the formation of ROS and hydrogen peroxide
(Minotti, 1989). The reactive species might then cause oxidative
stress, lipid peroxidation, damage to proteins and the mitochon-
drial membrane, oxidation of mitochondrial DNA, as well as the
activation of the redox-sensitive mitochondrial permeability tran-
sition pore (Sardao et al., 2008). Consequently, the bioenergetics of
the cells alters radically (Zhou et al., 2001). We were able to mon-
itor these effects in the cytosensor assay, in that cellular respira-
tion was significantly inhibited (IC50 of <5 lM) as a consequence
of mitochondrial damage that inhibits cellular respiration. In addi-
tion, an inhibition of cellular metabolic activity was observed.
These findings are in agreement with previous studies (Sardao
et al., 2008). Neither metabolic nor respiratory activities recovered
during the drug wash-out period, indicating irreversible impair-
ment of cellular adhesion, even at clinical relevant concentrations
(Table 1).
Using the multiparametric cytosensor system, we were able to
monitor alterations in cellular metabolism, respiration and imped-
ance in real-time. These changes were linked to chemical-induced
toxicological effects of the drug or its reactive metabolites. An
assessment of reversibility of the effects was used to acquire addi-
tional insight into the underlying mechanisms of toxicity. In con-
trast to the well-established cellular viability (MTT) endpoint
assay, the onset of toxic effects was monitored on-line, as opposed
to the determination of a physiological endpoint. Based on these
results, a Test-Flag-Risk Mitigation strategy (Fig. 4) is being intro-
duced; it can be used to extrapolate from an in vitro to an in vivo
situation and to determine risk of cytotoxicity of a given test com-
pound. We propose that signals from the cytosensor system should
trigger an alert (flag) that will determine a further course of action
and a follow-up strategy. Depending on concentrations used and
reversibility of effects, animal experiments will be needed. Such
studies can be combined with additional in vitro and/or in vivo
experiments (e.g. enzyme induction or inhibition, drug transporter
studies, etc.) to elucidate the mechanism of any adverse effect.
Such a Test-Flag-Risk Mitigation strategy helps reduce the risk of
cytotoxicity and therefore leads to better management of risks
associated with drug-induced injury. It remains to be elucidated
whether this approach can be extended to organ-specific cell lines
that are used to evaluate organ specific toxicity (Lin and Will,
2012).
5. Conclusions
A panel of eight marketed drugs was used to develop a novel
cytosensor-based in vitro toxicological assay. Reference drugs in
our study were classified as either non-toxic (D-sorbitol), as intrin-
sically toxic (antineoplastic drugs) or as potentially toxic under
conditions of exaggerated exposure observed as a consequence
of, for example, intentional intoxication, drug-drug interactions
or disease-induced physiological alterations. Drugs were tested
using concentrations equal to, above, and below the clinically rel-
evant plasma concentrations. Real-time monitoring of drug-in-
duced physiological effects in HepG2 cells revealed characteristic
signal patterns. Mechanistic insight into the action of these com-
pounds was used to predict detrimental events such as cell stress,
cell death or cytotoxicity in humans. In addition, information was
obtained on reversibility of the observed effects. All identified
alterations were rigidly concentration-dependent. Our findings
suggest that cytosensor-based toxicological investigations may
provide early indications of potential mechanisms of cytotoxicity,
which might be followed up by studies in experimental animal
models. The early indications of potential mechanisms of toxicity,
together with the Test-Flag-Risk Mitigation strategy (Fig. 4), may
therefore guide the design of specific follow-up studies in experi-
mental animals.
Fig. 4. Test-flag-risk-mitigation strategy based on findings in the cytosensor in vitro
assay. Decisions to be taken during the drug discovery and development process
will depend on the mechanism and extent of observed cytotoxicity relative to the
predicted therapeutic drug concentrations (i.e. classification as ‘‘low’’ or ‘‘high’’ drug
concentrations). Potential risks uncovered in the multiparametric cytosensor test
system will raise a flag and have to be addressed by confirmatory in vivo studies.
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 Abstract 
Under pathological conditions, the purinergic P2X7 receptor is activated by elevated 
concentrations of extracellular ATP. Thereby, the receptor forms a slowly dilating pore, 
allowing cations and, upon prolonged stimulation, large molecules to enter the cell. This 
process has a strong impact on cell signalling, metabolism, and viability. The present study 
aimed to establish a link between gradual P2X7 activation and pharmacological endpoints 
including oxidative stress, hydrogen peroxide generation, and cytotoxicity. We investigated 
the stimulatory effects of exogenously applied ATP or a more specific P2X7-receptor agonist 
(BzATP) on the P2X7 receptor, in combination with the selective P2X7-receptor antagonist 
AZD9056. Mechanisms of cellular stress and cytotoxicity were studied in P2X7-transfected 
HEK293 cells. P2X7-receptor activation was studied by patch-clamp experiments using a 
primary mouse microglia cell line. Oxidative stress induced by ATP or BzATP in target cells 
was monitored by hydrogen peroxide release in human mononuclear blood cells. We 
performed real-time monitoring of metabolic and respiratory activity of cells expressing the 
P2X7-receptor protein using a cytosensor system. Stimulation of the P2X7 receptor leads to 
cytotoxicity. Conversion of the P2X7 receptor from a small cation channel to a large pore 
occurring under prolonged stimulation could be monitored in real time. Our findings 
established a direct link between P2X7-receptor activation by extracellular ATP or BzATP 
and cellular events culminating in cytotoxicity. Mechanisms of toxicity include metabolic and 
oxidative stress, increase in intracellular calcium concentration, disturbance of mitochondrial 
membrane potential, and mitochondrial toxicity. 
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 Introduction 
Adenosine triphosphate (ATP) plays a central role in cell metabolism. Intracellular 
concentrations of ATP range from 1 to 10 mM (Beis and Newsholme, 1975). Extracellular 
ATP concentrations are regulated by ATPases (Burnstock, 2006), and are typically very low 
under physiological conditions. There are, however, conditions in which local extracellular 
ATP concentrations reach high levels (Volonte et al., 2003; Burnstock, 2006). For example, 
ATP is released at the synapses of neurons, where it acts as a neurotransmitter (Bardoni et al., 
1997; Pankratov et al., 2006). In addition, intracellular ATP is released into the extracellular 
space in conditions of cell necrosis or hypoxia (Billingsley et al., 2004; Rousseau et al., 2004; 
Sharnez et al., 2004; Schroder and Tschopp, 2010). Moreover, prolonged stimulation with 
ATP induces cell death in leukocytes and endothelial cells (Dawicki et al., 1997; Yoon et al., 
2006; Cosentino et al., 2011). These extreme effects occurring at extracellular ATP 
concentrations above 500 µM are thought to be induced, in part, by the purinergic receptor 
P2X7 (Chessell et al., 1998; Arbeloa et al., 2012). Such ATP concentrations are more than 
ten times higher than those required for activation of other P2X or P2Y receptors. Sustained 
exposure (> 1 min) to ATP levels above 500 µM enables the P2X7 receptor to form a large, 
non-selective pore, which allows molecules of up to 900 Dalton to enter the cell (Surprenant, 
1996). Prolonged opening of the P2X7 pore initiates several events with serious 
consequences for the cells, including cell death (Buisman et al., 1988; Ferrari et al., 1997; 
Labasi et al., 2002).  
Mechanistic studies indicated that activation of the P2X7 receptor leads to a distinct sequence 
of events (North, 2002). Electrophysiological studies have shown that opening of an ion 
channel selective for small cations (Na+, K+, and Ca2+) occurs within the first milliseconds of 
stimulation. After several seconds, permeability for larger organic cations increases 
progressively, with maximum dilatation of the ion channel reached after several minutes. 
However, the underlying molecular mechanisms of this process are still unclear (North, 
2002). 
Activation of the P2X7 receptor initiates a series of cellular responses that include 
depolarization, activation of phospholipase C, and a rise in intracellular Ca2+ concentrations, 
which stimulates caspase-1 activity, cytokine release, and activation of p38 mitogen-activated 
protein kinase [MAPK] (Armstrong et al., 2002; Ferrari et al., 2006). Such events, in turn, 
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 have a plethora of effects. For example, cytokine signalling provokes an inflammatory 
stimulus in cells of the immune system (Volonte et al., 2012). Some of these events are 
pathologically important, for example in neurodegeneration (Takenouchi et al., 2010), tumour 
growth (Ryu et al., 2011) and kidney disease (Birch et al., 2013). In transgenic mice, 
disruption of P2X7-receptor function has a detrimental impact on adipogenesis and lipid 
metabolism, pointing to an important physiological role of P2X7 in energy metabolism 
(Beaucage et al., 2013). Consequently, several P2X7 antagonists have been developed in 
recent years (Chrovian et al., 2014). One of these compounds is the selective P2X7-receptor 
antagonist AZD9056 (Bhattacharya et al., 2011) whose efficacy in rheumatoid arthritis was 
evaluated in a phase II clinical trials (Keystone et al., 2012). 
While many of the above-mentioned phenomena have been extensively characterized, their 
link to P2X7 activity has not been conclusively shown. In particular, it is difficult to monitor 
gradual activation of the P2X7 receptor on a time scale ranging from a few milliseconds up to 
minutes or hours. Thus, the present project aimed to study the dynamics of P2X7-receptor 
activation, using a P2X7-expressing mouse microglia cell line (BV2) and a recombinant 
human HEK293 cell line overexpressing P2X7 (HEK-hP2X7). To this end, we linked 
pharmacological endpoints, such as cytotoxicity or hydrogen peroxide (H2O2) release as an 
indicator of oxidative stress, to P2X7-receptor activation, altered ion flow, disturbance of 
membrane potential, cellular metabolism, and respiration. Real-time monitoring of metabolic 
and respiratory activity of P2X7-expressing cells was achieved using a novel cytosensor 
system (Seeland et al., 2013). This cell-based cytosensor system allows real-time monitoring 
of metabolic activity (pH changes), respiration (oxygen consumption), as well as cellular 
morphology and adhesion of cells (Thedinga et al., 2007). 
Materials and Methods 
Chemicals. ATP and BzATP were purchased from Sigma (Buchs, Switzerland), dissolved in 
water, and adjusted to pH 7.4 using sodium hydroxide. Fluo-4 acetoxymethyl ester 
(Fluo-4-AM) was obtained from Life Technologies (Basel, Switzerland). The cyanine dye 
JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimi dazolylcarbocyanine iodide) was 
obtained from Enzo Life Sciences (Lausen, Switzerland). Valinomycin was obtained from 
Sigma-Aldrich (St. Louis, MO). All other chemicals were of analytical quality. The P2X7-
receptor antagonist AZD9056 (Bhattacharya et al., 2011) was used as a stock solution in 
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 dimethyl sulfoxide (DMSO). Final DMSO concentrations in experiments did not exceed 
1.0% (v/v). As demonstrated by control incubations, these DMSO concentrations were not 
cytotoxic and did not interfere with the assays. The CellTiter-Blue cell viability assay was 
obtained from Promega (Dübendorf, Switzerland). 
Preparation of mononuclear blood cells (lymphocytes, monocytes, and macrophages). For 
the preparation of fresh mononuclear cells, 30 mL of male human blood containing 10% (v/v) 
sodium citrate as anticoagulant was collected, and mononuclear cells were isolated by 
Polymorphprep™ (Axis-Shield, Oslo, Norway) density centrifugation according to the 
manufacturer’s protocol. Briefly, 15 mL of human blood was layered on 17 mL of 
Polymorphprep buffer (Axis-Shield) in a 50 mL reaction tube and centrifuged at 500 g for 
30 min at 22°C. The resulting mononuclear cell band was transferred to a new 50 mL 
reaction tube and diluted with one equivalent of aqueous sodium chloride solution (0.45%, 
v/v) to restore physiological osmolarity. The solution was centrifuged at 450 g for 18 min at 
20°C and the supernatant removed. Subsequently, the cell pellet was reconstituted in 0.9% 
(w/v) aqueous sodium chloride solution and again centrifuged at 400 g for 10 min at 20°C. 
The supernatant was removed, and remaining red blood cells were hypertonically lysed by 
adding 9 mL of demineralized water for 17 s, and then centrifuged at 300 g for 10 min at 
20°C. The cell pellet obtained in the last centrifugation step was reconstituted in 20 mL of 
phosphate-buffered saline (PBS), and cell viability and concentration were analysed using a 
Vi-cell XR cell viability analyser (Beckman Coulter, Krefeld, Germany). Cell concentration 
was adjusted to 2 x 106 cells/mL, and a 250 µL aliquot of this cell suspension was dispensed 
into a 96-well plate and immediately used for experiments. 
Primary Wistar rat cortical cells. Freshly prepared cortical cultures originated from Wistar 
rat embryos 18 days after gestation. After enzymatic cell dissociation with papain 
(Worthington, Lakewood, NJ), the cells were resuspended and diluted to 3 x 105 cells/mL in 
neurobasal medium supplemented with 0.5 mM L-glutamine, 2% B27, 50 IU/mL penicillin, 
and 50 µg/mL streptomycin. Aliquots (50 µL) of this suspension were dispensed into poly-D-
lysine-coated BioCoat 384-well microplates (Becton Dickinson, Basel, Switzerland) and 
incubated at 37°C for about eight days in a humidified atmosphere containing 5% CO2. 
Primary cortical cells represented a mixed neuronal and astroglial culture system from which 
probably only the astroglial component contains P2X7 receptors. Animal experiments were 
carried out in accordance with local legislation on animal welfare and protection. 
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 HEK-hP2X7 cell line overexpressing P2X7. HEK293 cells (HEK-hP2X7) were generated 
according to established molecular cloning protocols. Specifically, RNA was extracted from 
human whole blood using the Qiagen RNeasy kit (Qiagen, Hombrechtikon, Switzerland) 
according to the manufacturer’s instructions. Subsequently, cDNA was generated 
(Superscript II, Life Technologies), and the human P2X7 gene (gene bank ref. BC011913) 
was amplified and ligated into a pcDNA3.1 (+) vector. HEK293 cells (CRL 1573, ATCC 
American type culture collection, Manassas, VA) were transfected with the pcDNA3.1 (+) 
hP2X7 plasmid using lipofectamine transfection reagent (Life Technologies) according to the 
manufacturer’s instructions. After exposure to DNA for 24 h, cells were trypsinised and re-
seeded at low density in the presence of 0.25 mg/mL geneticin. Geneticin-resistant cells were 
then selected in two consecutive rounds of cloning by serial limiting dilution with visual 
inspection. Individual clones were screened for P2X7 expression by applying ATP and 
recording the resulting uptake of YoPro1. A specific cell clone was chosen based on RNA 
and protein expression. Parental HEK293 cells and HEK-hP2X7 cells were cultured under 
standard cell culture conditions in Dulbecco’s modified Eagle medium (DMEM) with 
2.0 mM L-glutamine (Life Technologies) supplemented with 50 IU/mL penicillin, 50 µg/mL 
streptomycin, and 10% (v/v) foetal calf serum (BioConcept, Allschwil, Switzerland). 
Subcultures were obtained twice a week from confluent cell monolayers using a split ratio of 
1:5. HEK-hP2X7 cells were cultured in the presence of 0.25 mg/mL geneticin to maintain 
P2X7-expression levels. Under these conditions, cells expressed constant levels of P2X7 for 
at least 30 passages.  
Human umbilical vein endothelial cells (HUVEC). HUVEC were obtained from Lonza 
(CC-2517, Walkersville, MD) and maintained under standard cell culture conditions in 
EBM® medium with Clonetics® EGM® SingleQuots (Lonza) supplemented with 2% (v/v) 
foetal bovine serum (PAA Laboratories, Pasching, Austria), 1.0 µg/mL hydrocortisone 
(Lonza), 36 µg/mL bovine brain extract (Lonza), 3.0 ng/mL human embryonic growth factor 
(Lonza), 30 µg/mL gentamicin, 15 ng/mL amphotericin-B (Lonza), 50 IU/mL penicillin, and 
50 µg/mL streptomycin (Life Technologies). 
Mouse microglia BV2 cells. The mouse microglia BV2 cell line used for patch-clamp 
experiments was cultured under standard cell culture conditions. The cells were maintained in 
DMEM with 2 mM GlutaMAX (Life Technologies) supplemented with 50 IU/mL penicillin, 
50 µg/mL streptomycin, and 10% (v/v) foetal calf serum (BioConcept). 
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 Electrophysiology. For patch-clamp experiments, mouse microglia BV2 cells were analysed 
in the whole-cell patch-clamp configuration (Hamill et al., 1981). Patch electrodes were filled 
with intracellular buffer containing 120 mM KF, 20 mM KCl, 1.0 mM ethylene glycol-
bis(aminoethyl ether)-tetraacetic acid (EGTA), and 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (Hepes) adjusted to pH 7.2 with potassium hydroxide. 
Recordings were done at room temperature in external buffer containing 147 mM NaCl, 
2.0 mM KCl, 0.3 mM CaCl2, 10 mM Hepes, and 12 mM D-glucose adjusted to pH 7.4 with 
sodium hydroxide. At a constant holding potential of -70 mV, BzATP (100 µM) was added in 
the presence or absence of different concentrations of the P2X7-receptor antagonist by a 
computer-controlled application system. Agonist-induced steady-state currents were 
corrected for leak, and concentration-response curves were fitted to averaged current 
amplitudes derived from 3 to 4 cells.  
Fluo-4-AM calcium measurements. Intracellular calcium concentrations were determined 
using rat primary cortical cells at day 8 in culture. Cells were loaded with 1.0 µM Fluo-4-AM 
in Hank’s balanced salt solution (HBSS; Life Technologies) containing 20 mM Hepes, 
pH 7.4. Cells were washed once at 10 min before recording. After pre-incubation with 
0.01 µM to 10 µM of AZD9056 for 15 min, BzATP was added at a final concentration of 
250 µM. Fluorescence signals were measured using a fluorescent imaging plate reader. 
YoPro1 uptake analysis. The membrane-impermeable fluorescent dye YoPro1 was used to 
determine P2X7-receptor permeability for larger ions (Rassendren et al., 1997; Michel et al., 
1998). HEK-hP2X7 cells were diluted in cell culture medium without geneticin to a final 
concentration of 2 x 105 cells/mL, and an aliquot (50 µL) of this cell suspension was 
transferred to a poly-L-lysine pre-coated black-wall, clear-bottom plate and incubated at 37°C 
in a humidified atmosphere containing 5% CO2 for 48 h. The medium was then removed 
from cells, and assay buffer containing 0.5 µM YoPro1 was added to the wells. Cells were 
incubated with the indicated concentrations of AZD9056 and ATP at a final concentration of 
250 µM for 45 min. Fluorescence signals were measured using a fluorescent imaging plate 
reader (tetra, Molecular Device, Sunnyvale, CA). Excitation wavelength and emission 
wavelength were 485 nm and 530 nm, respectively. 
Hydrogen peroxide generation by mononuclear cells. Production of cellular H2O2 by 
mononuclear blood cells after stimulation with P2X7 agonists (ATP or BzATP) was 
determined by the Amplex Red assay (Life Technologies). Briefly, 5 x 105 mononuclear 
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 blood cells were incubated with 50 µM Amplex Red and 0.1 U/mL horseradish peroxidase 
for 0.5 h at 37°C in Krebs Ringer phosphate solution (145 mM NaCl, 5.7 mM sodium 
phosphate, 4.9 mM KCl, 0.5 mM CaCl2, 1.2 mM MgSO4, and 5.5 mM glucose) protected 
from light. After adding ATP (1 mM) or BzATP (0 - 400 µM) to the cells, the fluorescence 
was quantified by means of a microplate reader (Synergy MX, BioTek®, Luzern, 
Switzerland) at an excitation wavelength of 550 nm and absorbance wavelength of 600 nm. 
Background fluorescence was determined in a reaction without mononuclear blood cells.  
Dynamic mass redistribution assay. Dynamic mass distribution was determined using the 
Corning Epic system (Corning Inc., Tewksbury, MA), consisting of a temperature-controlled 
unit, optical detection unit, and on-board robotic liquid handling device. The Epic system 
measures changes in the index of refraction upon mass redistribution which can be ligand-
induced within the cell monolayer. HUVEC were detached by trypsination, and viability was 
analysed. Cells were then diluted in culture medium to reach a final concentration of 
4 x 105 cells/mL. An aliquot (30 µL) of this cell suspension was transferred to a fibronectin-
coated Epic 384-well microplate containing 10 µL HUVEC medium (see section ‘HUVEC 
cells’) and incubated at 37°C for 20 h in a humidified atmosphere containing 5% CO2 to 
reach a confluent monolayer. Each well bottom of the microplate contained a resonant 
waveguide-grating biosensor. Prior to starting the experiment, the medium was replaced by 
30 µL HBSS supplemented with 20 mM Hepes and 0.06% (w/v) bovine serum albumin. 
Subsequently, microplates were kept in the Epic reader for 2 h to equilibrate at a constant 
temperature (26°C). An initial baseline curve was recorded. Then, the ATP solution in assay 
buffer was dispensed into the microplate at concentrations ranging from 0 to 5.0 mM, and 
dynamic mass redistribution was monitored for 4000 s. Control experiments without ATP 
were performed under otherwise identical conditions. 
Cytosensor experiments. HEK-hP2X7 cells and parental HEK293 cells were detached by 
trypsination (Life Technologies), and cell viability was analysed. Cells were then diluted in 
culture medium to a final concentration of 5.7 x 105 cells/mL. An aliquot (0.35 mL) of this 
cell suspension was transferred to the pre-warmed fibronectin-coated sensor chip (SC1000) 
and incubated for at least 20 h prior to use. A cytosensor system (Bionas 1500 system, 
Bionas, Rostock, Germany) was used to continuously record cellular physiology parameters 
as described previously (Seeland et al., 2011). Briefly, a flow head with 50 µm spacers (as 
determined by the distance between the flow head and sensor chip surface) was used, leading 
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 to an effective chamber volume of 1.4 µL. The assay medium used was DMEMsupplemented 
with 2.0 mM L-glutamine, 0.1% (v/v) foetal bovine serum, 25 IU/mL penicillin, and 
25 µg/mL streptomycin. The assay medium contained neither Hepes nor NaHCO3 and was 
adjusted to pH 7.4 using sodium hydroxide. During analysis, the assay medium was delivered 
to the cells at a constant flow rate (63 µL/min) and interrupted periodically (stop phases of 
4 min and pump phases of 3 min). Signals from the microsensor chip were recorded after a 
stabilization phase of at least 3 h. During three stop/go cycles (21 min in total), cells were 
exposed to increasing concentrations of the agonist BzATP (0 - 100 µM) in assay medium 
and adjusted to pH 7.4 using sodium hydroxide. In experiments with BzATP, cells were 
exposed to AZD9056 (10 µM) prior to treatment with 50 µM BzATP. Stimulation and/or 
inhibition phases with BzATP and/or AZD9056 were followed by a wash-out phase of at 
least 4 h before a new stimulation phase was initiated.  
Cellular viability assay. The effect of agonists on cell viability was assessed in parental 
HEK293 cells and HEK-hP2X7 cells using the CellTiter-Blue assay according to the 
manufacturer's instructions. In brief, an aliquot (60 µL) of cell suspension with a nominal cell 
density of 8 x 106 cells/mL was dispensed into a 96-well plate. The cells were incubated for 
24 h in a humidified atmosphere containing 5% CO2 to allow cell attachment. At the end of 
the pre-incubation period, ATP or BzATP was added to the cells at concentration ranges up 
to 5 mM and 0.5 mM, respectively. For inhibition experiments, AZD9056 was added to the 
cells at concentrations up to 10 µM 5 min prior to the addition of ATP (2.5 mM) or BzATP 
(0.25 mM). After incubation for 30 min at 37°C, an aliquot (20 µL) of the pre-warmed 
CellTiter-Blue reagent was added. Samples were incubated for 1 h at 37°C. Fluorescence 
signals were measured using a fluorescent imaging plate reader (tetra, Molecular Device, 
Sunnyvale, CA). Excitation and emission wavelengths were 560 nm and 590 nm, 
respectively. 
Mitochondrial membrane potential. To determine mitochondrial membrane potential (Δψm), 
JC-1 cyanine dye was used as a marker for mitochondrial integrity. In cells with intact 
membrane potential, JC-1 dye forms orange aggregates within the mitochondria. 
Depolarization of the mitochondrial membrane leads to JC-1 disaggregation and a shift of the 
fluorescence emission wavelength. Parental HEK293 cells and HEK-hP2X7 cells were 
seeded on a poly-D-lysine–coated Ibidi µ-Slide (Vitaris AG, Baar, Switzerland) to reach a 
final cell density of 5 x 104 cells per well. Cells were allowed to adhere overnight. Then, JC-1 
3.6. P2X7 RECEPTORS AND CELLULAR STRESS
121
 dye was added to the medium at a final concentration of 10 µg/mL. Cells were incubated for 
15 min at 37°C allowing the dye to accumulate within the mitochondria. Subsequently, the 
medium was removed, and cells were carefully rinsed with pre-warmed PBS and incubated 
for 1 h at 37°C with medium containing BzATP at concentrations of 31.3 µM or 250 µM. 
The K+ ionophore valinomycin (1 mM) served as a positive control, while untreated cells 
were used as a negative control. Fluorescence emission was monitored with an IX81 
Olympus confocal microscope at 37 C in an atmosphere containing 5% CO2. JC-1 aggregates 
were excited with a laser at 559 nm, and emission was recorded with a wavelength filter in 
the range of 574 nm to 627 nm. JC-1 monomers were excited at 488 nm, and emission was 
recorded with a wavelength filter in the range of 500 nm to 535 nm as described earlier 
(Perelman et al., 2012). 
Data analysis and statistics. Concentration-response curves were obtained from experiments 
with the cell-based microsensor system in the presence or absence of the antagonist. 
Evaluation as well as kinetic and statistic calculations were performed using GraphPad Prism 
software (Version 5.04, GraphPad Software Inc., La Jolla, CA). Each experiment was 
performed at least in triplicate. Results were expressed as means ± SD or means with 95% 
confidence intervals (CI). 
Results 
Electrophysiology of P2X7-receptor activation and effects on calcium and YoPro1 dye influx. 
Fig. 1A shows the activation of the P2X7 receptor by BzATP as studied in patch-clamp 
experiments using the P2X7 receptor-expressing mouse microglia BV2 cell line. Effects were 
characterized by an EC50 of 197 ± 5.1 µM (mean ± SD, n = 5). The P2X7-receptor antagonist 
AZD9056 inhibited BzATP-induced currents in these cells (Fig. 1B). BzATP induced stable, 
inward currents at a holding potential of -70 mV that were blocked by AZD9056 with an IC50 
of 2.1 µM (95% CI, 1.8 – 2.5 µM, n ≥ 5; Fig. 1C). 
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 Figure 1: Patch-clamp experiments using P2X7-receptor–expressing mouse microglia 
BV2 cells. (A) Raw current signal pattern after stimulation of BV2 cells using 100 µM BzATP. (B) Raw 
current signal pattern after stimulation of BV2 cells using 100 µM BzATP in the presence of 10 µM of 
AZD9056. (C) Dose-dependent inhibition of membrane currents in mouse microglia BV2 cells using AZD9056. 
Cells were stimulated using 100 µM BzATP. (D) Intracellular Ca2+ increase after 100 µM BzATP stimulation of 
rat cortical cells in the presence of increasing concentrations of AZD9056. (E) YoPro1 dye membrane 
permeability measurements using P2X7-overexpressing HEK-hP2X7 cells stimulated by 250 µM ATP in the 
presence of increasing concentrations of AZD9056. (C, D, E). Values are means ± SD, n ≥ 4. 
When measuring Ca2+ influx via P2X7 receptors using a calcium-sensitive fluorescent dye in 
primary cortical cultures from rat embryonic brains, AZD9056 inhibited BzATP-induced 
Ca2+ influx with an IC50 of 3.2 µM (95% CI, 2.8 – 3.7 µM, n ≥ 4; Fig. 1D). YoPro1 influx 
was determined upon stimulation of HEK-hP2X7 cells with BzATP for 45 min. Observed 
effects were antagonised with an IC50 of 11.2 nM (95% CI, 9.6 – 13.2 nM; Fig. 1E). 
ATP-induced hydrogen peroxide release by mononuclear blood cells and dynamic mass 
redistribution in HUVEC cells. Mononuclear cells were freshly prepared from human donor 
blood. Within 20 min, exogenously applied ATP induced a marked, concentration-dependent 
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 increase in H2O2 release with an EC50 of 558 ± 8.7 µM (mean ± SD, n = 3), as depicted in 
Fig. 2A. The P2X7-specific receptor antagonist AZD9056 elicited moderate inhibition of 
H2O2 formation with an IC50 of 3.0 ± 0.9 µM (mean ± SD, n = 3) at 1 mM ATP, indicating 
involvement of the P2X7 receptor (Fig. 2B). When we tested the effect of extracellular ATP 
on dynamic mass redistribution in HUVEC cells, we observed a concentration-response 
correlation with an EC50 of 933 ± 156 µM (mean ± SD, n = 3 independent experiments; 
Fig. 2C). 
 
Figure 2: P2X7-mediated cellular formation of hydrogen peroxide and mass 
redistribution. (A) Rate of H2O2 formation in mononuclear blood cells after stimulation with 
extracellular ATP. (B) Effect of AZD9056) on H2O2 levels in mononuclear blood cells stimulated with 
1 mM ATP. (C) Morphological changes as determined by mass redistribution of human umbilical-vein 
endothelial cells (HUVEC) upon treatment with exogenously applied ATP. 
BzATP-induced metabolic activation of HEK239 cells and HEK-hP2X7 cells overexpressing 
P2X7. We used a cytosensor system for real-time monitoring of metabolic activation of 
HEK-hP2X7 cells. Measured parameters were oxygen concentration, pH, and cell impedance. 
The sensor system was optimized with respect to maximum stimulation amplitudes, as 
described previously (Seeland et al., 2011). Optimal cell density was 2 x 105 attached cells 
per sensor chip and an effective incubation chamber volume of 1.4 µL. Viability of cells was 
monitored continuously by measuring cellular impedance. Continuous deviations from initial 
values in the order of approx. ± 1.2% per hour were considered acceptable and were 
attributed to cell proliferation or cell release from the chip. HEK-hP2X7 cells responded 
immediately to BzATP in a concentration-dependent manner (Fig. 3). In HEK-hP2X7 cells 
but not in HEK293 control cells, metabolic activity (i.e., acidification) and cellular respiration 
increased in a concentration-dependent manner upon BzATP treatment (Fig. 3A). At high 
BzATP concentrations (100 µM), a sharp decrease in cellular respiration was observed, 
which was in strict contrast to cellular acidification (Fig. 3A). Maximum changes in cell 
morphology (i.e., impedance) were reached at 100 µM BzATP (Fig. 3B). Compared to 
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 HEK-hP2X7 cells, parental HEK293 cells showed only negligible effects on the impedance 
sensor (Fig. 3B). 
 
Figure 3: Cytosensor measurements in HEK-hP2X7 cells overexpressing P2X7 and 
parental HEK293 cells. (A) Concentration-dependent stimulation of HEK-hP2X7 cells (solid lines, 
black circles) and parental HEK293 cells (dotted lines, inverted triangles) by BzATP as analysed using a 
cytosensor system. Parental HEK293 cells and human HEK-hP2X7 cells were compared with respect to 
respiration and metabolic activity (acidification). Respiratory inhibition in HEK-hP2X7 cells at 100 µM 
BzATP was indicative of cellular toxicity. Level of significance: *p < 0.05, **p < 0.01, ***p < 0.001, 
n = 4. (B) Cell impedance as a function of stimulation of P2X7 using BzATP. Curve was fitted to 
HEK-hP2X7 signals (solid line, black circles) using an enzyme kinetic model. Parental HEK293 cells were 
used as a control (inverted triangles). Level of significance: *p < 0.05, **p < 0.01, n = 4. 
Activation of the P2X7 receptor by BzATP was saturated at high concentrations and was 
characterized by an EC50 of 9.6 ± 1.8 µM (mean ± SD, n = 5; Fig. 3B). These effects were 
inhibited by AZD9056 (Fig. 4). Inhibitory effects of AZD9056 were reversible since 
responsiveness of the cells towards BzATP was partially restored by washing out the 
antagonist (Fig. 4). Inhibition of the BzATP-induced effects observed in HEK-hP2X7 cells 
overexpressing P2X7 did not take place in the parental HEK293 cells (Fig. 4). 
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Figure 4: Reversible inhibition of BzATP-induced effects by AZD9056. Cytosensor 
measurements using HEK-hP2X7 cells and parental HEK293 cells in the presence and absence of 10 µM 
AZD9056. After a wash-out period of 4 h, the cells were again stimulated with 50 µM BzATP to assess 
regeneration and reactivation. Level of significance in the presence and absence of antagonist: *p < 0.05, 
n = 4. 
ATP- and BzATP-induced cytotoxicity. Stimulation of P2X7-expressing HEK-hP2X7 cells 
with ATP (Fig. 5A) or BzATP (Fig. 5B) resulted in concentration-dependent cytotoxic 
effects. These effects were absent in parental HEK293 cells. LD50 values for HEK-hP2X7 
cells were 1017 ± 81 µM (mean ± SD, n = 3) for ATP and 119.7 ± 4.4 µM (mean ± SD, 
n = 3) for BzATP. These effects were antagonised by AZD9056 with an IC50 of 
11.4 ± 1.8 nM (mean ± SD, n = 3) at 2.5 mM ATP (Fig. 5C) and 5.62 ± 0.75 nM (mean ± SD, 
n = 3) at 0.25 mM BzATP (Fig. 5D). Again, parental HEK293 cells were not responsive to 
ATP, BzATP, or AZD9056 (Fig.. 5C and Fig. 5D). 
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Figure 5: Cellular viability of parental HEK293 cells (empty circles) and HEK-hP2X7 
cells (filled squares). Cellular viability was analysed in the presence of increasing concentrations of the 
two P2X7 agonists (A: ATP; B: BzATP). A cell-protective function of the P2X7-specific antagonist 
AZD9056 was demonstrated in inhibition experiments where cells were pre-incubated with increasing 
concentrations of a P2X7-specific antagonist (AZD9056) prior to addition of the agonists ATP (C: 
2.5 mM) or BzATP (D: 0.25 mM). Values are means ± SD, n = 3. 
BzATP-induced mitochondrial toxicity. Figure 6 shows a decrease of mitochondrial 
membrane potential (Δψm) in BzATP-treated HEK-hP2X7 cells (but not in P2X7-deficient 
control cells) as visualized by a change from red to green fluorescent signals in the target 
cells. The shift in the emission spectrum of the cyanine dye JC-1 was monitored upon 
stimulation of HEK-hP2X7 cells for 1 h with elevated concentrations of BzATP (30 -
 250 µM). Valinomycin, a K+ ionophore, served as a positive control. 
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Figure 6: Induction of mitochondrial toxicity in HEK-hP2X7 cells. Parental HEK293 (left 
panel) and HEK-hP2X7 (right panel) cells were stimulated using 250 µM BzATP. A decrease in 
mitochondrial membrane potential is indicated by a shift from red fluorescent signals to green fluorescent 
signals. Insert, left panel: 1 mM valinomycin was used as a positive control. Size of bars: 40 µm. 
Discussion  
The present study investigated the effect of the P2X7-receptor agonists ATP and the 
metabolically stable analogue BzATP (Le Feuvre et al., 2003) on different P2X7-expressing 
cell lines. Real-time monitoring of the effects for the timescale of seconds was achieved 
electrophysiologically and for the timescales up to minutes and hours by using a novel 
cytosensor system. The effects were highly specific for P2X7 as demonstrated by the use of 
P2X7-deficient control cells and the selective P2X7-receptor antagonist AZD9056 
(Bhattacharya et al., 2011; Elsby et al., 2011). Activation of P2X7 had a direct impact on 
membrane permeability for ions, intracellular calcium release, cell morphology (i.e. 
swelling), and cellular respiration and metabolism (Table 1). This induced oxidative and 
metabolic stress in target cells, ultimately leading to cellular toxicity and cell death.  
In order to characterize the human P2X7 receptor, a recombinant HEK-hP2X7 cell line was 
prepared. Functionality of the recombinant human P2X7 receptor was confirmed using the 
YoPro1 uptake assay upon stimulation of the target cells with ATP. The antagonist AZD9056 
blocked P2X7 receptors with an IC50 of 11.2 nM, indicating a high selectivity of the 
antagonist for the P2X7 receptor. This IC50 value is comparable to values determined 
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 previously for mouse and rat P2X7 receptors (in the order of 1 - 2 nM, data not shown). Thus, 
the YoPro1 uptake experiment allowed comparing and confirming the pharmacological 
properties of the P2X7 receptor in our study with those determined with methods traditionally 
used for studying the P2X7 receptor.  
Table 1: Summary of agonist-induced and antagonist-induced effects mediated by the P2X7 receptor 
Assay Cells Agonist 1 
[µM] 
P2X7-receptor 
antagonist 2 
[µM] 
IC50 or 
% inhibition 
     
Peroxide 
release 
Mononuclear 
blood cells 
1000 0 - 25 3.0 µM 
     
YoPro1 uptake HEK-hP2X7 3000 3.8 x 10-5 - 10 11.2 nM 
     
Fluo-4-AM Rat cortex 250 0.01 - 10 3.2 µM 
     
Patch-clamp Mouse microglia 100 0.3 - 10 
2.1 µM 
96% 3 
     
Sensor system 
respiration 
HEK-hP2X7 50 10 92% 
     
Sensor system 
acidification 
HEK-hP2X7 50 10 77% 
     
Sensor system 
impedance 
HEK-hP2X7 50 10 77% 
          
1 Assays for H2O2 release and YoPro1 uptake were performed with ATP, all other assays with BzATP; 
2 P2X7-receptor antagonist AZD9056; 3 at 10 µM AZD9056. 
Furthermore, the characteristics of human P2X7 receptor in this cell line were similar to those 
of rodent P2X7 receptor expressed by mouse microglia BV2 cells and rat cortical cells, as 
3.6. P2X7 RECEPTORS AND CELLULAR STRESS
129
 demonstrated electrophysiologically. In these experiments, patch-clamp techniques were used 
to measure directly the flux of small, inorganic ions across the P2X7 channels.  
Mouse microglia BV2 cells express both P2X7 and P2X4 receptors (Bernier et al., 2012). 
BzATP showed distinct effects on receptor activity, and the P2X7-receptor antagonist 
AZD9056 had a clear inhibitory effect (IC50 = 2.1 µM), which allows to attribute the effects 
to the P2X7 receptor. 
Activation of the P2X7 receptor triggers Ca2+ influx and thus cell depolarization. We used 
primary rat cortical cells for these experiments because P2X-mediated Ca2+ influx cannot be 
determined in HEK293 cells due to co-activation of endogenously expressed purinergic P2Y 
receptors (He et al., 2003). As shown previously (Takenouchi et al., 2005; Donnelly-Roberts 
et al., 2009), exogenously triggered P2X7 activation led to an increased Ca2+ signal in the 
cells and was blocked by the P2X7 receptor antagonist AZD9056 (IC50 = 3.2 µM) with 
inhibitory affinity similar to that observed in patch-camp experiments. 
It is not possible to deduce a clear pathway from ATP-gated channel opening to the activation 
of cellular metabolism. However, small cations (e.g., Ca2+) as well as larger molecules 
entering the cell upon P2X7-receptor pore opening are known to trigger further downstream 
effects such as interleukin-1β release, MAPK activation, apoptosis, etc., and are therefore 
linked to cell signalling and cell death (Kukley et al., 2005; Ferrari et al., 2006). Hydrogen 
peroxide (H2O2), a metabolic side product of cell respiration, can be used as a marker for 
cellular toxicity (Giorgio et al., 2007). We measured H2O2 released in human mononuclear 
blood cells upon ATP treatment and found that ATP induced a concentration-dependent 
increase in H2O2 release, confirming previous reports (Skaper et al., 2006). It should be noted 
that the concentration-response curve for ATP induction of H2O2 release with an EC50 above 
0.5 mM did not fit with the ATP sensitivity of the 12 known metabotropic P2Y receptors. 
Only the P2X7 receptor exhibits such low sensitivity to extracellular ATP (Coddou et al., 
2011). In addition, assessment of the mass redistribution of HUVEC cells as a second, 
independent variable resulted in EC50 values above 900 µM. Morphological changes upon 
ATP treatment are an indication of ligand binding to the human P2X7 receptor (Pfeiffer et al., 
2004) and can therefore be used to calculate EC50 values of activation. Based on the 
similarity of EC50 values, we hypothesized that the P2X7 receptor was involved in mediating 
the concentration-dependent increase in metabolic activity and morphological changes. Our 
hypothesis was supported by experiments with the antagonist AZD9056 that achieved 
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 concentration-dependent inhibition of ATP-induced H2O2 release in human mononuclear 
blood cells. Furthermore, AZD9056 (10 µM) showed no inhibition of signalling on P2 
receptors in recombinant 1321N1 cells overexpressing P2X1, P2X2, P2X3, and P2X4 when 
measuring Ca2+ flux after ATP stimulation (data not shown). AZD9056 can therefore be 
considered to be selective for the P2X7 receptor, in contrast to other known antagonists of P2 
receptors such as suramin and pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid 
(PPADS) (Chessell et al., 1998; Ralevic and Burnstock, 1998). The concentration of BzATP 
used was one tenth (400 µM) of the concentration of ATP (4000 µM) and induced equal 
H2O2 release from human mononuclear blood cells at these concentrations. BzATP was 
chosen for these experiments since it is a specific agonist for both P2X4 and P2X7 receptors 
with only partial activity towards P2X1, P2X2, and P2X3 receptors (Coddou et al., 2011). 
We subsequently used the HEK-hP2X7 cells overexpressing P2X7 to study changes in 
metabolic activity in real time by means of a cell-based cytosensor system. We were able to 
record simultaneously extracellular acidification as a marker for metabolic activity, oxygen 
consumption as a measure for cellular respiration, and impedance as a means to assess 
changes in cell morphology and adhesion. P2X7 receptors are co-localized with α-actin, 
β-actin, and the β2-integrin subunit, i.e., factors that determine changes in the cytoskeleton 
(Kim et al., 2001). Pfeiffer et al. previously described morphological changes in cells 
expressing P2X7 receptors when P2X7 agonists were present (Pfeiffer et al., 2004). We 
confirmed these morphological changes by measuring cellular impedance. In addition, 
HEK-hP2X7 cells exhibited concentration-dependent swelling upon treatment with BzATP, 
possibly reflecting the osmotic influx of water into the cells due to pore dilatation. We 
estimated the potency of BzATP to induced morphological changes using an enzyme kinetic 
model (EC50 = 9.6 µM). Cellular respiration was maximally increased at 50 µM BzATP when 
compared with parental cells. Treatment with 100 µM BzATP, however, led to a sharp drop 
in respiration, which indicates mitochondrial toxicity (Gandelman et al., 2010). Strong 
amplification of metabolic activity under these conditions (monitored by an increase in 
extracellular acidification) clearly indicates a compensatory cellular response in terms of 
enhanced glycolysis. Reduction in cellular respiration was probably linked to both the 
formation of reactive oxygen species (Skaper et al., 2006) and activation of the apoptosis 
cascade (Hillman et al., 2003). The distinctness of stimulatory effects observed in the 
cytosensor system confirms that the effects mostly derived from the highly expressed P2X7 
receptors rather than from other endogenously expressed P2 receptors in HEK293 cells. 
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 These results are in line with our findings for H2O2 formation by mononuclear cells. Using 
the cytosensor system, we were able to determine simultaneously multiple variables of 
cellular metabolism, thus providing a more complete picture of how ATP affects cellular 
metabolism via the P2X7 receptor. All effects on cell morphology, mitochondrial respiration, 
and metabolic activity were induced at 50 µM BzATP and were inhibited with 10 µM 
AZD9056 at potencies between 77% and 92%. Because parental HEK293 cells did not 
respond to activation or inhibition, all effects observed in HEK-hP2X7 cells appear to be 
mediated by the human P2X7 receptor. 
Prolonged stimulation of HEK-hP2X7 cells with ATP or BzATP led to cytotoxicity. This 
effect was also dose-dependent, was antagonised by AZD9056, and was not observed in 
P2X7-deficient HEK293 control cells. Our mechanistic studies revealed a collapse of 
mitochondrial membrane potential and mitochondrial integrity under these conditions. These 
findings are in line with our results from cytosensor studies and confirm that mitochondrial 
toxicity is indeed a trigger for P2X7-mediated cytotoxicity. 
We conclude that an increase in membrane leakiness led to disturbance of mitochondrial 
membrane potential, mitochondrial toxicity, and oxidative stress. Metabolic activity by 
glycolysis increased as a compensatory mechanism due to the lack of energy generated by 
oxidative phosphorylation. Prolonged stimulation led to morphological changes and 
cytotoxicity. Further experiments are necessary to investigate the specificity of these effects 
and to clarify their role under normal or pathological conditions. Extracellular ATP has been 
shown to be a key player in triggering inflammatory processes, cellular stress, and apoptosis. 
Our investigations demonstrate that these processes are tightly linked to oxidative and 
metabolic activity, which we were able to monitor in real-time simultaneously with an 
additional confirmation of agonist-induced changes in cell morphology.  
List of references 
Arbeloa J, Perez-Samartin A, Gottlieb M and Matute C (2012) P2X7 receptor blockade 
prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. 
Neurobiol Dis 45:954-961. 
Armstrong JN, Brust TB, Lewis RG and MacVicar BA (2002) Activation of presynaptic 
P2X7-like receptors depresses mossy fiber-CA3 synaptic transmission through p38 
mitogen-activated protein kinase. J Neurosci 22:5938-5945. 
CHAPTER 3. PUBLISHED AND SUBMITTED RESULTS
132
 Bardoni R, Goldstein PA, Lee CJ, Gu JG and MacDermott AB (1997) ATP P2X receptors 
mediate fast synaptic transmission in the dorsal horn of the rat spinal cord. J Neurosci 
17:5297-5304. 
Beaucage KL, Xiao A, Pollmann SI, Grol MW, Beach RJ, Holdsworth DW, Sims SM, 
Darling MR and Dixon SJ (2013) Loss of P2X7 nucleotide receptor function leads to 
abnormal fat distribution in mice. Purinergic Signal. 
Beis I and Newsholme EA (1975) The contents of adenine nucleotides, phosphagens and 
some glycolytic intermediates in resting muscles from vertebrates and invertebrates. 
Biochem J 152:23-32. 
Bernier LP, Ase AR, Boue-Grabot E and Seguela P (2012) P2X4 receptor channels form 
large noncytolytic pores in resting and activated microglia. Glia 60:728-737. 
Bhattacharya A, Neff RA and Wickenden AD (2011) The physiology, pharmacology and 
future of P2X7 as an analgesic drug target: hype or promise? Curr Pharm Biotechnol 
12:1698-1706. 
Billingsley KG, Stern LE, Lowy AM, Kahlenberg MS and Thomas CR, Jr. (2004) 
Uncommon anal neoplasms. Surg Oncol Clin N Am 13:375-388. 
Birch RE, Schwiebert EM, Peppiatt-Wildman CM and Wildman SS (2013) Emerging key 
roles for P2X receptors in the kidney. Front Physiol 4:262. 
Buisman HP, Steinberg TH, Fischbarg J, Silverstein SC, Vogelzang SA, Ince C, Ypey DL 
and Leijh PC (1988) Extracellular ATP induces a large nonselective conductance in 
macrophage plasma membranes. Proc Natl Acad Sci U S A 85:7988-7992. 
Burnstock G (2006) Historical review: ATP as a neurotransmitter. Trends Pharmacol Sci 
27:166-176. 
Chessell IP, Michel AD and Humphrey PP (1998) Effects of antagonists at the human 
recombinant P2X7 receptor. Br J Pharmacol 124:1314-1320. 
Chrovian CC, Rech JC, Bhattacharya A and Letavic MA (2014) P2X7 Antagonists as 
Potential Therapeutic Agents for the Treatment of CNS Disorders. Prog Med Chem 
53:65-100. 
Coddou C, Yan Z, Obsil T, Huidobro-Toro JP and Stojilkovic SS (2011) Activation and 
regulation of purinergic P2X receptor channels. Pharmacol Rev 63:641-683. 
Cosentino S, Banfi C, Burbiel JC, Luo H, Tremoli E and Abbracchio MP (2011) 
Cardiomyocyte death induced by ischemic/hypoxic stress is differentially affected by 
distinct purinergic P2 receptors. J Cell Mol Med 16:1074-1084. 
3.6. P2X7 RECEPTORS AND CELLULAR STRESS
133
 Dawicki DD, Chatterjee D, Wyche J and Rounds S (1997) Extracellular ATP and adenosine 
cause apoptosis of pulmonary artery endothelial cells. Am J Physiol 273:L485-494. 
Donnelly-Roberts DL, Namovic MT, Han P and Jarvis MF (2009) Mammalian P2X7 
receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 
receptors. Br J Pharmacol 157:1203-1214. 
Elsby R, Fox L, Stresser D, Layton M, Butters C, Sharma P, Smith V and Surry D (2011) In 
vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug 
interaction with methotrexate. Eur J Pharm Sci 43:41-49. 
Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Collo G, Buell G and Di Virgilio F (1997) 
ATP-mediated cytotoxicity in microglial cells. Neuropharmacology 36:1295-1301. 
Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E and Di Virgilio 
F (2006) The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 
176:3877-3883. 
Gandelman M, Peluffo H, Beckman JS, Cassina P and Barbeito L (2010) Extracellular ATP 
and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for 
amyotrophic lateral sclerosis. J Neuroinflammation 7:33. 
Giorgio M, Trinei M, Migliaccio E and Pelicci PG (2007) Hydrogen peroxide: a metabolic 
by-product or a common mediator of ageing signals? Nat Rev Mol Cell Biol 8:722-
728. 
Hamill OP, Marty A, Neher E, Sakmann B and Sigworth FJ (1981) Improved patch-clamp 
techniques for high-resolution current recording from cells and cell-free membrane 
patches. Pflugers Arch 391:85-100. 
He M-L, Zemkova H, Koshimizu T-a, Tomic M and Stojilkovic SS (2003) Intracellular 
calcium measurements as a method in studies on activity of purinergic P2X receptor 
channels. American Journal of Physiology - Cell Physiology 285:C467-C479. 
Hillman KA, Harada H, Chan CM, Townsend-Nicholson A, Moss SE, Miyamoto K, Suketa 
Y, Burnstock G, Unwin RJ and Dunn PM (2003) Chicken DT40 cells stably 
transfected with the rat P2X7 receptor ion channel: a system suitable for the study of 
purine receptor-mediated cell death. Biochem Pharmacol 66:415-424. 
Keystone EC, Wang MM, Layton M, Hollis S and McInnes IB (2012) Clinical evaluation of 
the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and 
symptoms of rheumatoid arthritis in patients with active disease despite treatment 
with methotrexate or sulphasalazine. Ann Rheum Dis 71:1630-1635. 
CHAPTER 3. PUBLISHED AND SUBMITTED RESULTS
134
 Kim M, Jiang LH, Wilson HL, North RA and Surprenant A (2001) Proteomic and functional 
evidence for a P2X7 receptor signalling complex. EMBO J 20:6347-6358. 
Kukley M, Schwan M, Fredholm BB and Dietrich D (2005) The role of extracellular 
adenosine in regulating mossy fiber synaptic plasticity. J Neurosci 25:2832-2837. 
Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks 
JR, Audoly L and Gabel CA (2002) Absence of the P2X7 receptor alters leukocyte 
function and attenuates an inflammatory response. J Immunol 168:6436-6445. 
Le Feuvre RA, Brough D, Touzani O and Rothwell NJ (2003) Role of P2X7 receptors in 
ischemic and excitotoxic brain injury in vivo. J Cereb Blood Flow Metab 23:381-384. 
Michel AD, Chessell IP, Hibell AD, Simon J and Humphrey PP (1998) Identification and 
characterization of an endogenous P2X7 (P2Z) receptor in CHO-K1 cells. Br J 
Pharmacol 125:1194-1201. 
North RA (2002) Molecular Physiology of P2X Receptors. Physiological Reviews 82:1013-
1067. 
Pankratov Y, Lalo U, Verkhratsky A and North RA (2006) Vesicular release of ATP at 
central synapses. Pflugers Arch 452:589-597. 
Perelman A, Wachtel C, Cohen M, Haupt S, Shapiro H and Tzur A (2012) JC-1: alternative 
excitation wavelengths facilitate mitochondrial membrane potential cytometry. Cell 
Death Dis 3:e430. 
Pfeiffer ZA, Aga M, Prabhu U, Watters JJ, Hall DJ and Bertics PJ (2004) The nucleotide 
receptor P2X7 mediates actin reorganization and membrane blebbing in RAW 264.7 
macrophages via p38 MAP kinase and Rho. J Leukoc Biol 75:1173-1182. 
Ralevic V and Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 
50:413-492. 
Rassendren F, Buell GN, Virginio C, Collo G, North RA and Surprenant A (1997) The 
permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J 
Biol Chem 272:5482-5486. 
Rousseau DL, Jr., Petrelli NJ and Kahlenberg MS (2004) Overview of anal cancer for the 
surgeon. Surg Oncol Clin N Am 13:249-262. 
Ryu JK, Jantaratnotai N, Serrano-Perez MC, McGeer PL and McLarnon JG (2011) Block of 
purinergic P2X7R inhibits tumor growth in a C6 glioma brain tumor animal model. J 
Neuropathol Exp Neurol 70:13-22. 
Schroder K and Tschopp J (2010) The inflammasomes. Cell 140:821-832. 
3.6. P2X7 RECEPTORS AND CELLULAR STRESS
135
 Seeland S, Torok M, Kettiger H, Treiber A, Hafner M and Huwyler J (2013) A cell-based, 
multiparametric sensor approach characterises drug-induced cytotoxicity in human 
liver HepG2 cells. Toxicol In Vitro 27:1109-1120. 
Seeland S, Treiber A, Hafner M and Huwyler J (2011) On-line identification of P-
glycoprotein substrates by monitoring of extracellular acidification and respiration 
rates in living cells. Biochim Biophys Acta 1808:1827-1831. 
Sharnez R, Lathia J, Kahlenberg D, Prabhu S and Dekleva M (2004) In situ monitoring of 
soil dissolution dynamics: a rapid and simple method for determining worst-case soils 
for cleaning validation. PDA J Pharm Sci Technol 58:203-214. 
Skaper SD, Facci L, Culbert AA, Evans NA, Chessell I, Davis JB and Richardson JC (2006) 
P2X(7) receptors on microglial cells mediate injury to cortical neurons in vitro. Glia 
54:234-242. 
Surprenant A (1996) Functional properties of native and cloned P2X receptors. Ciba Found 
Symp 198:208-219; discussion 219-222. 
Takenouchi T, Ogihara K, Sato M and Kitani H (2005) Inhibitory effects of U73122 and 
U73343 on Ca2+ influx and pore formation induced by the activation of P2X7 
nucleotide receptors in mouse microglial cell line. Biochim Biophys Acta 1726:177-
186. 
Takenouchi T, Sekiyama K, Sekigawa A, Fujita M, Waragai M, Sugama S, Iwamaru Y, 
Kitani H and Hashimoto M (2010) P2X7 receptor signaling pathway as a therapeutic 
target for neurodegenerative diseases. Arch Immunol Ther Exp (Warsz) 58:91-96. 
Thedinga E, Kob A, Holst H, Keuer A, Drechsler S, Niendorf R, Baumann W, Freund I, 
Lehmann M and Ehret R (2007) Online monitoring of cell metabolism for studying 
pharmacodynamic effects. Toxicol Appl Pharmacol 220:33-44. 
Volonte C, Amadio S, Cavaliere F, D'Ambrosi N, Vacca F and Bernardi G (2003) 
Extracellular ATP and neurodegeneration. Curr Drug Targets CNS Neurol Disord 
2:403-412. 
Volonte C, Apolloni S, Skaper SD and Burnstock G (2012) P2X7 receptors: channels, pores 
and more. CNS Neurol Disord Drug Targets 11:705-721. 
Yoon MJ, Lee HJ, Kim JH and Kim DK (2006) Extracellular ATP induces apoptotic 
signaling in human monocyte leukemic cells, HL-60 and F-36P. Arch Pharm Res 
29:1032-1041. 
 
CHAPTER 3. PUBLISHED AND SUBMITTED RESULTS
136
Chapter 4
Discussion
The aim of this thesis was to investigate different aspects in nanotoxicology. Firstly, a suitable
reference particle was chosen, synthesized, and characterized. An in-depth understanding of the
synthesis allowed modifying the particles with regard to size, specific surface area, and surface
groups. Hence, a library consisting of different SNPs was synthesized. The cytotoxic effect of each
SNP was tested in three cell lines. The most interesting SNP was studied in depth regarding its
hemolytic potential.
4.1 The importance of characterized material
The literature described a size-dependent toxicity for SNPs [81]. Hence, the first parameter of in-
terest was the size. Could a size dependent toxicity be observed in the size range of DDS? The
second parameter was the specific surface area. By keeping the size constant, mesopores were in-
troduced into the SNPs to enhance their specific surface area. It has been reported that the specific
surface area can influence toxicity in an indirect manner, namely by depleting nutrients from the
medium [56]. The third parameter was the surface charge. It was reported that a high, especially
positive charge density results in cytotoxicity [27]. This is related to the electrostatic interaction
with the cell membrane, which carries an overall negative charge [82].
As described earlier, different synthesis methods exist to obtain SNPs. For the SNPs explored in
this thesis, the basic growth approach ("Stöber" method) has shown to be the most reproducible
one. Apart from the reproducibility, particles synthesized in-house have a known thermal history.
This knowledge is important since it could be the reason for contradictory outcome of SNP toxic-
ity in the literature [37]. Of course, there are other factors influencing outcomes, such as the choice
of the cell line and the inclusion or abduction of serum proteins in an in vitro assay.
Appropriate protocols to observe critical steps in the synthesis (eg. drying or removal of surfac-
tant) with critical steps which could alter the physico-chemical properties of a nanoparticle [48].
This applies not only to SNPs, but for any nanoparticles (synthesized in house or obtained from
a commercial supplier): trace metals from the synthesis, additives to maintain colloidal stability,
and the synthesis history of a nanoparticle can influence the toxicity profile. Trace metals as yt-
trium caused toxicity of carbon nanotubes [83]. Surfactants added to maintain colloidal stability
may exert three distinct pitfalls. The first one is that adsorbed surfactants change the appearance
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of the particle (own experience and [18]). The second one is the toxicity of the surfactant itself
and the third is that upon dilution of the stock suspension, the surfactant also gets diluted. This
then results in agglomeration of nanoparticles. Dispersion protocols can also influence cytotoxic-
ity. This has been shown by Wick, where the dispersion protocol lead to totally different outcomes
for carbon nanotube cytotoxicity [84]. The third one is the cytotoxicity of the dispersant. With the
SNPs in house synthesis and characterization, several of these pitfalls were minimized.
As mentioned in the introduction, degradation of nanoparticles and release of metal ions or trace
metals could lead to cytotoxicity. Mesoporous SNPs also degrade [85], so the effect of the degra-
dation products was tested (data not shown). The degradation products showed no cytotoxicity.
This is in agreement with previous published data [86]. The degradation kinetic was explored in
cell-free environment and with in cells using live-cell imaging. This fast degradation process of
mesoporous SNPs was responsible for the absence of hemolysis. Overall, several pitfalls can be ex-
cluded when synthesizing own nanoparticles, while others (degradation and toxicity of degraded
products for instance) always need to be tested.
4.2 Experimental considerations
4.2.1 Choice of assay
As described in the introduction, numerous assays are available, starting from live-dead assays
like trypan blue staining to highly sophisticated assays to localize the site of production of ROS
[87]. This high amount of assays leaves numerous of choices in what we want to observe. Before
choosing an assay, it is important to consider (a) the endpoints, (b) the time frame of the investi-
gated endpoint, (c) appropriate controls. As mentioned in the introduction, common nanotoxicity
studies mainly address viability, genotoxicity, inflammation, and oxidative stress.
Here, we have chosen three assays to screen our SNPs due to the following reasons: The MTT was
chosen for viability, since it is measuring an important endpoint. For oxidative stress we have cho-
sen the DCFH-DA since its results show if oxidative stress is present or not. The generation of ROS
has been described to be a main contributor for nanotoxicity [4]. With minor modifications, this
assay also allows measuring the oxidative stress in cell-free environment. The hemolysis assay
was chosen to study the interaction between negatively charged SNPs and the cellular membrane
exclusively, since RBC lack of the endocytic machinery.
4.2.2 Cell lines and cell density
The literature has described that not all cell-lines are equally sensitive towards nano-mediated
toxicity. Moreover there is no reliable evidence that phagocytic cells are more sensitive. A recent
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study has compared 23 nanoparticles in 10 cell lines and found that the same nanoparticle exerted
various responses. This was dependent on the cell line and the endpoint chosen [61].
In this thesis, three cell lines were used. They differed in their mechanisms of uptake, where
the leukemic monocytes (human) (THP-1) is able to take up bigger nanoparticles (see review in
section 3.1). Liver hepatocellular cells (human) (HepG2) are not able of phagocytosis, but still able
of incorporating nanoparticles up to a certain size. The third cell line is fresh sheep RBC, which
totally lack an endocytic machinery. Another difference is their origin. HepG2 cells are resident
cells in the liver and not involved in the first line defense. THP-1 cells were chosen because they
play a main role in the first line defense mechanism in our body. Sheep RBC are constituents of
the blood and come into contact with nanoparticles immediately upon i.v. injection.
Cell density for nanotoxicological studies play a key role, as depicted in Figure 4.1. Here, different
Figure 4.1: Viability decrease is cell-number dependent. HepG2 cells were seeded at various
cell densities (expressed as numbers per well) and incubated for 24h with positively charged
polystyrene beads at 60 µg/ml.
cells per well were seeded and treated with the same concentration of highly positively charged
polystyrene beads at 60 µg/mL. The viability is plotted against the cells seeded per well. The plot
shows the vast difference in cell viability, based solely on the amounts of seeded cells. Ideally,
toxicity assays should be performed, when the cells are growing in the log-phase. A confluence of
70% is normally recommended. The percentage implies that for each cell line the amount of cells
needs to be adjusted to reach this value. Throughout this thesis, experiments were conducted at
70% confluence.
4.2.3 Plasma proteins
The interaction of nanoparticles with the soft surfaces of biological systems (i.e. plasma mem-
brane) plays a key role in their beneficial (medical) and adverse (toxicological) functions. The first
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encounter of a nanoparticle with a biological constituent is most probably the preparation of the
dispersion for cell-based experiments. Here, serum proteins adsorb to the particle, dependent of
size, surface charge, wettability, and other factors [15, 80, 88, 89]. Hence, a biological identity, a so-
called protein corona is formed. It has been shown that upon serum addition some nanoparticles
start to agglomerate, whereas other nanoparticles de-agglomerate [90]. It is therefore important
to study the suspension stability (or simply the behavior of the suspension) prior to cell-based
assays, where proteins are added. Some researchers refrained from using serum in assays and
thus retaining the native surface of the nanoparticle. It was shown that the protein corona adds
a "protection" to the nanoparticles, rendering them less cytotoxic [91, 92]. Furthermore, the pro-
tein corona can modulate the uptake pathway into a specific cell and the subsequent intracellular
distribution [93,94]. In this work, we have decided to use serum for the MTT assay and the DCFH-
DA assay, since it is closer to the in vivo situation (for details see section 3.1). For hemolysis, we
refrained to use serum, since the interaction of SNPs surface groups was the main interest.
4.2.4 Interference
In the case of nanoparticles, not only a positive control and a negative control need to be con-
sidered in each assay. It has been described in the literature that numerous particles, especially
carbonaceous materials interfere with the assay readout and therefore causing either false-positive
or false-negative results [95]. Essentially, three interferences can be caused by nanoparticles when
using a colorimetric or fluorimetric assay, as depicted in Figure 4.2. The first interference is of op-
Figure 4.2: Interferences of nanoparticles with reporters. A: optical interference, B: catalytic inter-
ference, C: adsorptive interference, D: assay-specific interference.
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tical nature (denoted as A): if the particles are interfering with the measured wavelength (may be
the case for some gold- or iron nanoparticles), this amplifies the measured outcome. Even without
an optical property at the respective wavelength, the suspension can increase the absorbance by
reducing the transmittance non-specifically. This interference is mostly present for black material
or for any material at higher concentrations [61, 95]. In contrary, if there is a quenching of fluo-
rescence, the result is underestimated. Optical interference can be easily controlled by subtract-
ing a background from the measured values ("blank control"). However, if the particles interfere
strongly, additional washing steps prior to the optical measurement may reduce this interference.
Some researchers propose to centrifuge their samples, however toxicity assays are performed in a
96-well plate. The centrifugation speed for 96-well plates is very limited and it is unlikely to bring
forth a particle-free supernatant.
Interference B is a catalytic interference, where the high specific surface area (and therefore the
high surface reactivity) can convert a substrate in the absence of cells. Hence, an overestimation
of the measured outcome is the consequence. This means that the outcome (oxidative stress for
example) generated by the cells is overestimated, since some signal is coming from the dye solely
converted by the catalytic surface of a nanoparticle. This effect has been described for multi-
walled carbon nanotubes and the DCFH-DA assay, where in absence of cells, a highly fluorescent
signal was detected. Estimating this interference in a cell-free environment, the dye can be first
deacetylated and then the conversion from non-fluorescent to fluorescent dye is measured in pres-
ence and absence of the nanoparticles [96]. Interference C is explained by the surface characteris-
tics of the nanoparticle. Numerous substances can adsorb to the surface of particles and therefore
not contributing to a final readout [97]. Adsorptive interference can be tested by incubating the
nanoparticles with the reporter, subsequent centrifugation and readout of the supernatant. Each
nanoparticle needs to be tested for these interferences separately. Already size or surface group
change can alter the behavior in adsorptive, optical, and catalytic interferences. Besides these three
interferences, specific interferences for each assay still need to be kept in mind, which is denoted
as D in Figure 4.2. One of them is the exocytosis of formazan crystals (see publication in section
3.2).
4.2.5 Mechanistic studies
In this thesis, the underlying mechanism of hemolysis caused by SNPs was studied in depth with
the aid of biophysical methods. The interactions investigated were those with bare nanoparticles
(i.e. not coated with proteins) and RBC.
The proposed mechanism of hemolysis in literature suggests that an electrostatic interaction of the
silanols (deprotonated at pH 7.4 and hence negatively charged) with the quaternary ammonia of
the choline head group is responsible for hemolysis [36]. Therefore, a hemolytic SNP was chosen
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to elucidate its mechanism of toxicity towards RBC using a biophysical approach. This involved
methods such as dye leakage assay with variant model membranes (according to the natural com-
position of RBC) to study the influence of the membrane lipid components [98]. Furthermore, ITC
was used to measure the enthalpy of the interaction of model membranes and hemolytic and non-
hemolytic SNPs. In a last step, solid state nuclear magnetic resonance (ssNMR) experiments were
conducted to see where the interaction of the phospholipid and the surface silanols are located
(tail, phosphorus region, headgroup).
The biophysical investigation suggests, that the interaction between surface silanols and phospho-
lipids plays a minor role in the hemolytic effect. ITC results showed no electrostatic interaction
between nanoparticles and lipid membrane and additional data obtained from DLS and ssNMR
suggest a rather adsorptive process. This adsorptive process may result in membrane wrapping
or forming of smaller lipid vesicles of 100 nm size (see chapter 3.4 for detailed discussion). It is
important to point out, that the composition of the RBC membrane differs from other cells [82],
so a translation from hemolysis to results obtained from the MTT with other cells is not possible.
Furthermore, the viability decrease may be due to either internalized SNPs or adsorption to the
surface. This remains to be further elucidated. Overall, further research, especially in the field
of membrane-protein unfolding may shed light to this underlying mechanism. More research on
the membrane protein-SNP interaction would complete the picture how and to which extents the
particle-bilayer and particle-protein interaction lead to hemolysis.
4.3 Translation of knowledge to small molecule toxicity
Table 1.1. from the introduction displays the main differences for small molecules and nanoparti-
cles, i.e. size, motion forces, physico-chemical characteristics, and interaction with cells. This table
further strengthens the need of considering an own nanoparticle-related toxicological science.
Chemical properties matter, physical properties matter, and the biological system interaction mat-
ters. These three key factors have been explored in this thesis, as depicted in Figure 1.5.
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In this thesis, silica nanoparticles were tested in three different assays. A concentration-, time-,
surface group-dependent, and specific surface area-dependent cytotoxicity was observed. It was
shown that not one exclusive physico-chemical parameter was responsible for viability decrease.
No oxidative stress was detected in the given setup. Introduction of primary amines into the SNPs
reduced the hemolytic effect of the SNPs, irrespective of their size or specific surface area. All neg-
atively charged SNPs caused hemolysis, except the small mesoporous SNPs, because of their fast
degradation in aqueous solutions.
For a hemolytic SNP, biophysical approaches were chosen to obtain insight into the mechanism
of hemolysis. Our findings suggest that the interaction of surface silanols and a model membrane
composed of phosphatidyl choline is rather low. ITC data showed no significant change in en-
thalpy at different temperatures and salt concentrations, which would be present for electrostatic
interactions. Also ssNMR data indicated that an interaction with the choline headgroup is not
prevalent, but the phosphorus spectrum pointed towards formation of faster (i.e. smaller) tum-
bling species. The presence of these species could be confirmed by flow cytometry. Even though
the effects measured were rather small, there was a clear difference between hemolytic and non-
hemolytic SNPs. Hemolysis may be partly explained by our data, however, more research needs
to be conducted, also involving membrane proteins and osmotic pressure.
Combining the gained knowledge from the nanotoxicological studies, the mechanistic studies on
hemolysis and the cytotoxicity studies for small molecules, it is of utmost importance to distin-
guish between these two domains in toxicology. Small molecule toxicity has to address other con-
cerns than nanotoxicology prior to a cell experiment. Other parameters mitigate toxicity: small
molecules may interact very specifically with a receptor or transporter, whereas nanoparticles may
exert their toxicity by unfolding a protein or disturbing the membrane. Mechanistic studies for
nanoparticles are challenging, because the effect on a certain receptor may be delayed and not
readily detectable. Furthermore, particle for positive controls in mechanistic pathways only exist
partially. Hence, these two classes cannot be compared. The bulk material (microparticles) does
not exert the quantum effects as observed for nanoparticles. This transitional nano-zone remains
a challenge for safety assessment.
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Particle modification
• For toxicological studies, more SNPs with different shapes could be included. The density of
the surface groups can be varied with the post-grafting synthesis approach. With a step-wise
change in surface density of various groups, a cytotoxicity threshold may be established.
• For drug delivery, more complex silane precursors can be introduced to the SNPs to ren-
der them biocompatible. Advanced SNPs, release-on-demand systems, could be explored to
reduce cytotoxicity (side effects) of their cargo.
Advanced in vitro models
• Co-cultures, where two or even more different cell types are cultivated in close proximity,
might give insight in how the communication between cell types is influenced by nanopar-
ticles. This approach has already been shown to work for lung co-cultures, and the idea
should be translated to other organs as well.
• If SNPs are used as DDS, their uptake, distribution, and degradation should be studied
under flow conditions, where shear forces influence strongly the exposure of the particles to
the cells. With this flow approach, a more realistic scenario of both, therapeutic efficacy and
toxicology (degradation or exocytosis) can be studied. Taken together, these data and the
data from co-culture, display a better prediction as with 2D cell culture models.
• Expand the array of in vitro assays to assure biocompatibility. This may include testing of
hemacompatibility, the ability of SNPs to cross barriers like the blood brain barrier or the
gut wall.
Upcoming mechanistic approaches
• The interactions of SNPs with model membranes are rather weak as shown in this thesis.
One reason could be that the model does not take the osmotic influences in account, or
that intra- and extracellular ions play a pivotal role. Another important aspect is to study
the mechanistic approach of interaction with SNPs with membrane proteins. Here, mass
spectrometry and labeling of certain amino acids could give insight into this process in more
detail.
In vivo strategies for nanosafety
• Not many in vivo studies involving nanoparticles are available. Most of the studies inves-
tigate the effect of a high single dose in in vivo studies, with the aim to show the efficiency
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of accumulation in a tumor. However, biodistribution studies upon multiple injections in
subtoxic dosages are of strong interest for drug delivery systems, since patients may need
multiple injections over longer time periods up to several years. Additionally, chronic in-
flammation in the vasculature strongly influences the tolerance of such a carrier.
• In vivo studies that investigate the biodistribution by varying the route of entry. Oral vs.
inhalation or oral vs. i.v injection give information about the organs, where most of the
SNPs are distributed to. Hence, safety should address the degradation of the SNPs in these
organs.
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